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Abstract 
Objective: Proline metabolism has been implied in cancer, with changes found to support the 
growth and metastasis of cancer cells. Based on this, proline metabolism has been proposed 
as a safe and specific target for cancer therapy. However, the mechanisms by which proline 
metabolism alters cell programming is not well-characterised. It is not known about the role 
of proline metabolism in normal cell growth and how proline metabolism regulates cellular 
programs. Embryonic stem (ES) cell differentiation is a non-pathological cell system, in which 
proline metabolism was suggested to play a role. Studying proline metabolism in ES cell 
differentiation will provide useful information about the metabolic control of cell 
programming and will identify potential targets for future research in cancers.  
Background: Proline metabolism is an important node of a complex metabolic network that 
connects mitochondrial and cytoplasmic activities. Proline metabolism involves multiple 
reactions that are divided into three steps: proline uptake, catabolism and biosynthesis. The 
key reaction is the oxidation of proline, which is performed inside the mitochondria by a single 
enzyme: proline dehydrogenase (PRODH). PRODH oxidises proline to form pyrroline-5-
carboxylate (P5C) and reactive oxygen species (ROS) as a by-product. In mouse ES cells, the 
primary transporter of proline, Snat2, was found to be involved in proline-induced 
differentiation. The use of amino acids to compete with proline transport via Snat2 was 
effective to prevent the formation of differentiated cells, suggesting that proline uptake via 
Snat2 is essential. In addition, the use of Prodh inhibitors and the neutralisation of ROS by 
antioxidants resulted in a decreased number of proline-induced differentiated cells. This 
evidence suggests that Prodh activity and the formation of ROS are required for ES cell 
differentiation. Furthermore, ROS-activated proteins, such as p38-MAPK and Src, were 
reported to be involved in proline-induced differentiation of ES cells. However, it is currently 
not known what connects proline metabolism and ROS production with ES cell differentiation. 
As a result, the precise mechanism of proline-induced ES cell differentiation is unclear. Taken 
together, it is hypothesised that ROS derived from proline metabolism play a role in ES cell 
differentiation. 
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Aims and Methods: To test this hypothesis, two lines of mouse ES cells: D3 and WA30 were 
investigated in three experiments. The first experiment aimed to examine the expression of 
the proline metabolic enzyme family to confirm potential proline metabolic reactions. The 
expression of proline transporter, Snat2, is differentially regulated in two different pluripotent 
states of ES cells: naïve and primed states. It was questioned if the regulation of Snat2 would 
affect proline metabolism and proline-induced differentiation in these ES cell states. Thus, the 
expression of the proline metabolic enzyme family was examined in different pluripotent 
states of ES cells. In the second experiment, the level of mitochondrial ROS production was 
used as an indicator of proline oxidation. The changes in ROS levels was also detected in 
different time courses to investigate the dynamics of proline response in naïve and primed ES 
cells. The third experiment aimed to correlate ROS production with proline metabolism and 
ES cell differentiation to examine the precise mechanism of proline-induced differentiation.  
Results: The data showed that proline metabolic enzyme family is differentially expressed in 
different pluripotent states of ES cells. It was also found that naïve and primed ES cells have 
different distribution of the proline metabolic enzymes. The measurement of mitochondrial 
ROS production revealed heterogeneous populations of ES cells that produced different ROS 
levels. Up-regulated expression of proline metabolic enzyme, Prodh, in primed ES cells 
resulted in increased ROS production in the addition of proline, which is correlated with 
proline-induced differentiation. However, these mitochondrial ROS were not primarily 
required for the differentiation process. Proline-induced ROS production may not necessarily 
be correlated with proline metabolism and the role of Prodh needs further clarification.  
Discussion: This is the first study to examine proline metabolism in ES cells following their 
pluripotent lineage specification and differentiation. The data suggest a proline metabolic 
switch in ES cell programming and differentiation, which could be used to distinguish ES cells 
of different pluripotent states. These findings indicate that proline metabolism is an important 
factor in mitochondrial metabolic regulation, which has been previously demonstrated in ES 
cell programming. The investigation of ROS production has revealed that mitochondrial 
metabolism can be used to profile ES cells in different pluripotent states. Even though no firm 
conclusion can be made on the role of proline metabolism and Prodh in ES cell differentiation, 
the findings of this study indicate that other proline acceptor sites in the cellular environment 
should be considered for future investigation of proline-induced changes in ES cells. It is 
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suggested that a model of Prodh knock-out ES cell line can be useful to study the role of Prodh 
and proline metabolism in ES cell differentiation. 
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Chapter 1 Introduction 
1.1. Metabolism and the role in cell programming 
1.1.1. Overview of cellular metabolism 
Cell metabolism can be described as a chain of chemical reactions and transformations 
that occur within a cell and that are required for the maintenance of life. In higher eukaryote 
cells like mammals, metabolic pathways form a complex network to provide energy and 
building blocks that are needed for cell growth and development; moreover, recent 
discoveries have shown that metabolism is involved in most cellular processes, which covers 
almost every cell compartment and plays an important role in regulating cell behaviours 
(DeBerardinis and Thompson, 2012, Snaebjornsson and Schulze, 2018). There are a number 
of regulatory mechanisms that have been proposed to describe the crosstalk between 
metabolic activities and cell programming, which do suggest that metabolism plays a critical 
role in cell fate definition (DeBerardinis and Thompson, 2012). Research also proposes that 
the controlling of cell functions can occur at any stage along the metabolic pathway. In some 
circumstances, metabolic regulation is reported to take place when cells sense the presence 
of particular metabolites (Yuan et al., 2013) and a number of nutrient sensing mechanisms 
have also been identified, such as the AMPK (energy sensing), GLUT2 (glucose sensing) and 
mTOR (glucose and amino acid sensing) pathways (Efeyan et al., 2015). This indicates that 
metabolism is an effective way for cells to respond to environmental resources. Indeed, 
metabolism coordinates the cells and the exogenous environment, which supports the cells 
to cope with the changes in physiological conditions and nutrition availability (Metallo and 
Vander Heiden, 2013), and thus, cell programming and metabolic programming should be 
considered at the same time in biological investigation. The question of how different types 
of metabolism control cell fate has been well-established and there is a growing number of 
studies that are looking to better understand the metabolic control over cell programming, 
which has made metabolism an emerging topic of medical research in recent years.  
1.1.2. Metabolism and cell programming 
Metabolic regulation and cell programming are affected by changes in the 
microenvironment, the response to the new conditions can lead to metabolic modifications 
to prepare the cells for growth and function (Metallo and Vander Heiden, 2013). However, it 
is still undetermined as to which factors are first initiated in the relationship between 
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metabolic regulation and cell programming. In other words, the question of whether the cell 
modifications result in metabolic programming or metabolic programming precedes cell 
regulation is critical to determine what is actually being manipulated to alter the cell fate. This 
research will provide useful information for future attempts to control cell behaviours.  
1.1.2.1. Non-canonical subcellular translocation of metabolic enzymes reveals non-
metabolic functions 
Metabolic enzymes are the key players in many cellular reactions. Spatial cellular 
arrangement of metabolic enzymes and metabolites in the cells have an important function 
in balancing the cell physiology and has been shown to be involved in the direct regulation of 
cell fate (van der Knaap and Verrijzer, 2016, Li et al., 2018). Apart from metabolic functions, 
metabolic enzymes are found to play an additional role in the regulation of different types of 
biological activity, which is their non-canonical function (Snaebjornsson and Schulze, 2018). 
In general, metabolic enzymes are required to localise into specific cell compartments to 
perform particular chemical reactions. For example, glycolytic enzymes are mostly located in 
the cytosol and TCA cycle enzymes are found in the mitochondria. When performing non-
canonical functions, metabolic enzymes are known to reside into different cell compartments 
including the nuclei. The translocation into subcellular compartments allows metabolic 
enzymes to regulate cell cycle, apoptosis, epigenetic modifications, and gene expression, 
which results in alterations to cell growth, proliferation, and pathological progression 
(Huangyang and Simon, 2018). For instance, glycolytic enzyme phosphofructokinase (PFK) has 
been shown to localise into the nuclei and interact with transcriptional activators YAP/TAZ 
(Enzo et al., 2015). The protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is 
reported to activate nuclear protein PARP1 (Nakajima et al., 2015). Cytosolic enzyme 
fumarase, which is known to translocate itself into the nuclei to perform DNA repair in cancer 
cells, is actually a metabolic enzyme of the TCA cycle and is responsible for the reversible 
catalysis of fumarate to malate (Jiang et al., 2015). The enzyme pyruvate kinase isozyme type 
2 (PKM2), which is involved in glycolytic reactions, is known to interact with the transcription 
factor OCT-4 (also called POU5), being a key regulator of pluripotency, in the nuclei (Lee et 
al., 2008). Evidence shows that intracellular migration of cell compartments also plays a role 
in controlling cell growth and behaviours. For example, mitochondria have been shown to 
migrate to different sites within pluripotent stem cells during differentiation (Lees et al., 
2017). Accordingly, this process is associated with mitochondrial rejuvenation and maturation 
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and is required for cellular homeostasis (Lees et al., 2017), thus, it is important to consider 
translocation and distribution of the metabolic enzymes in relation to the metabolic 
regulation of cell behaviours. 
1.1.2.2. Nutrient sensing pathway and cell programming 
The sensing of nutrient availability, both endogeneously and exogenously, is an 
example of metabolic regulation and has been described as a conservational mechanism 
throughout evolution (Chantranupong et al., 2015). There are specific metabolites, which 
activate cell programming by triggering the acceptor and transducer proteins. Furthermore, 
depending on the type of nutrients, nutrient sensors can be located either on the cell 
membrane or inside the cytosol. For example, in glucose sensing, the glucose transporter 2 
(GLUT2) is located on the cell membrane to detect glucose availability in the 
microenvironment while the enzyme glucokinase (GCK) alternatively senses intracellular 
glucose levels (Thorens, 2015, Matschinsky, 1990). As these glucose sensors are 
contributative to the development of diseases such as diabetes, they have been put forward 
as potential targets for diabetic treatment (Matschinsky, 2002). Sensing amino acid 
availability can be performed by the activation of the proteins general control 
nonderepressible 2 (GCN2) kinase and mammalian (or mechanistic) target of rapamycin 
complex 1 (mTORC1) (Yuan et al., 2013). GCN2 senses amino acid availability during protein 
synthesis inside the cells. Any reduction in amino acid pool can lead to uncharged tRNAs and 
activate GCN2 to prevent initiation of the protein translation process and activate protein 
degradation to refill amino acid content (Efeyan et al., 2015).  
mTOR is a pivotal pathway of nutrient sensing, which responds to both intracellular 
and exogenous amino acids, glucose and energy. mTOR is known to play an important role in 
cell growth and proliferation (Jewell and Guan, 2013), however, mTOR is not equally 
controlled by all amino acid availability. Amino acids such as leucine and arginine are shown 
to activate mTOR more vigorously than other amino acids (Hara et al., 1998). Only recently, 
glutamine and glutamine metabolism were found to play a role in regulating mTOR (van der 
Vos and Coffer, 2012, Nicklin et al., 2009, Jewell et al., 2015). The mTOR complex 1 (mTORC1) 
is not itself an amino acid sensor. Intracellular amino acids activate mTOR via the induction of 
the transducer proteins Rag and Rheb GTPases (Kim et al., 2008, Parmar and Tamanoi, 2010). 
There is evidence that growth factors and amino acids are both required to activate mTOR. 
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Additionaly, mTOR regulation of cell programming may involve  different pathways (Jewell 
and Guan, 2013). While the actual sensors of the mTOR pathway remain unclear, the 
activation sites include the lysosomal surface and possibly the Golgi apparatus (Jewell and 
Guan, 2013, Goberdhan et al., 2016). It was also suggested that amino acid transporters such 
as members of the solute carrier family (SLC): SLC38A9, SLC38A2, SLC1A5 and SLC3A2 could 
transduce signals to activate mTOR via the transport of specific amino acids (Nicklin et al., 
2009, Pinilla et al., 2011, Rebsamen et al., 2015). Upstream regulation of mTOR includes the 
roles of AMPK (AMP-activated protein kinase) or PI3K (class I phosphoinositide 3-kinase) 
(Dibble and Cantley, 2015, Jewell and Guan, 2013). AMPK senses energy and glucose 
availability, which is activated by increased intracellular AMP and ADP levels (Jewell and Guan, 
2013). Downstream regulation of mTOR includes changes occured in the translation of mRNA 
via the suppression of initiation factor 4E-BP1 (4E-binding protein 1), S6K (S6 kinase) and 
other metabolic and biosynthetic effects (Dibble and Manning, 2013). In fact, GCN2 has been 
shown to inhibit mTOR pathway and this inhibition may be mediated by the deprivation of 
amino acids such as leucine and arginine (Rebsamen et al., 2015), suggesting that mTOR and 
other nutrient sensors may be important to the regulation of cell programming. In conclusion, 
it appears that nutrient sensing is comprised of complex systems of metabolic regulation, this 
suggests that the metabolic regulation of the cell fate is monitored at different levels and can 
occur as early as when the cells first acquire metabolites. Understanding the involvement of 
nutrient sensing is critical in controlling cell behaviours and this will fulfil the mechanism of 
metabolic regulation of the cell fate. 
1.1.2.3. Metabolic profiles and cell fate determination 
The changes in metabolic profiles have been reported to be involved in disease 
progression (DeBerardinis and Thompson, 2012). A number of studies have shown that at 
critical points of the decision making process, metabolic profiles play an important role in 
defining cell fate and determining the outcomes of the cell functions (Pavlova and Thompson, 
2016, Dang, 2012, Galgani et al., 2015). In metabolic diseases such as diabetes, metabolic 
profiles and mitochondrial functions have been extensively discussed for their roles in the 
development of these diseases (Wollheim and Maechler, 2002, Kaufman et al., 2015). In high 
glucose condition or hyperglycaemia, pancreatic insulin-secreting cells, also known as β-cells, 
showed significant changes in gene expression and metabolic pathways that favoured glucose 
metabolism and glycogen synthesis, which eventually results in glycogen accumulation and 
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cell death fundamental of type 2 diabetes (Brereton et al., 2016). The metabolic effects on 
cell functions can also be observed in age-related diseases such as Alzheimer’s disease. The 
role of glucose uptake has been discussed in the development of cognitive impairment 
associated with aging (Yin et al., 2016), example, the increased activity of PI3K/Akt and mTOR 
has been suggested to be important in the homeostasis process of amyloid β (Aβ) and tau, 
the two major proteins that are linked to neurodegeneration in aged people (C, 2013). The 
evidence shows that metabolic profiles, which take part in defining the pool of metabolites, 
are critical in the development of disease initiation. As such, cell metabolism has become a 
potentially important area for research on the pathway to new therapeutic treatments.  
The metabolic control of cell fate has been targeted to direct immune cell 
programming of the immune system. During T cell differentiation, naïve CD4+ T cells give rise 
to cell subsets with a specific immune function. It was shown that daughter T cells with higher 
glycolytic profile and mTOR activity are more likely to become effector cells, which respond 
quickly to immune stimuli (Michalek et al., 2011). On the other hand, enhanced lipid oxidation 
promotes differentiated T cells into regulatory T cells, which function to suppress other cells 
of the immune system (Michalek et al., 2011). Similarly, asymmetric division of CD8+ T cells 
results in different subsets of high and low mTORC1 activities that are correlated with 
different metabolic profiles in these cells (Pollizzi et al., 2016). Accordingly, CD8+ T cells with 
lower mTORC1 activity possess higher mitochondrial mass and lipid metabolism and are 
associated with long-lived characteristics (Pollizzi et al., 2016). Indeed, the understanding of 
metabolic profiles in immune cells does suggest several applications in which, manipulating 
metabolism could enhance and direct functions of the immune cells to defend cancers and 
reduce autoimmunity effects (Galgani et al., 2015, Sukumar et al., 2017, Pearce et al., 2009).  
Alternatively, different cell types may utilise their metabolism differently to support 
the cell functions. An efficient use of metabolic regulation requires cells to have appropriate 
metabolic programs in different cell states, for instance, in cancers, the changes in metabolic 
profiles are required for cancer cells to adapt to high proliferation characteristic, and in many 
cases, to support the cells to escape the immune system (Cascone et al., 2018, Kerkar and 
Restifo, 2012). Cancer cells are found to possess the ability to perform glycolysis in the 
presence of oxygen, which is called the Warburg effect (Warburg, 1956). The main purpose 
of the Warburg effect is to support cancer cell growth in low nutrient and unstable conditions 
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by generating energy in a shorter time period compared to oxidative phosphorylation 
(OXPHOS) (Epstein et al., 2017, Liberti and Locasale, 2016). Cancer cells also acquire multiple 
metabolic programs and mitochondrial metabolism to progress during their development 
(Pavlova and Thompson, 2016, Dang, 2012). For instance, cancer cells are shown to have 
higher fatty acid oxidation (FAO) and the inhibition of FAO can result in the cell apoptosis 
(Samudio et al., 2010). To support the growth of cancer cells, myeloid derived suppressor cells 
(MDSC) are able to escape the immune system by depleting cysteine and limiting cysteine 
availability, which is required for T cell activation (Srivastava et al., 2010). Other metabolic 
elements have also been identified to contribute to the progression of disease (Sica et al., 
2017, Pavlova and Thompson, 2016, Galluzzi et al., 2013). Glutamine addiction is a feature of 
many types of cancers and glutamine metabolism has been proposed as a potential 
therapeutic target (Wang et al., 2018). In fact, many metabolic elements are currently under 
development including preclinical trials (Samudio et al., 2010, Galluzzi et al., 2013, Pavlova 
and Thompson, 2016). However, the potential for targeting metabolism in diseases remains 
challenging due to the limitations in understanding the global effect of metabolic regulation 
on cell functions and development. The understanding of how metabolism is contributing to 
the control of cell physiology will enhance the potential to be able to perform cell fate control 
and manipulation that can be applied to pathological diseases. 
1.1.3. Metabolic programming and pluripotent stem cell development 
PSCs are highly proliferative cells which possess the ability to manifest into numerous 
cell types. Dynamic changes of PSCs during differentiation demonstrate the modifications that 
occur in cell functions and activities. Hence, PSC differentiation presents as a robust model 
for the study of the metabolic regulation on cell fate determination. PSC reprogramming or 
differentiation are acquired not only by metabolic modification but are associated with 
mitochondrial rejuvenation and specification (Lees et al., 2017, Suhr et al., 2010). Given 
mitochondria are the major sites of metabolism and metabolic homeostasis, the changes in 
mitochondrial activities and metabolism have been shown to be important to support PSC 
fate (Lees et al., 2017). Together with mitochondrial changes, the rewiring of basic 
metabolism such as glycolysis, oxidative phosphorylation and amino acid metabolism have 
been identified to play a critical role in the PSC reprograming and differentiation process.  
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1.1.3.1. Glycolysis is the preferred metabolism in pluripotent stem cells 
Glycolysis and low oxygen consumption are known to be the preferred metabolism in 
PSCs such as human ES cells (hESCs), murine ES cells and iPSCs (Moussaieff et al., 2015, Folmes 
et al., 2011). Mice ES cells derived from day 4.5 embryo displayed a high rate of glycolysis with 
a high expression of glycolytic enzymes and increased glycolytic flux (Kondoh et al., 2007). In 
hESCs, the expression of protein hexokinase II (HKII) was found to significantly elevate when 
compared to their differentiated counterparts (Varum et al., 2011). As HKII is a glycolytic 
enzyme catalysing the first reaction in glycolysis, it is suggested that PSCs require high 
glycolysis. In addition, by measuring the rate of oxygen consumption and the extracellular 
acidification rate from lactate production, it is reported that human pluripotent cells 
predominantly use glycolysis for ATP production (Zhang et al., 2011a). In fact, ES cells still rely 
on glycolysis for ATP generation even when they are exposed to a high oxygen environment 
(Kondoh et al., 2007, Chung et al., 2007). To further support the idea that glycolysis is more 
favoured than oxidative phosphorylation (OXPHOS) in these cells, pyruvate dehydrogenase 
(PDH), the enzyme that promotes the TCA (tricarboxylic acid) cycle from OXPHOS-derived 
pyruvate, has been reported to be inactivated in human PSCs (Varum et al., 2011, Zhang et 
al., 2011a). This suggests that the selection of glycolysis over OXPHOS in PSCs is correlated to 
the maintenance of pluripotency.  
In pluripotent reprograming, the preference for glycolysis in pluripotent cells is 
demonstrated by a metabolic switch from OXPHOS in somatic cells to glycolysis in iPSCs 
(Folmes et al., 2011). A study in mice iPSCs has found that glycolytic profiles were highly 
expressed about one week before pluripotent genes could be detected in iPSCs and a 
reduction in glucose content in the environment is associated with the inhibitory effect on 
the formation of iPSCs (Folmes et al., 2011). Increased glycolytic genes was also found to be 
associated with cell fate reprogramming, which is modulated by the hypoxic inducible factor 
1 alpha (HIF-1α) (Prigione et al., 2014). Given that iPSCs generation from somatic cells involves 
nuclear reprograming (Takahashi and Yamanaka, 2006), the metabolic switch from OXPHOS 
to glycolysis was found to have a role in increasing reprograming efficiency to drive the cells 
towards pluripotency (Folmes et al., 2011). Since ES cells and iPSCs possess high proliferation, 
glycolysis is a preferred metabolism in PSCs. This can be explained by the fact that glycolysis 
provides energy and building blocks rapidly, which supports biosynthesis for self-renewal and 
proliferation (Varum et al., 2011, Zhang et al., 2011a, Kondoh et al., 2007). Furthermore, 
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OXPHOS is prevented in these cells as it produces increased amounts of the by-product 
reactive oxygen species (ROS), causing damage to the PSC genetic integrity and also affecting 
the cell survival (Ito and Suda, 2014). It has been shown that the induction of hiPSCs is 
followed by a change in defences against ROS, similarly to what is observed in hESCs 
(Armstrong et al., 2010). A decrease in mitochondrial numbers and the increased expression 
of ROS defencive genes are associated with OXPHOS repression to provide the cells with 
protection from oxidative stress (Armstrong et al., 2010). More studies are required to fully 
understand the roles of the glycolytic switch and its metabolites in PSC differentiation and 
reprogramming.  
Glycolysis preference in PSCs is supported by mitochondrial infrastructure, which 
reduces oxidative reactions by restricting the number of mitochondria (Varum et al., 2011, 
Zhang et al., 2011a, Armstrong et al., 2010). PSCs such as hESCs and murine ES cells possess 
a low number of spherical and immature mitochondria, which are arranged around the nuclei 
and are characterised with low membrane potential and undeveloped inner membrane 
cristae (Cho et al., 2006b, Chung et al., 2010). These features favour anaerobic glycolysis in ES 
cells by preventing other substrates that are metabolised by oxidation from entering the 
mitochondria, thus, the cells are protected from damaging oxidative stress (Zhang et al., 
2011a, Chung et al., 2010, Cho et al., 2006b). In human PSCs, mitochondrial membrane 
potential is maintained through the hydrolytic process of glycolytic ATP, which is performed 
by the enzyme ATP hydrolase, to support the cell proliferation and viability (Zhang et al., 
2011a). The changes in mitochondrial infrastructure are correlated with the entrance 
permission to particular substrates, which results in different mitochondrial metabolism that 
is correlated with different cell functions. Modifications in mitochondrial features and their 
location in the cells were reported to be important in cardiogenesis of ES cells (Chung et al., 
2008). Perhaps, in PSC differentiation, mitochondrial features and functions appear to be 
correlated and more investigation is required to explore this aspect of PSC biology. 
1.1.3.2. Amino acid metabolism in pluripotent stem cells 
Amino acid metabolism has been shown to be an important aspect in PSC 
programming and functions and even though PSCs possess low amino acid metabolism, it in 
fact resembles pluripotent cells of the embryos (Beckman et al., 1990, Schultz et al., 1981, 
Meissen et al., 2012, Beckman et al., 1991). Oocytes and embryonic cells in the pre-
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implantation period are adapted to the low nutrient availability of the embryonic 
environment and are shown to have limited amino acid metabolism compared to somatic 
cells (Schultz et al., 1981, Meissen et al., 2012). This characteristic is carried over into in vitro 
environment and somatic cells reduce amino acid metabolism when reprogramed to PSCs 
(Meissen et al., 2012). Studies on embryonic amino acid pools suggest that limited amino acid 
metabolism is responsible for the maintenance and development of the embryos and the 
transportation of amino acids may function as a regulator for successful implantation (Van 
Winkle and Dickinson, 1995), however, the mechanism of amino acid metabolism in 
embryonic development is still under investigation.  
In in vitro studies, amino acid metabolism is responsible for PSC cell maintenance and 
differentiation, the mechanism of which highlighted the involvement of the generation of 
specific metabolites. For instance, threonine (Thr) metabolism has been shown to be 
important for ES cells to effectively regulate the proliferation and differentiation (Wang et al., 
2009). Threonine is oxidised by the enzyme threonine dehydrogenase (TDH) in the 
mitochondria to produce two elements, glycine and acetyl-CoA (Wang et al., 2009). TDH 
expression in ES cells was found to be about 1000-fold higher than which that was observed 
in the differentiated cells and the deprivation of threonine in the medium inhibits ES cell 
growth (check context) (Wang et al., 2009). An analogue of threonine, 3-hydroxynorvaline, 
can give rise to glycine and propionyl-CoA similarly to threonine oxidation but it is insufficient 
to maintain ES cell growth (Wang et al., 2009). The supplement of glycine itself was inefficient 
in rescuing the cells. The findings showed that among the two elements of threonine 
metabolism, only TDH-mediated acetyl-CoA has a role in ES cell maintenance (Wang et al., 
2009). This selective metabolite appears to be a common regulatory mechanism in ES cells 
and similar effect of threonine metabolism has also been observed in vivo, suggesting that 
threonine is a critical element for early embryonic development in mice (Wang et al., 2009).  
Metabolic products from methionine (Met) metabolism are required to trigger 
differentiation of human PSCs (Shiraki et al., 2014). S-adenosylmethionine (SAM) is an 
important metabolite generated directly from methionine catabolism by the methionine 
adenosyltransferase (MAT). MAT converts methionine and ATP into SAM (Finkelstein, 1990). 
It is reported that undifferentiated cells show a higher Met metabolic rate than their 
differentiated counterparts and deprivation of Met results in rapid loss of intracellular SAM 
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and decreased methionine metabolism enzymes, including DNA methyltransferase 3B 
(DNMT3B) (Shiraki et al., 2014). Decreased SAM levels in methionine depletion can result in 
reduced proliferation, G0/G1 phase arrested in cell cycle and will eventually result in 
apoptosis if depletion prolongs (Shiraki et al., 2014). Treatment with SAM was shown to be 
effective to rescue Met deprivation, suggesting that SAM is an essential regulator of ES cell 
self-renewal and survival. In addition, SAM is also a product of threonine metabolism acting 
as a methyl donating molecule for transmethylation reaction (Shiraki et al., 2014). This 
process converts SAM to S-adenosyl-homocysteine (SAH) (Shyh-Chang et al., 2013), which is 
shown to inhibit the transmethylation reaction catalysed by methyltransferase enzymes such 
as DNA methyltransferases (DMNTs) (Shyh-Chang et al., 2013).  
Another example of amino acid metabolism-induced differentiation is L-proline 
metabolism, which was shown to promote ES cell differentiation (Washington et al., 2010). In 
the addition of exogeneous L-proline, ES cells change morphology, gene expression, and the 
ability to form chimeras in vivo (Washington et al., 2010, Rathjen et al., 1999). Recently, a 
study has shown that L-proline addition leads to remodelling of ES cell transcriptome and 
epigenetic modification at H3K26me2 and K3K9me3, which marks a distinguished pluripotent 
state (Comes et al., 2013). Even though the precise mechanism of L-proline activity in ES cell 
differentiation has not been explored, it has been suggested to involve the process of 
metabolism and metabolic enzymes (Comes et al., 2013). Further investigation is ongoing to 
understand how L-proline metabolism influence the nuclei to perform ES cell programming.  
1.1.4. The crosstalk between metabolism and nuclear programming in pluripotent 
stem cells 
1.1.4.1. Metabolic products and epigenetic regulation in pluripotent stem cells 
The generation of metabolites from PSC metabolism has been shown to be associated 
with the changes in the epigenetic landscape during the differentiation and reprogramming 
steps (Figure 1.1.4). For example, the synthesis of SAM from glycine and acetyle-CoA has been 
reported to create a link to epigenetic modifications in mice ES cells through the histone 
methylation process (Shyh-Chang et al., 2013). A reduction in threonine content in the culture 
medium resulted in an 80% reduction of glycine pool in the ES cell intracellular environment 
and caused a significant decrease in SAM/SAH ratio in the cells (Shyh-Chang et al., 2013). 
Consequently, a reduction in SAM/SAH ratio results in the loss of histone H3 lysine 4 tri- 
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(H3K4me3) and di-methylation (H3K4me2) (Shyh-Chang et al., 2013). Similar results were 
observed in methionine metabolism, which produces SAM/SAH for epigenetic modifications 
in hES cells and supports the cell maintenance (Shiraki et al., 2014). However, H3 methylation 
when induced by SAM/SAH has not been found on other lysine residues except for lysine 4 
(K4), suggesting that SAM/SAH may have a specific site of reaction, in other words, histone 
methylation in ES cells may be controlled by a network of multiple epigenetic regulators.   
In mammalian cells, epigenetics can be regulated by different metabolic elements and 
is specific to different types of metabolites. For instance, the enzyme lysine-specific 
demethylase 1 (LSD1 or KDM1a) was found to be specific for mono- and di-methylated H3K4 
and H3K9 in demethylation. LSD1 protein contains a flavin-site, where it binds to flavin 
adenine dinucleotide (FAD) (Shi et al., 2004, Forneris et al., 2005). FAD is required for LSD1 to 
target methylated histone, the reaction of which, requires the reduction of FAD to FADH2 and 
then the reoxidisation of FADH2 to produce formaldehyde and hydrogen peroxide H2O2 
(Forneris et al., 2005).  During H3 histone demethylation, the regulation of trimethylation at 
K9, K27 and K36 is proven to be associated with the production of α-ketoglutarate (αKG), 
which is important to the maintenance of ES cell pluripotency (Carey et al., 2015). αKG is an 
intermediate product of glucose and glutamine metabolism in fuelling the TCA cycle. The 
depletion of glutamine results in reduced histone monomethylation and increased 
trimethylation on H3K9, H3K27, H3K36 and H4K20 in ES cells (Carey et al., 2015). The 
supplementation of αKG could only reverse H3K27me3 and H4K20me3, suggesting that only 
glutamine-dependent αKG is sufficient to promote these changes (Carey et al., 2015). 
Furthermore, αKG is directly fed to TCA cycle for energenesis. In the TCA cycle, the conversion 
of αKG to succinate has been shown to regulate αKG-dependent dioxygenase family to induce 
demethylation (Kaelin, 2011). As these enzymes comprise of the Jumonji C (JmjC) domain of 
histone demethylases and Tet DNA demethylases family, the demethylation activity of these 
enzymes is then correlated to αKG production (Tsukada et al., 2006, Yang et al., 2014). At 
least ten translocation DNA methylation sites are Tet dependent and are regulated by 
αKG/succinate ratio (Carey et al., 2015).  
Similar to methylation, the acetylation process is subjected to metabolic regulation. 
Research has successfully indicated the links between acetylation and glucose metabolism in 
mice ES cells. Acetyl-CoA derived from citrate of glycolysis can serve as substrates for 
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acetylation of H3K4/K27, resulting in delayed early differentiation of ES cells (Moussaieff et 
al., 2015). This evidence suggests that glycolysis not only provides energy and building blocks 
for proliferation, it can also promote epigenetic modifications in differentiation. Histone 
deacetylation occurs when the acetyl group is removed from the histone residues by histone 
deacetylases (HDAC) and histone acetyltransferases (HAT) (Gong and Miller, 2013). Sirtuins 
(SIRTs) are a class of histone deacetylases that can convert the acetyl group and NAD+ to 
acetyl containing ribose during histone deacetylation (Ryall, 2012). As SIRTs require NAD+ and 
their activity affects the NAD+/NADH reduction/oxidation, SIRTs are often linked to redox 
sensing pathways (Canto et al., 2015). This relationship has been highlighted in a recent study 
that the reduction of NAD+ from increased glycolytic activity promotes SIRT1 mediated 
deacetylation on histone H4K16 (Ryall et al., 2015). Since PSCs possess high glycolytic profiles, 
there is possibly a link between glycolysis, the TCA cycle, redox status and SIRTs activity in the 
regulation of epigenetics. This reveals that changes in metabolite pools can lead to 
modifications in PSC gene regulation, indeed, selective metabolic components are associated 
with a typical cellular change via specific epigenetic modifications. This may suggest that the 
metabolic regulation network, while complexed, its specificity works toward increasing the 
efficiency in controlling PSC fate.  
 
 
 
 
 
 
 
 
A number of metabolic pathways have been shown to generate specific metabolites that are 
involved in the regulation of epigenetic landscape in ES cells, which in turn, regulates the cell 
fate determination. SAM: S-adenosylmethionine, SAH: S-adenosyl-homocysteine, TCA: 
tricarboxylic acid, αKG: α-ketoglutarate, NAD: Nicotinamide adenine dinucleotide. 
Figure 1.1.1. Metabolism and specificity in epigenetic modifications. 
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1.1.4.2. Metabolic regulation of redox homeostasis in pluripotent stem cells 
Redox homeostasis plays an important role in maintaining cell growth and functions 
(Holmstrom and Finkel, 2014). Metabolism is the major source of redox molecules, which 
provides a variety of different redox potent substances such as nicotinamide adenine 
dinucleotide (NAD+) coenzyme derivatives, reactive oxygen species (ROS), flavin adenine 
dinucleotide (FAD+) cofactor family and multiple antioxidants (Forman et al., 2014). Redox 
molecules are mediated by specific regulatory enzymes and factors that involve NADPH 
oxidases (NOXs), forkhead box O (FoxO) proteins and hypoxic inducible factors (HIFs) (Yeo et 
al., 2013, Murray et al., 2013, Zou et al., 2007). The interaction between redox regulators and 
redox molecules forms a controlled network to guarantee the optimal cell function.  
PSCs are characterised by the ability to infinitely self-renew and proliferate in vitro. 
Changes in redox status of the cells can induce the cells to leave the undifferentiated state to 
enter differentiation (Sart et al., 2015). ROS is the dominant redox molecule in PSC biology. 
ROS family includes superoxide anion (O2-), hydrogen peroxide (H2O2) and hydroxyl radical 
(HO-) (Nordberg and Arner, 2001). The major intracellular sources of ROS are result from the 
mitochondrial respiration and metabolisms (Holmstrom and Finkel, 2014). Mitochondria are 
thought to produce the most amount of ROS among ROS sources, mainly from ATP production 
through the electron transport chain (Murphy, 2009). Superoxide anion O2- is formed by the 
addition of an electron to oxygen molecules, which often takes place in an electron rich 
aerobic environment such as the respiratory chain on the inner mitochondrial membrane, or 
through the oxidation process of the mitochondrial enzymes such as flavoenzymes and 
lipoxygenase (Nordberg and Arner, 2001). O2- anions are unable to cross lipid membranes and 
thus are compartmentalised to where it is produced (Nordberg and Arner, 2001). Superoxide 
O2- anions can also be produced by NADPH-dependent oxidase (NOXs), which consumes 
NADPH to generate O2-, and subsequently, H2O2, with the additional activity of superoxide 
dismutases (SODs) (Fridovich, 1997). Hydrogen peroxide H2O2 is not a free radical, however, 
its long half-life and the ability to penetrate lipid membrane make it the main ROS species in 
intracellular signalling (Holmstrom and Finkel, 2014). H2O2 can react with metal ions in protein 
complex to form hydroxyl radical HO- and increase ROS levels inside the cells (Nordberg and 
Arner, 2001). In response to the increased levels of H2O2, which may cause damage to the 
DNA integrity, the cells upregulate the expression of antioxidant enzymes such as catalyse, 
glutathione (GSH) peroxidase and peroxiredoxins to inhibit H2O2 activities (Chae et al., 1999b, 
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Chae et al., 1999a). The differentiation of ES cells to vascular smooth muscle cells has been 
shown to be specifically mediated by H2O2 generated from NADPH oxidase 4 (Nox4) activity 
and it was suggested that different sources of ROS might correlate with a specific 
differentiation program (Xiao et al., 2009). Thus, ROS is an important metabolic player in the 
redox system of PSC biology. To compensate with the increase in oxidative stress that occurs 
during the differentiation process PSCs can regulate the mitochondria and the stress 
pathways to minimise the damage to the cells (Prigione et al., 2010). Reducing agents are 
involved in this fine modulation process of redox balance. Glutathione (GSH) and ascorbic acid 
are two strong reducing agents that have been shown to respond to differentiation (Yanes et 
al., 2010). GSSG is an oxidised form of GSH and a decrease in GSH/GSSG ratio has been  shown 
to be associated with ES cell differentiation, which is accompanied by an increase in ascorbic 
acid levels (Yanes et al., 2010). This suggests that ES cells have a well-regulated redox system 
to safeguard them during the differentiation process. 
The activities of redox enzymes and the transcription factors are reported to 
autoregulate homeostasis in stem cells as they adapt to oxidative stress, which indirectly 
regulates stem cell function. For example, the enzyme thioredoxin can dissociate and prevent 
the effect of Cys oxidation and restore the DNA binding activity of Oct4 to maintain ES cell 
self-renewal (Guo et al., 2004). In the case of the forkhead box O (FoxO) family, which is a 
transcription factor family, they can respond to oxidative stress as part of their functions 
(Brunet et al., 2004, Storz, 2011). FoxO targeted genes include those that are involved in ROS 
detoxification such as SOD2 and catalase, which act to neutralise intracellular ROS (Storz, 
2011). In turn, FoxO proteins are triggered by the AMP kinase and suppressed by the PI3K 
signalling pathways, which are upstream of mTOR (Tothova and Gilliland, 2007). FoxO1 has a 
role in ES cell maintenance and self-renewal and when absent can result in the 
downregulation of Oct4, Nanog and Sox2, known as key factors of pluripotency (Zhang et al., 
2011b). In addition, FoxO3 can coordinate the metabolism pathways of glutamine and glucose 
by directly activating the expression of metabolic enzymes to maintain the proliferation 
potential of neural stem cells (Yeo et al., 2013). This may be the mechanism that explains why 
FoxO3-/- neural stem cells have been reported to exhibit decreased self-renewal and the loss 
in the ability to differentiate to neural lineages (Renault et al., 2009).   
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Redox regulation can be extended to regulating the master transcription factors such 
as p53 and Nanog in ES cells (Han et al., 2008). Accordingly, the production of ROS activates 
p53 translocation into the mitochondria under the modulation of Sirt1. Based on this, the 
absence of Sirt1 led to ROS-induced p53 translocation into the nucleus to suppress the 
expression of Nanog (Han et al., 2008). As a result, ROS supports ES cell differentiation due to 
the reduction in Nanog expression, a key pluripotent gene in ES cell maintenance. Indeed, 
metabolic regulation of the PSC fate can imply multiple mechanisms that cover a wide 
network of signalling pathways. Regulation of ES cell proliferation has been shown to be 
controlled by PPARδ or peroxisome proliferator-activated receptor delta, a known nuclear 
receptor protein (Jeong et al., 2009). Particularly, PPARδ agonist increased the ROS 
production of ES cells, which led to the activation of p38-MAPK and possibly the canonical 
signal transduction Wnt/β-catenin pathway. It is shown that vitamin C and taurine, two ROS 
antioxidants, effectively reduce both Wnt protein levels and cell proliferation (Jeong et al., 
2009). Redox regulation can be performed by a wide range of proteins. The protein Ape1, 
which is involved in regulating DNA binding of transcription factors such as p53 and HIF1a, 
has been shown to perform a regulatory function of the haematopoiesis from ES cells (Zou et 
al., 2007). The inhibition of Ape1 redox activity appears to prevent the development of 
haemangioblast from embryoid bodies (Zou et al., 2007). Thus, the evidence suggests that the 
autoregulating ROS levels via the redox sensors and metabolism are important in the  
maintainance oif stem cell activities and functions. Exploring different types of metabolism in 
relation to the function of cell programming will enhance and improve the currently limited 
ability of sceince in the application and management of PSCs. Understanding metabolism and 
its roles in PSCs will also develop different opportunities for using PSCs in regenerative 
medicine and can be applied in research related to metabolic driven pathology. 
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Table 1.1.1. Redox homeostasis and the effects in ES cell programming  
Redox homeostasis Redox species Cell effects 
NADPH oxidase 4 (Nox4) H2O2  Vascular smooth muscle 
differentiation 
GSH/GSSG balance, Ascorbic acid 
production (Yanes et al., 2010) 
Possibly H2O2 and 
other ROS 
Neuronal and cardiac differentiation 
Thioredoxin (Guo et al., 2004) Possibly ROS Cysteine oxidation to restore DNA 
binding of Oct4 to maintain ES cell 
renewal 
FoxO3 expression, GSH/GSSG 
balance (Yeo et al., 2013) 
ROS Neural stem cell self-renewal 
Sirt1 expression (Han et al., 
2008) 
ROS p53 translocation into the nucleus 
to suppress Nanog 
PPARδ expression, Ascobic 
acid and Taurine production 
(Jeong et al., 2009) 
ROS p38-MAPK and possibly Wnt/β-
catenin in cell proliferation 
1.2. Embryonic stem cell differentiation and the involvement of L-
proline metabolism 
1.2.1. Early primitive ectoderm-like cell formation from embryonic stem cells 
reveals the involvement of L-proline metabolism in ES cell differentiation 
1.2.1.1. Early primitive ectoderm-like cell (EPL) formation from embryonic stem cells 
cultured in conditioned media reveals the role of L-proline 
 Early primitive ectoderm-like cells (EPL) are characterised as a lineage of mice 
PSCs and are distinguished from ES cells (Rathjen et al., 1999). The formation of EPL cells are 
the result of ES cells responding to two bioactive factors present in the conditioned MEDII 
medium (Rathjen et al., 1999) and these two factors have been identified and consist of one 
as a larger molecular mass (>30kDa) and one smaller molecule mass (<3kDa) (Rathjen et al., 
1999, Washington et al., 2010). The smaller molecule was further characterised and identified 
to be the amino acid L-proline (Rathjen et al., 1999, Washington et al., 2010, Rathjen et al., 
2003). The addition of proline in ES cell culture was shown to be associated with the activation 
of the amino acid response via the mTOR signalling pathway (Washington et al., 2010). Other 
amino acids such as L-leucine and glycine are shown to activate mTOR, but they were not able 
to perform the L-proline activities in differentiating ES cells (Washington et al., 2010). This 
suggests that mTOR is not essential for ES cells differentiation and ES cell differentiation is 
only specific for L-proline content in MEDII. Even though the addition of L-proline on its own 
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is not sufficient enough to fully result in the EPL cell formation process, ES cells showed signs 
of differentiation towards EPL cell characteristics (Washington et al., 2010). 
1.2.1.2. The characterisation of early primitive ectoderm-like cell (EPL) showed the 
transition of pluripotent lineages 
Murine ES cells and EPL cells are distinct in morphology, gene expression and the 
ability to give rise of chimeric offspring (Rathjen et al., 1999). Morphologically, ES cell colonies 
are domed with defined edges and EPL cell colonies are monolayered colonies with irregular 
edges (Rathjen et al., 1999). It is known that EPL cells proliferate at a higher rate compared to 
ES cells (Rathjen et al., 1999). Both of the cell types show a high expression of three 
transcription factors Oct4, Sox2 and Nanog, which are typical markers of pluripotent stem 
cells (Tang et al., 2010, Boroviak et al., 2014) and they are able to self-renew and differentiate 
infinitely in vitro (Evans and Kaufman, 1981, Rathjen et al., 1999, Washington et al., 2010). 
When ES cells are injected to a host blastocyst for embryonic development, they are able to 
give rise to all germ lines and somatic cells in chimeric offspring, which is not possible for EPL 
cells (Bradley et al., 1984, Rathjen et al., 1999). This should not be confused with the fact that 
EPL cells are pluripotent and they are able to differentiate to all cell types as a typical 
characteristic of PSCs. In the differentiation from embryoid bodies (EBs), the 3D aggregates 
of cell clusters, ES and EPL cell possess different abilities which give rise to the three germ 
layers (Lake et al., 2000). Particularly, EPL cell EBs are able to differentiate themselves into 
parietal endoderm but not visceral endoderm and they form mesoderm earlier and more 
intensive than ES cell EBs (Lake et al., 2000). EPL cells are marked with high gene expression 
of Fgf5 (fibroblast growth factor 5), Otx2 and Espl1, which are not seen in ES cells (Rathjen et 
al., 1999, Hughes et al., 2009, Lake et al., 2000, Pelton et al., 2002). The formation of EPL cells 
is associated with the decreased levels of Rex1, Gbx2, Rmb27, Spp1 and Nanog genes, which 
are the markers of ES cells (Rathjen et al., 1999). EPL cells also show higher expression levels 
of the DNA methyltransferase gene Dnmt3b (Hughes et al., 2009, Washington et al., 2010), 
which is associated with DNA methylation. Mice ES cells have been shown to share most of 
the characteristics of the pre-implantation E4.5 ICM cells (Beddington and Robertson, 1989) 
and EPL cells are suggested to share characteristics of pluripotent primitive ectoderm cells or 
epiblast cells at E5.5-E6.0 (Rathjen et al., 1999). Phenotypic changes in EPL cell formation have 
suggested that the transition from ES cell to EPL cell may recapitulate the differentiation 
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process from ICM cells (about E4.5) to early primitive ectoderm cells (about E5.5) in the 
embryo (Lake et al., 2000, Rathjen and Rathjen, 2003).  
1.2.1.3. Differentiation of ES cell in response to proline is specific to primed pluripotency. 
 The observations of current published data show evidence that perhaps only ES 
cells at a certain pluripotent state or lineages may differentiate in response to proline (Tan et 
al., 2016a). In vitro, ES cells can be maintained infinitely in two pluripotent states: naïve and 
primed. ES cells of these pluripotent stats are distinct in their characteristics and 
differentiation potential (Nichols and Smith, 2009). Differentiation potential of ES cells is 
initiated by the activation of glycogen synthase kinase 3 (GSK-3) and Fgf4 stimulation from 
extracellular signal-regulated kinase-1 and 2 (Erk1/2) pathways (Kunath et al., 2007, Sato et 
al., 2004). Inhibition of these pathways restricts the ES cell ability to differentiate, which helps 
to maintain ES cells in naïve state (Plusa and Hadjantonakis, 2014, Nichols and Smith, 2009, 
Kunath, 2011, Ying et al., 2008). Naïve state of ES cells in vitro can be reserved by the addition 
of Gsk-3 and Mek/Erk1/2 inhibitors (2i) and the relief of these inhibitors confers the ES cell 
primed state (Plusa and Hadjantonakis, 2014, Ying et al., 2008). A distinct characteristic of 
naïve ES cells is the capacity of extensive clonal propagation in 2i medium (Boroviak et al., 
2014). Without the inhibition of Gsk-3 and Mer/Erk-1/2 (or the relief from 2i), ES cells are 
primed for differentiation (Plusa and Hadjantonakis, 2014, Nichols and Smith, 2009, Kunath, 
2011, Ying et al., 2008). Primed ES cells show higher levels of DNA methylation (>70% 
methylcytosine or mC) compared to naïve ES cells (Smith et al., 2012, Meissner et al., 2008). 
2i medium has been shown to sufficiently return ES cell genome to low levels of DNA 
methylation (30%mC) (Ficz et al., 2013, Habibi et al., 2013). The addition of L-proline and 
PD0325901, a Mek1 inhibitor, was insufficient to confer ES cell differentiation (Tan et al., 
2016a), this suggests that there is no bypass process to proline-induced differentiation from 
naïve ES cells. Thus, L-proline-induced differentiation is only specific for primed ES cells. The 
changes from naïve- to primed- and then to proline-induced differentiated cells recapitulate 
a lineage development of PSCs (Figure 1.2-1). Understanding the role of proline and proline 
metabolism in the specification of pluripotency will enhance our knowledge of the functional 
role of amino acids and metabolism in embryonic development.  
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A. Naïve ES cells are round and domed and appear to be regular and compact. The cells are 
maintained in the presence of 2i (GSK-3 and Mek/Erk1/2 inhibitors). B. Primed ES cells are 
less compact and domed when compared to naïve ES cells. The cells are conferred in the 
removal of 2i . C. Proline-induced differentiated cells are flat and irregular, formed from ES 
cells cultured with the addition of L-proline. Scale = 100 μm. 
 
1.2.2. L-proline and proline metabolism in embryonic stem cells 
1.2.2.1. L-proline-induced differentiation in ES cells involves L-proline amino acid sensing 
pathways 
L-proline (here called proline if not specified) is a nonessential amino acid and proline 
metabolism is conserved from prokaryotes to eukaryote cells. Proline is among the amino 
acids that can be incorporated into proteins. Its conformation comprises of an amine group 
binding to both alkyl groups to form a pyrrolidine ring. Proline is also classified as an imino 
acid as it contains both an imine (R-C=NH) and a carboxyl groups (R-COOH). The L- form of 
proline is commonly seen in nature and is known for its biological functions (Kaul et al., 2008, 
Qamar et al., 2015, Zhu et al., 2002). These special characteristics classify proline as the only 
imino acid that is involved in biochemistry. This unique conformation also makes proline 
unable to be metabolised by classical metabolism such as aminotransferation, 
decarboxylation and racemisation (Adams and Frank, 1980). Proline metabolism is present in 
plants and mammals. In mammals, proline is metabolised by a single mitochondrial enzyme 
called proline dehydrogenase (PRODH) (Adams and Frank, 1980).  
Figure 1.2.1. The lineage development of pluripotent stem cells.  
A B C 
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Proline activities in mice ES cells have been shown to involve two nutrient sensing 
pathways, mTOR and the nutrition stress pathway Gcn2-Atf4 (D'Aniello et al., 2015, 
Washington et al., 2010). In the proline-induced differentiation of ES cells, the activation of 
mTOR is required for the formation of EPL cells because the addition of mTOR inhibitor, 
rapamycin, significantly inhibits the activity of proline in differentiating the cells (Washington 
et al., 2010). The downstream mTOR pathway substrates were also shown to be reduced in 
ES cells that were treated with rapamycin (Washington et al., 2010). However, mTOR is not 
the main pathway that stimulates ES cell differentiation, suggesting that proline has other 
mechanisms which affect ES cell programming. In fact, proline was also shown to control ES 
cell identity through the stress pathway known as the amino acid starvation response (AAR) 
(D'Aniello et al., 2015). In ES cells, the addition of proline to the medium downregulated 
stress-activated transcription factor 4 (Atf4) in nonessential amino acid biosynthesis, which in 
turn, increased the synthesis of endogenous proline (D'Aniello et al., 2015). As a result, this 
relieved the cell dependence on exogenous proline and at the same time, increased 
proliferation (D'Aniello et al., 2015). As ES cells are starved for proline, they reduce the 
expression of genes necessary for proline synthesis and increase the requirement for proline 
uptake, which helps to maintain ES cell identity (D'Aniello et al., 2015). Thus, proline sensing 
is important in ES cell maintenance that includes the autoregulation of both proline 
biosynthesis enzymes and proline metabolism (D'Aniello et al., 2015), it suggests that amino 
acid sensing may not be the only mechanism at play in relation to the proline-induced 
regulation on ES cell fate.  
1.2.2.2. Proline metabolism is involved in ES cell differentiation 
The differentiation of ES cells requires the activity of exogenous proline at a 
concentration level of more than 40 μM  (Rathjen et al., 2003, Washington et al., 2010). The 
uptake of proline to ES cells via the key transporter Snat2 was reported to play a part in 
mediating the differentiation process (Tan et al., 2011). Inhibition of proline transport through 
Snat2 was performed by using other amino acids such as L-alanine, glycine and L-glutamate, 
which are also transported by Snat2 into ES cells (Tan et al., 2011). It is known that ES cells 
cultured in the addition of excessive amino acids L-alanine, glycine, L-glutamate and other 
Snat2 substrates, have reduced differentiation compared to the addition of other amino 
acids, which are not Snat2 substrates (Tan et al., 2011). This suggests that proline uptake is 
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required for the differentiation and proline performed effect on ES cell programming 
internally. 
The role of proline metabolic enzyme has been indicated to play a role in ES cell 
differentiation, demonstrating that the proline metabolism process is involved (Casalino et 
al., 2011). In mammalian cells, the first step of the proline breakdown process is proline 
oxidation, which is performed by the mitochondrial enzyme proline dehydrogenase (PRODH) 
(Adams and Frank, 1980). PRODH is the only enzyme that catabolises proline in mammalian 
cells (Pandhare et al., 2006, Ostrander et al., 2009). The use of proline analogue such as 3,4-
dehydro-L-proline (DHP) can inhibit proline catabolism by competing for the binding sites of 
proline on Prodh (Smith et al., 1962). It has been shown that in the addition of DHP, changes 
of ES cells towards differentiated morphology in response to proline were prevented 
(Casalino et al., 2011). Differentiated gene expression such as Otx2 and Dnmt3b was also 
reported to decrease in the addition of DHP (Tan et al., 2016a). This suggests that the process 
of L-proline metabolism by Prodh is important for ES cell differentiation.  
1.2.3. Proline metabolism in mammals and embryonic stem cells 
1.2.3.1. Transportation of proline in embryonic stem cells 
Proline transportation is a sodium dependent transport system (Broer, 2014, Yao et 
al., 2000). Amino acid transport systems can be classified by their characteristics such as 
substrate affinity (eg. system Gly), sodium dependence (eg. System A and XAG-/system ASC) 
and pH association (eg. System y+); or by their genetic families of the solute carriers (SLC) 
(Taylor, 2014, Kilberg et al., 1993, Dawson and Baltz, 1997). Depending on the tissues type, 
transportation of amino acid can be metabolic or non-metabolic (Taylor, 2014, Kilberg et al., 
1993, Dawson and Baltz, 1997). The transportation of proline as osmolality regulation has 
been shown to be efficient in rescuing the early development of the 8-cell stage emryo to the 
blastocyst formation (Van Winkle, 2001), yet, little is known about the role of the metabolic 
transport of proline in early embryonic development. Two transporters of the system A 
transporters, SNAT1 and SNAT2 are known for their function in transporting L-proline 
intracellularly (Broer, 2014). SNAT1 (SLC38A1) and SNAT2 (SLC38A2) of system A transporters, 
which are characterised as sodium-amino acid cotransporters and highly pH sensitive, belong 
the SLC38 family and support the transport of small and neutral amino acids such as alanine, 
proline, glutamine and serine (Palacin et al., 1998, Broer, 2014). Different rates and 
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preferences of these amino acid transport processes support the specificity of SNAT1 and 
SNAT2 (Sugawara et al., 2000, Reimer et al., 2000, Yao et al., 2000, Hyde et al., 2007).  
Among the two, SNAT2 is the main transporter of proline in the mice ES cells (Broer, 
2014). Snat2 protein structure is comprised of eleven transmembrane domains with an 
intracellular N terminus and a highly conserved extracellular C-terminal histidine residue 
(Zhang et al., 2011c, Hyde et al., 2007). The N and C termini play a role in regulating amino 
acid transportation, particularly, C terminus is associated with pH sensitivity through the 
voltage independent process, whereas N terminus is critical to stabilise the expression of 
Snat2 on the cell membrane in response to environmental amino acid pool (Zhang et al., 
2011c, Hyde et al., 2007). Snat2 but not Snat1 has been confirmed to be the major transporter 
of proline in mice ES cells and play a role in regulating the uptake of proline in differentiation 
(Tan et al., 2011). Snat2 is suggested to function as a transceptor, which is capable of 
detecting amino acid availability in both intra- and extracellular environment (Hyde et al., 
2007). Snat2 transports proline via a sodium dependent manner and it is able to transport 
amino acids that are substrates for the System A transporters such as L-alanine, L-serine and 
glycine (Broer, 2014). Transportation of these amino acids through Snat2 effectively inhibits 
the uptake of proline into ES cells and consequently, prevents ES cell differentiation (Tan et 
al., 2011). However, the excessive amount of other amino acids that are not Snat2 substrates 
has been shown to be insufficient to prevent ES cell differentiation (Tan et al., 2011), 
suggesting that the differentition process is regulated by the uptake of L-proline by Snat2 and 
is specific for L-proline.  
1.2.3.2. Proline dehydrogenase specifically metabolise proline in the mitochondria 
Due to the special chemistry conformation, proline is only metabolised by the 
flavoprotein dependent enzyme proline dehydrogenase (PRODH) (or also called proline 
oxidase, POX) in the mitochondria. PRODH gene homologous to Drosophila melanogaster 
sluggish A (slgA) is present on the human and the mice chromosome 22q11 and is encoded 
by p53-induced gene 6 (PIG6) (Campbell et al., 1997, Donald et al., 2001). In mice, Prodh 
transcript has been identified with the length of 2.4-2.5 kb of various tissues including the 
brain (Gogos et al., 1999). Mutations of PRODH gene decrease catalysis efficiency and cause 
the accumulation of proline, which can lead to diseases in various organisms (Campbell et al., 
1997, Luo et al., 2012, Gogos et al., 1999, Blake et al., 1976). Isolation of PRODH protein in 
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bacteria shows that the structure of PRODH undergoes conformational changes to perform 
proline catalysis (Ostrander et al., 2009, Zhang et al., 2004). It is suggested from the structural 
models that proline is buried inside the complex as the first step of proline oxidation occurs 
(Ostrander et al., 2009, Zhang et al., 2004, Luo et al., 2012). Oxidation of proline by PRODH to 
Δ-pyrroline-5-carboxylate (P5C) is coupled with the reduction of cofactor flavin adenine 
dinucleotide (FAD), which produces two electrons and feeds the electron transport chain for 
further ATP (adenine-5’-triphosphate) production (Tanner, 2008, Zhang et al., 2004). PRODH 
catalytic activity is controlled by the active gate formed from the ion pair associated with FAD 
chain on PRODH protein (Luo et al., 2012). These conformation changes of the active ion gate 
allow the access of electron acceptors to reduce FAD and at the same time, to facilitate the 
release of products (Luo et al., 2012).  
The PRODH function for proline metabolism can be regulated by introducing inhibitors 
through the substrate recognition domains (Zhang et al., 2004, Adams and Frank, 1980). 
PRODH isolated from rat livers have been shown to be inhibited reversibly by L-lactate and 
pyruvate whereas D-lactate can inhibit PRODH in bacteria (Adams and Frank, 1980). Other 
substrate analogous to proline such as L-tetrahydro-2-furoic acid (THFA) and acetate are also 
reversible inhibitors of PRODH activity in proline metabolism (Zhu et al., 2002, Zhang et al., 
2004), among them, 3,4-dehydroproline (DHP) is an antagonist of PRODH that can reversibly 
inhibit the proline catalysis process by competing for the binding sites on PRODH (Smith et 
al., 1962). Proline metabolism is activated by the recognition of three functional groups on 
the proline molecule, including carboxyl, amine and the methylene groups (C3-C5) of the ring 
(Zhang et al., 2004). Inhibitors of PRODH can compete with proline for the binding domains 
and the reduction by FAD on PRODH complex (Tanner, 2008). Irreversible inhibition of PRODH 
is introduced by N-propargylglycine through mechanism-based inactivation, in which, the 
oxidation of N-propargylglycine is concomitant to the reduction of FAD, being the first step of 
proline metabolism (White et al., 2008). PRODH has been shown to be involved in a number 
of cellular pathways that are associated with proline catabolism and the formation of 
products (Phang et al., 2008a, Phang et al., 2008b). For example, the production of ROS 
induced by PRODH activity in proline metabolism under the regulation of p53 has been shown 
to play a role in apoptosis (Rivera and Maxwell, 2005). The expression of PRODH has also been 
shown to increase in response to inflammatory and genotoxic stress, suggesting its critical 
role in various cellular effects (Pandhare et al., 2006, Hu et al., 2007). Inhibition of PRODH by 
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dehydroproline (DHP) has been shown to counteract proline activity to formation of EPL cells 
from ES cells, indicating that the activity of PRODH is required for this process (Casalino et al., 
2011). However, the PRODH inhibitors can also interfere with other cellular activities. For 
example, the addition of DHP to human and mice fibroblasts in culture has been shown to 
affect the formation of collagen synthesis and propyl hydrolase activities (Kerwar and Felix, 
1976), suggesting that the cellular outcomes may be generated from the effects of multiple 
inhibition, thus, specifying the important role of PRODH and PRODH activity in ES cells may 
require the understanding of the proline network and the characteristics of the proline 
metabolic pathway.  
1.2.3.3. Proline metabolic reactions in mammalian cells  
Proline catabolism: Proline is oxidised when two electrons are removed from its molecule by 
the cofactor FAD on PRODH which determines the formation of P5C. The electrons once 
removed from proline are stored in the reduced form of FAD, which will be subsequently 
transferred to the electron transport chain through ubiquinone proteins. The accumulation 
of these electrons is an essential source for the production of ROS. Production of ROS from 
proline metabolism has been shown to be involved in a number of biological pathways, which 
can regulate cellular activity (Donald et al., 2001, Liu et al., 2006). The next step in proline 
metabolism is the non-enzymatic hydrolysis of P5C that opens the ring structure in a process 
called tautomerisation to form the intermediate gama-glutamate semialdehyde (GSA), which 
will be further oxidised by P5C dehydrogenase (P5CDH) enzyme to form glutamate as the final 
product to contribute to the source of the TCA cycle. Both PRODH and P5CDH are conserved 
in eukaryote and prokaryote cells (Adams and Frank, 1980). Monofunctional P5CDH enzymes  
are typically 400-600 amino acids (reviewed in (Arentson et al., 2012)) and they are located 
in the mitochondria. P5CDH enzyme is one of the aldehyde dehydrogenase (ALDH) 
superfamily. Human and mice P5CDH genes belong to the ALDH family 4 and are referred to 
as ALDH4A1 (Sophos and Vasiliou, 2003). P5CDH uses the coenzyme NAD+ (nicotinamide 
adenine dinucleotide) as an electron acceptor to oxidise GSA, which is the real substrate for 
P5CDH rather than P5C (Adams and Frank, 1980), suggesting that proline metabolism involves 
a variety of intermediates that create a complexed and dynamic metabolic network (Figure 
1.2.3). 
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Proline synthesis: Proline can be synthesised inside the cells from different sources such as 
glutamate, ornithine and P5C. The synthesis of proline from glutamate is initiated by 
mitochondrial P5C synthase (P5CS) enzymes through the functioning of two domains, 
gamma-glutamyl kinase (GK), and gamma-glutamyl phosphate reductase (GPR), which use 
ATP and NADPH (nicotinamide adenine dinucleotide phosphate) to produce GSA from 
glutamate (Adams and Frank, 1980). GSA circles its arms into a ring and become P5C. A 
complete structure of P5CS is not yet constructed, however, GK and GPR domains have been 
studied in bacteria (Marco-Marin et al., 2007, Perez-Arellano et al., 2006). In mammalian cells, 
P5CS proteins undergo splicing to form two isoforms, both differing with the addition of two 
amino acids at the N-terminal of the GK site (Hu et al., 1999). The short isoforms are present 
in gut cells and the long isoforms are present in all tissue (Hu et al., 1999). In human and mice, 
the P5C synthase  gene is an 18A1 member of the ALDH family (known as ALDH18A1) (Hu et 
al., 1999, Liu et al., 1996). In mice, the activity of P5CS enzyme was first measured in Chinese 
hamster ovary cells through the formation of the intermediate P5C (Smith et al., 1980). P5C 
can act as an intermediate to synthesise both proline and ornithine from glutamate (Adams 
and Frank, 1980). The synthesis of ornithine from P5C requires the ornithine 
aminotransferase (OAT) enzyme, which reverses ornithine back to P5C (Adams and Frank, 
1980). In mice, the OAT gene is located on chromosome 7q26 and some related sequences of 
the gene, which are found on X chromosome and chromosome 3, have been identified as 
pseudo genes (Ramesh et al., 1992). The final enzyme in the proline metabolic pathway is the 
enzyme catalysing the reduction of P5C to proline in the cytosol, P5C reductase (P5CR), the 
reaction of which requires the conversion of NADPH to NADP+. P5CR proteins have two 
isozymes P5CR1 and P5CR2 encoded by Pycr1 and Pycr2 with a conserved N-terminal fold for 
NADPH binding (Arentson et al., 2012, Hu et al., 2008). Both of the isozymes are located within 
the cytoplasm causing P5C to leave the mitochondria to be converted back to proline 
(Arentson et al., 2012, Hu et al., 2008). As proline synthesis can use different sources of 
substrates to generate proline, it is necessary to understand how the cell environment 
regulate the L-proline pool and support the cell needs.  
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PRODH (Prodh): proline dehydrogenase. P5CR (Pycr1): P5C reductase. P5CDH (Aldh4a1): 
P5C dehydrogenase. OAT (Oat): ornithine aminotransferase. P5CS (Aldh18a1): P5C synthase. 
P4HA1: Prolyl 4-hydroxghovbylase subunit alpha 1 (P4ha1) P5C: ∆-pyrroline-5-carboxylate. 
ROS: reactive oxygen species. GSA: glutamic-gamma-semialdehyde. 
Yellow arrows: Proline catabolism: Proline enters ES cells primarily through the transporter 
SNAT2 and is oxidised by the enzyme PRODH in the mitochondria, which releases two 
products ROS and P5C. P5C is autoconverted into GSA, which can be used to synthesise 
glutamate via the enzyme P5CDH or orthine via the enzyme OAT. Glutamate can then enter 
other pahtways such as the TCA cycle and ornithine enters the urea cycle. Blue arrows: 
Proline biosynthesis: Proline can be synthesised from glutamate by the enzyme P5CS or 
from ornithine by the enzyme OAT, which form the intermediate product GSA/P5C. P5C is 
converted back to proline via the enzyme P5CR.  
  
Figure 1.2.2.Proline metabolism and synthesis in ES cells.  
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1.2.3.4. Biological roles of pyrroline-5-carboxylate and the involvement of pyrroline-5-
carboxylate in early primitive ectoderm-like cell formation  
P5C is a bioactive and labile intermediate substrate that can be directly involved in cell 
signalling (Nomura and Takagi, 2004, Farrant et al., 2001, Phang, 1985). In yeast, P5C has been 
found to be a direct inhibitor of mitochondria respiration, resulting in the generation of 
intracellular ROS (Nishimura et al., 2012). P5C has also been shown to be a vitamin B6 
antagonist which effectively reacts with aldehydes and ketones to form adducts in type II 
hyperprolinemia disease (Farrant et al., 2001). The conversion of P5C to proline creates a 
proline-P5C cycle associating with the NADPH/NADP+ redox regulation inside the cell 
microenvironment (Adams and Frank, 1980). The proline-P5C cycle is important to maintain 
the level of NADP+ between the mitochondria and the cytosol for the pentose phosphate 
pathway (Hagedorn and Phang, 1983, Hagedorn and Phang, 1986). The end products of the 
pentose phosphate pathway are critical for the nucleotide synthesis process (Phang, 1985), 
which is suggested to influence the caspase activities resulting in cell death in some tumour 
cells and thus affecting cell growth (Maxwell and Davis, 2000). In the cellular 
microenvironment, P5C achieves an equilibrium with its tautomeric form, GSA, which makes 
P5C an intermediate agent for various important metabolic pathways (Pandhare et al., 2009, 
Arentson et al., 2012, Tanner, 2008, Adams and Frank, 1980).  
The characterisation P5C and its biological studies have been performed in plants, 
yeasts and human plasma, which revealed aspects of their regulatory effect (Fleming et al., 
1984, Nishimura et al., 2012, Qamar et al., 2015). However, the P5C biological role still 
remains to be further examined in mammalian cells. The reason for the limitation in studies 
around P5C might be due to its high bioactivity, which makes it difficult to measure and 
manipulate P5C production even though radioactive methods have been applied (Hu et al., 
1999, Smith et al., 1980).  
In ES cells, the attempt to increase L-proline synthesis and P5C production from 
ornithine has been carried out by using DMSO and shown to prevent ornithine from entering 
the polyamine synthesis processes, forcing ornithine to enter the proline synthesis pathway 
(Casalino et al., 2011). The result has suggested that P5C formation in this direction plays an 
important role in the morphological changes in ES cells (Casalino et al., 2011). However, given 
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that P5C is an intermediate for different metabolism pathways, the chance for P5C formation 
from ornithine to be returned to L-proline would be possible (Alonso and Rubio, 1989). Thus, 
further investigation is required to identify the role of P5C. 
1.2.4. Pyrroline-5-carboxylate and reactive oxygen species are suggested to be 
involved in proline-induced ES cell differentiation 
1.2.4.1. Biological roles of reactive oxygen species in embryonic stem cell differentiation  
PSCs tend to utilise high levels of glycolysis and low levels of OXPHOS to secure their 
DNA integrity. It is also important for PSCs to maintain their redox homeostasis to self-renew 
and to differentiate (Folmes et al., 2012, Ito and Suda, 2014, Wang et al., 2013). It has been 
shown that when adult stem cells maintain quiescence in the hypoxic niche, the production 
of ROS in normoxia forces the cells into a more proliferative state (Tothova and Gilliland, 2007, 
Chen et al., 2008, Renault et al., 2009).  
In the proline metabolic process, ROS is formed from the oxidation reaction of proline 
by PRODH to produce free electrons to feed the electron transport chain, which subsequently 
generate ROS (Murphy, 2009, Liu et al., 2009). It has been shown that inside the mitochondria, 
and in the presence of proline, PRODH is not the dominant source of ROS, particularly 
superoxide and H2O2 (Goncalves et al., 2014). Instead, PRODH is an important source for 
electrons that are directly fed to the electron transport chain through ubiquinone reduction, 
and indirectly through other sites from the downstream metabolism (Liu et al., 2009). The 
formation of ROS in proline metabolism involves different metabolic processes making it 
potential for a role in cellular activity. Current data propose that ROS production is a key factor 
in proline metabolic regulation of ES cell programming. The addition of the PRODH inhibitor, 
DHP, is effective to return ROS levels to the basal level (Tan et al., 2016a). Thus, ROS level 
changes in ES cells may be correlated with proline metabolism in ES cells.  Antioxidants are 
known as ROS neutralisers and the addition of glutathione as an antioxidant to ES cell culture 
in the L-proline-containing medium has been shown to reduce ROS level (Tan et al., 2016a). 
In addition, the inhibition of L-proline metabolism-induced ROS by introducing antioxidants 
such as glutathione (GSH), N-acetyl-L-cysteine (NAC) and especially vitamin C, has been shown 
to  effectively prevent the morphological and gene expression changes of ES cells towards 
differentiated cells (Casalino et al., 2011, Comes et al., 2013). However, the link connecting 
this evidence is still to be discovered. Research is still attempting to discover whether the 
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source of ROS is the result of proline oxidation or is it the result of proline-induced stress in 
the cells (Tan et al., 2016a), thus, proline may play a different role. It is also critical to 
understand if the enzyme Prodh and its catalytic activity are necessary to provide ROS for ES 
cell differentiation and just how specific this ROS is to the differentiation process, this given 
the fact that the presence of proline metabolic enzymes in ES cells are unknown and whether 
these different enzyme activities would have an effect on directing the proline metabolism in 
ES cells. Even though the changes in ES cell morphology were observed in Prodh and ROS 
inhibition, it still needs to be confirmed if these changes actually reflect the differentiation 
process rather than the stress responses (Casalino et al., 2011).  
Two redox sensing molecules have been identified to be involved in ES cell 
differentiation, c-Src (proto-oncogene tyrosine-protein kinase Src) and p38-MAPK (p38-
mitogen activated-protein kinase) (Tan et al., 2016a). In previous studies, c-Src are known to 
be directly involved in the differentiation process of ES cells to primitive ectoderm cells (Meyn 
and Smithgall, 2009, Meyn et al., 2005). In addition, p38-MAPK is important for ES cell 
regulation of the self-renewal and differentiation process (Ding et al., 2008). Studies indicate 
that with the addition of the inhibitor of Scr tyrosine phosphorylation into proline containing 
media can result in a reduction in proline-induced differentatiated cells (Tan et al., 2016a). 
However, the inhibitory effects are unable to fully prevent differentiation as the 
differentiated morphology and gene expression changes are not complete or maintained (Tan 
et al., 2016a). This suggests that Src protein kinases may play a role in maintening 
differentiated phenotype and ROS may be the regulatory factor as c-Src is a ROS sensing 
molecule. In addition, the lack of p38-MAPK, an isoform of p38-MAPK directly affects the 
formation of differentiated cells and ES cells fail to downregulate pluripotent gene expression 
in proline containing media (Tan et al., 2016a). Futhermore, p38-MAPK signalling has no role 
in maintenaning differentiated cells (Tan et al., 2016a). Both c-Src and p38-MAPK can be 
directly activated by ROS induced-oxidation  (Giannoni et al., 2005, Ding et al., 2008), 
suggesting the role of ROS in these signalling pathways. However, the precise mechanism of 
this signalling pathway is not well-characterised. Filling in these gaps will greatly contribute 
to a more complete picture of the proline metabolism process and ES cell differentiation.  
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1.3. Objectives 
Metabolism provides the foundation and the source of energy required for sustaining 
life. As the microstructure of life, cellular metabolism is gaining interest as research 
demonstrates that metabolism operates well beyond the simple function of life maintenance 
(Mason and Rathmell, 2011, Metallo and Vander Heiden, 2013). The involvement of 
metabolism in regulating cell programming has made metabolism an important factor in 
disease progression and opened up new avenues for the discovery of treatments (Dang, 2012, 
Cunnane et al., 2011). Understanding the different types of metabolism and how they impact 
upon and affect cell biology, and cell development, will enhance and increase our knowledge 
base and provide new approaches for future studies on the search toward providing improved 
treatment solutions for diseases.  
L-proline metabolism is conserved in plants and eukaryote organisms and is an 
essential requirement for cell growth and development (Miller et al., 2009, Nishimura et al., 
2012, Phang et al., 2015). Proline metabolism plays a pivotal role in the regulation of cancer 
cell progression and is nominated as a potential area for study in therapeutic development 
(Elia et al., 2017, Phang et al., 2012). Proline metabolism was first known to be involved with 
eukaryote cell programming (Donald et al., 2001, Phang et al., 2008a), however, the precise 
mechanism have not yet been completely established. Proline is shown to activate ES cell 
differentiation, this provides an opportunity and a system for investigation into the central 
role of proline metabolism and its functions in relation to cell programming. In conclusion, 
further examination into understanding how proline metabolism function in ES cells, and how 
each element of the proline metabolic system contributes specifically to ES cell differentiation 
is required.  
1.4. Hypothesis and Aims: 
The overarching hypothesis of the work in this thesis is that the L-proline metabolic product, 
ROS, is directly involved in the differentiation process of ES cells. To address this hypothesis 
the following aims will be explored: 
1. To determine the proline metabolic system in ES cells via the expression and 
localisation of the proline metabolic enzyme family, 
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2. To quantify proline metabolism-induced ROS production in response to the 
addition of  proline to ES cell culture, 
3. To determine the roles of proline oxidation and ROS production in ES cell 
differentiation.
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Chapter 2 Methodology 
2.1. Tissue culture 
2.1.1. Mouse ES cells:  
D3 ES cell line (Doetschman et al., 1985) was generously given by Dr Lindsay Williams, 
Ludwig Institute, Melbourne. WA30 ES cell line were obtained by Dr. Marnie Blewitt, Walter and 
Eliza Hall, Australia and maintained in naïve state conditions as described below.  
2.1.2. Culturing media:  
Medium to maintain D3 ES cell line is described below1, this medium will be referred as 
basal medium.  
Components Final concentration 
FBS 10% 
DMEM 90% 
Pen-strept 100 units/mL (U/mL) 
βME 0.1 mM 
LIF 1 unit (U) 
 
Medium to maintain WA30 ES cell line contained basal medium with the addition of 
PD0325901 and CHIR99021 following the concentration below: 
PD0325901 1 μM 
CHIR99021 3 μM 
 
All cells were maintained on a 6mm tissue culture treated dishes in the incubator at 
37oC and 5% CO2 supply. All cells were passaged every 2-4 days and cells that reached passage 
29 were discarded. To passage the cells, they were washed 2 times with PBS before being 
trypsinised by 500 μL of trypsin for 2 minutes (Life technology, 12563011). Then 1 mL of 
                                                     
1 All reagents are to be referred to the list of reagents (Table 2.1) 
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medium was added to the dish to deactivate and wash the cells off the surface. The mixture 
was then transferred into a fresh 15mL falcon tube. Trypsin-medium mixture was removed 
by centrifugation and the cells were resuspended in 1 ml of new media. 5x105 – 1x106 cells 
were seeded in a new dish for maintenance.  
Table 2.1.1. List of reagents 
Abbrev. Name Company Reference 
DHP 3,4-Dehydroproline Sigma Aldrich D4893 
DMEM Dulbecco’s Modified Eagle Medium Life Technologies 11965-084 
DMSO Dimethyl sulfoxide Sigma Aldrich 472301 
DTT Bolt Reducing Agent Life Technology B0009 
DTT DL-Dithiothreitol Sigma Aldrich D9163 
EDTA Ethylenediaminetetraacetic acid 
disodium salt dihydrate 
Sigma Aldrich E5134 
EGTA Ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid 
Sigma Aldrich E3889 
FBS Heat inactivated Foetal Bovine Serum  Life Technologies 10082-139 
GSH Glutathione      
LIF Leukaemia Inhibitory Factor  Produced in house (Smith, 1991) - 
NAC N-acetyl-cysteine Sigma Aldrich A9165 
Pen-
strep 
Penicillin (10 000 units/mL) - 
Streptomycin (10 000 μg/mL)  
Life Technologies 15140-122 
SDS Sodium dodecyl sulfate Sigma Aldrich L3771 
THFA L-Tetrahydro-2-furoic acid Sigma Aldrich 341517 
Tris Trizma-base Sigma Aldrich T1503 
Vit C Vitamin C Sigma Aldrich A4403 
βME Beta-mercaptoethanol Sigma Aldrich M3148 
  Acetic acid, glacial Sigma Aldrich ARK2183 
  CHIR 99021 Stem cell technologies 252917-06-9 
  Chloroform Sigma Aldrich C2432 
 Gelatine Sigma Aldrich G1890 
  Glycerol Sigma Aldrich G5150 
  Glycine Sigma Aldrich G8898-1KG 
  GoTag Green Promega M712C 
  HEPES Sigma Aldrich H3375 
  IGEPAL CA-630 Sigma Aldrich I8896-100ML 
  L-Ornithine monohydro-chloride Sigma Aldrich O6503-25G 
  L-Proline Sigma Aldrich P6607-25G 
  PD 0325901 Stem cell technologies 391210-10-9 
  Potassium chloride Sigma Aldrich P9541 
  Sodium chloride Sigma Aldrich S3014-1KG 
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  Triton X-100 Sigma Aldrich T8787-50ML 
  Trizol Life Technologies 15596026 
  Tween-20 Sigma Aldrich P9416 
  Ultrapure Water Invitrogen 10977-015 
 
Acetic acid, glacial From general laboratory resources 
 
 
 
 
 
 
  Ethanol 
  HCl 
  Methanol 
PCA Perchloric acid 
  Potassium hydroxide 
2.2. Gene expression analysis via PCR 
2.2.1. RNA extraction 
RNA was extracted from cell pellet with 200 μL Trizol/sample. Samples were incubated 
on ice for 20-30 minutes before Trizol reagent was separated by adding 1:5 (40 μL) 
chloroform. Mixture of Trizol : Chloroform was inverted for 2 minutes and returned on ice. 
After Trizol : Chloroform mixture settle in the tube, RNA in each sample was separated from 
the trizol : chloroform  mixture using centrifugation at the highest speed for 10 minutes. 
Aqueous layer of RNA in each sample was transferred and mixed with isopropanol in a new 
tube. RNA precipitation was set overnight at -20oC. Precipitated RNA was collected by 
centrifugation at the 10,000g speed for 10 minutes at 4oC. RNA samples were washed with 
ice cold ethanol 70%. RNA pellets were resuspended in 20 μL ultra-pure (nuclease free) water 
and stored at -80oC. 
2.2.2. DNase treatment for RNA samples 
Ten (10) μL of each RNA sample (or at least 1.5 μg of RNA) were DNase treated to 
remove DNA contamination. DNase treatment kit (DNA-free™ DNA Removal Kit) was 
purchased from Life-technology (Ref: AM1906) and DNA treatment was performed following 
the manufacture instruction. Particularly, 1 μL (or 1/10 RNA volume) of 10x DNase I buffer 
was added to each RNA sample, followed by 1 μL of rDNase I. The combination was gently 
mixed and then incubated on a heat block at 37oC for 20-30 minutes. This was followed by 
adding 2 uL DNase Inactivation Reagent. The final combination was incubated and mixed 
occasionally for two minutes at room temperature. The precipitated reagents were removed 
by centrifugation at 10,000 g speed for 1.5 minutes. Treated RNA in the aqueous layer was 
transferred to a clean tube and stored at -80oC.  
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2.2.3. cDNA synthesis by reverse transcription 
Treated RNAs were quantitated on the Nano drop machine (Spectrometer ND1000) 
using ND-1000 program (version V3.3.1). 1 μg of RNA from each sample was used for cDNA 
synthesis by reverse transcription. cDNA synthesis was performed following the provided 
protocol (GoScript™ Reverse Transcriptase, Promega, Ref: A5001). Accordingly, 0.5 μL (or 1 
μg) of Oligo-dT was added to each RNA sample and water to make 10 μL of template mix. This 
was then incubated at 70oC for 5 minutes, following by chilling on ice for 5 minutes. Reaction 
master mixture was prepared as the following:  
Components Concentration 
5x GoTaq Reaction Buffer 1x 
MgCl2  1.5 mM 
PCR Nucleotide Mix 0.5mM 
RNasin® Ribonuclease Inhibitor 20 U 
GoScript™ Reverse Transcriptase 1 μl 
Water  
Total 10 μl 
 
Then, 10 μl of reaction master mixture was added to the ice-cold template and gently mixed 
to form 20 μl/reaction. The final reaction mixture was sit for 5 minutes at room temperature 
and then incubated on a heatblock for 90-120 minutes at 42oC and 15 minutes at 70oC. The 
cDNA products were diluted 1 in 2.5 by the addition of 30μL of ultra-pure water before use. 
Negative controls with two sample of i/a none-GoScript™ Reverse Transcriptase sample and 
ii/a none-RNA sample were included for every cDNA synthesis procedure. 
2.2.4. Real time PCR (PCR) 
Each PCR reaction mix contained 1 μL of cDNA (from cDNA synthesis), 1x GoTag Green 
(Promega, M7122), 0.5 μM forward and reverse primers. PCR condition for each reaction is 
listed in Table 2.2.1.  
PCR products were loaded on 2% Agarose gel (Promega, Ref: V3121) containing 1 μL 
SYBR Safe DNA dye (Invitrogen, Ref: S33102). Separation of PCR was performed in TAE buffer 
(recipe below) and observed under UV in the Bio-rad Chemidox XRS Imager.  
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Table 2.2.1: General conditions for real time PCR examination 
 
 
 
 
 
 
 
TAE buffer: 
Components  Concentration 
Tris-Base 40mM 
Acetic acid 20 mM 
EDTA 1 mM 
 
2.2.5. Quantitative real time PCR (qPCR) 
qPCR for each sample was run in triplicates (3 reactions/sample/gene) in a Roche Light 
Cycler 480 II. Data were collected by LightCycler 480 program version 1.5.1.62.SP3. For each 
reaction, 1 μL of cDNA from each sample (from cDNA synthesis) was mixed with 0.5 μM 
forward and reverse primers in 12.5 μL GoTaq® qPCR Master Mix (Promega #A6001). PCR 
conditions were optimised for different genes and will be described where applicable. 
General condition is described in table 2.2.1. 
Table 2.2.2: General conditions for qPCR examination 
Denaturation 95oC for 15mins 
Cycling  
x40 cycles 
95oC for 15 seconds 
55oC for 20 seconds** 
72oC for 20 seconds 
Melting 95oC for 1 minute 
50oC for 1 minute 
95oC continuous 
Cooling 40oC for 2 minutes 
 
** for pluripotent marker genes, this was set at 40 seconds 
Denaturation 95oC for 1 mins 
Cycling  
X25 cycles 
95oC for 30 seconds 
55oC for 30 seconds 
74oC for 30 seconds 
Melting 95oC for 1 minute 
50oC for 1 minute 
95oC continuous 
Cooling 40oC for 2 minutes 
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2.2.6. Statistical analysis of qPCR data 
Ct values were collected as raw data. Raw data were then cleaned to exclude outliner 
and curated. Ct values were collected from each gene were normalised to the house keeping 
gene Beta-actin using qGene method (Simon, 2003). Mean normalised expression values 
were used for statistical analysis. Statistical analysis was done in Graphpad Prism program 
version 6.05. Mean normalised expression (MNE) values were used as the inputs to perform 
t-test to compare the gene expression in different treatment or pluripotent states to primed 
(Serum + LIF) ES cells. The values were set up for paired-ratio 2-tailed t-tests (test the fold 
change of each treatment to the control primed ES cells). Extended analysis included paired 
2-tailed t-tests, which looked at the absolute difference in gene expression. Ratio- and 
difference statistical analyses of qPCR data provide different aspects to view the data. Graphs 
were generated based on the mean of MNE values for each gene in each cultivation condition. 
Error bars were generated from standard error of the mean (SEM) of all replicates of the same 
condition. 
2.3. Flow cytometry 
2.3.1. Reactive oxygen species (ROS) measurement 
D3 ES cells were maintained in either 2i+LIF or Serum + LIF conditions before being 
seeded on a gelatine coated 24-well plates at the density of 3.2-4x105 cells/well in 500 μL of 
similar media. The cells were incubated at 37oC, 5% CO2 for 24 hours before ROS 
measurement occurred. 30 minutes before ROS measurement, cells were checked for the 
confluence of 80-100%, if media turned yellow, cells were disqualified for further procedure. 
Qualified cells were incubated with 7.5 μM of MitoSOX Red dye (Life technologies, M36008) 
for 30 minutes. After this incubation, cells were washed 2 times in warm PBS and detached 
with 100 μL trypsin for 2 minutes. Trypsin was gently removed to prevent cell loss and 500μL 
of imaging buffer containing 10% FBS and 0.1 mM βME in DMEM, no phenol red (Life 
technologies, 21063029) was added to suspend single cells. All cells were transferred into 
FACS tubes and ready to be analysed by flow cytometry. Beckman Coulter CyAn ADP flow 
cytometry machine was used at single tube sample mode to analyse cell samples. Data were 
collected by Summit program version 4.3. The protocol of detection input was set for 
Threshold of 13% and Gain of 1.0. Forward scatter (FS) was acquiring peak and area with no 
voltage specificity. Side scatter (SS) was acquiring Peak and Area at the voltage of 450. 
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Channel FL-3 was set for MitoSOX Red to acquire Peak, Area and Log at the voltage of 595 and 
FL-6 was set for DAPI at the voltage of 490. All samples were analysed by the machine and 
sample flow was set at medium speed. The maximum of 125000 cells (or also called events) 
were detected and features were recorded for final analysis. 
For time point measurement of ROS production in response to proline, D3 ES cells 
were grown for 24 hours. Proline was added to the cells at 24, 12, 6, 3, 1 and 0.5 hours before 
staining with 7.5 μM MitoSOX Red dyes. Three technical replicates were used for each time 
points. At least three independent experiments at different cell passages were done for each 
time point. Technical control included samples with no staining and single colour staining. 
Untreated ES cells were used as biological controls.  
N-acetyl-cysteine (NAC), glutathione (GSH) and vitamin C (Vit C) were used as 
antioxidants. These antioxidants were added to the cells 4 hours before ROS measurement. 
3, 4-Dehydroproline (DHP) and L-Tetrahydro-2-furoic acid (THFA) were used as Prodh 
inhibitors. These inhibitors were added to the cells at the same time with proline. The 
concentration of use for each chemical is summarised in Table 2.3.1. 
Table 2.3.1: The concentration of different treatments to ES cells 
 
 
 
 
 
2.3.2. Mitochondrial membrane potential (MMP) measurement  
 Mitotracker Green was used to measure MMP in ES cells at the same time with ROS 
measurement. At the same time with Mitosox Red addition, 3 mM Mitotracker Green 
(M7514) was added to a random technical repeat of each treatment. The cells were then 
analysed by flow cytometry machine. Mitrotracker Green was detected in FL-1 channel at the 
voltage of 500 to acquire the Peak, Area and Log of each event. Four independent 
experiments were repeated for statistical analysis. Single colour samples were included for 
technical control and compensation.  
  Concentration 
NAC 50 μM 
GSH 1 mM 
Vit C 500 μM 
DHP 200 μM 
THFA 200 μM 
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2.3.3. Analysing Flow cytometry data 
Data acquired by Summit program was analysed in Kaluza Analysis program version 
1.5a. Gating from side scatter (SS) and forward scatter (FS) parameters allowed the selection 
of cells acquisitions (or also called “Events”). Events of the same size and granular complexity 
represented “ES cells” population. “ES cells” were further selected for “Singlets” based on 
their area as larger area were associated with doublets or cell clumps. “Singlets” cells were 
gated for “DAPI negative” population to select live cells. Live cells (DAPI negative) were 
analysed in a histogram graph that was set for count of cells and MitoSOX Red parameter. 
Two population of ROS was gated in the histogram to analyse cells with high (ROShi) and low 
(ROSlo) ROS level. An example of gating strategy is demonstrated in Figure 2.3.1. If cells were 
double stained with MitoSOX Red and Mitotracker Green, further gating was required (Figure 
2.3.2). ROShi and ROSlo cells were analysed in a new histogram under the green parameter for 
statistical numbers (Figure 2.3.3).  
From the histograms, information about the number of cells based and their 
fluorescent intensity were accessed. Based on the data provided by Summit, Kaluza program 
provided statistic values that could be used to identify the characteristics of MitoSOX Red (or 
ROS production) from each sample. Among these values, percentages of gated populations, 
geometric mean fluorescent intensity, mode (largest population among the events) and the 
minimum and maximum values of all gated events were accessed for further analysis and 
comparisons in statistical analysis. Definitions of statistical values are to be referred to 
“Instructions for Use” from Kaluza Flow cytometry analysis software (ref. “Instructions for Use 
- Kaluza Flow Cytometry Analysis Software”, A75667AC, September 2011, Manufactured by 
Beckman Coulter, Inc. 250 S. Kraemer Blvd. Brea, CA 92821). The manual can be accessed 
from on the manufacturer website. 
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A. Gating all events for ES cell population. B. ES cells gated for singlet cells. C. Gating from singlets to 
DAPI negative or live cells (DAPI neg). D. ROS production from live cell was visualised and quantitated 
for MitoSOX Red parameter. 
2.3.4. Flow cytometry compensation 
Compensation was performed to prevent the spill over of fluorescence from one 
channel to another, which may cause auto-fluorescence in a channel without actual staining. 
Red single colour control was first adjusted for the spill over to green channel. This adjustment 
was applied to Green single colour control, where further adjustment was applied on the top 
of the previous one to prevent the spill over from green to red channel. These adjustments 
were then applied to all samples. Figure 2.3.2 showed the differences of single- and double 
colour staining before and after compensation. Table 2.3.1 showed the compensation matrix 
generated from Figure 2.3.2. Compensation was repeated for each biological replicate or each 
independent experiments.
Figure 2.3.1. Flow cytometry plots and gating strategy for analysis and statistics.  
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Primary gating was performed similarly to Figure 2.3.1. Red single colour was compensated for the spill-over of fluorescence to the green 
channel. This compensation was applied to Green single colour control for further adjustment. Blue circles showed where spill-over appeared, 
red circles showed spill-over was corrected. All adjustments were combined in a matrix to apply to double colour staining.
Figure 2.3.2: Flow cytometry compensation.  
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Table 2.3.2. Compensation matrix applied to all samples in one experiment. 
Auto fluorescent (%) FL1 FL3 FL6 FL8 
FL1 100 1.1 0 0 
FL3 11.89 100 0 0 
FL6 0 0 100 0 
FL8 0 0 0 100 
 
 
 
Gated ROSlo and ROShi populations were overlayed under Mitotracker Green parameter. Overlay 
histogram was used to generate statistical numbers for Green fluorescence. 
 
 
  
Overlay 
Figure 2.3.3. Mitochondrial membrane potential of ROSlo and ROShi populations 
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2.3.5. Statistical analysis of flow cytometry data 
GraphPad Prism version 6.05 were used for statistical analysis. The comparison between two 
conditions was performed in paired 2-tailed t-tests. Paired-difference and paired-ratio were 
acquired to examine the different and fold change difference in each treatment when compared to 
controls. Graphs were generated from the mean values from all replicates. SEM (standard error of 
the mean) was used to generate error bars.  
2.4. Western Blot 
2.4.1. Buffer preparation 
i. Hypotonic buffer 
Components Concentration 
HEPES 10 mM 
KCl 10 mM 
EDTA 0.1 mM 
EGTA 0.1 mM 
Protease inhibitor cocktails 1U (freshly added before use) 
DTT 1 mM  
 
ii. 4x Laemlli buffer 
Components Concentration 
Tris HCl pH 6.8 50mM 
SDS 2% 
Glycerol 10% 
 
iii. SDS-PAGE running buffer – Freshly made and cooled before use 
Components Concentration 
Glycine 25 mM 
Tris base 192 mM 
SDS 0.1% 
 
iv. Transferring buffer 
Components Concentration 
Glycine 25 mM 
Tris base 192 mM 
Methanol 20% 
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v. Washing (TBST) buffer 
Components Concentration 
Tris pH 7.4 50 mM 
NaCl 150 mM 
Tween 20 0.5% 
  
vi. Blocking buffer 
5% skim milk in PBST  
2.4.2. Protein extraction 
 Cells were collected into Eppendorf tubes and washed with PBS. Cell pellets were snap 
frozen in liquid nitrogen and stored at -80oC. Cells were lysed in ice cold hypotonic buffer lysis buffer. 
After 15 minutes incubation on ice, 1/10 volume of 10% IGEPAL CA-630 (Sigma, I8896) was added 
to the lysed cell, vortexed for 10 seconds and returned on ice. To ensure full protein extraction, 
lysed cells were sonicated for the total time of 30 seconds (3x 10 second intervals). Cell lysates were 
inverted for another 30 minutes on a rotator in the 4oC cold room. Cell lysates were then centrifuged 
at 15000 rcf at 4oC to remove cell debris. The supernatants containing soluble proteins were 
transferred into new labelled Eppendorf tubes. After the quantification step of protein 
concentration, cell lysate was diluted to the concentration of 2mg/mL in Laemlli buffer and aliquots 
were immediately stored at -20oC for short term use and at -80oC for long-termed use.  
2.4.3. Protein quantitation 
Protein quantitation was performed using a Pierce BCA protein assay kit (Thermo Scienctific, 
Ref: 23227) following the protocol provided by the manufacturer. Accordingly, 5 μL of each lysate 
was diluted into 20 μL of PBS (1:5 dilution). Then, 8 μL of each dilution was measured in duplicates 
in a 96-well clear plate at the same time with standard protein samples. Each well were mixed with 
64 μL of 50:1 mixture of Reagent A – Reagent B. The plates were then incubated at 37oC for 5 
minutes before detection for quantitation. Colours of protein-reagent mixture were absorbed at 
550 nm in the Spark 20M Tecan plate reader. 
2.4.4. SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
Before loading on the gel, fresh 10mM DTT and 5% βME were added to the protein lysate 
and boiled for 10 minutes at 90oC. Cooled 20 μg protein lysate from each sample was loaded on 12% 
acrylamide gel (Bio-rad, Ref: 546-1045) at the same time with pre-stained protein ladder (Thermo 
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Fisher, Ref: 26619). The. SDS-PAGE was performed in cold running buffer using Bio-rad 
electrophoresis equipments at room temperature at 160 V for 50 minutes. Protein from the gel was 
then transferred onto a nitrocellulose membrane (Thermo Fisher, Ref: 88018) using a transferring 
cassete from Bio-rad. The cassete was then merged into cold transferring buffer. Transfering was 
performed using Bio-rad transferring tank in a cold room at 4oC at 110 V for 65 minutes. After 
transferring, the membrane was washed twice (5 minutes/each) in TBST buffer and then incubated 
in blocking buffer for an hour at room temperature on a orbital shaker at low speed.  
2.4.5. Blotting the proteins and visualisation  
 The membrane was incubated with primary antibodies (listed in Table 2.4) in 1:5 dilution of 
blocking buffer overnight at 4oC with regular mixing. The membrane was then washed 3-4 times in 
TBTS (5 minutes/each) and incubated again in HRP conjugated secondary antibodies (listed in Table 
2.4) for an hour at room temperature with regular mixing. Finally, the membrane was washed 3-4 
times in TBST (5 minutes/each) and incubated with ECL mixture (Amersham ECL Western Blotting 
Analysis sytem, Ref: RPN2109) for 3 minutes. The membrane was visualised under chemluminescent 
exposure in the AI600 Amersham imager.  
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Table 2.4.1. List of antibodies 
 Antibodies Company Cat# Lot# Dilution 
      WB IF Flow cytometry 
Primary Ab 
Rabbit polyclonal - Anti-Mouse Oat Abcam Ab137679 
GR145275-
29 
1:1000 
1:500/ 
1:750 
  
Rabbit polyclonal - Anti-Mouse Prodh Abcam Ab93210 GR293737-1 
1:100/  
1:200 
1:100/ 
1:200 
  
Mouse monoclonal - Anti-COX IV Abcam Ab33985 -  1:500 1:500   
Secondary Ab HRP-conjugated Goat polyclonal - Anti-Rabbit DAKO P0448 000072118 1:5000     
Alexa Fluor 488-Goat Anti-Rabbit IgG Invitrogen A11034 760000   1:1000   
Alexa Fluor 594 Goat Anti-Mouse IgG Invitrogen A11032 621333   1:1000   
Dyes DAPI (4′,6-Diamidine-2′-phenylindole dihydrochloride) Sigma Aldrich 32670 -   1 μg/ml 1 μg/ml 
  MitoSOX Red Life Technologies M36008      5 mM 
  MitoTracker Green Life Technologies M7514      3 mM 
  Hoechst Life Technologies H3570     1 μg/ml   
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2.4.6. Western Blot quantitation 
 Data collected from Amersham Imager AI600 were analysed either from provided program 
conjugated with the Imager program or by a separated program, ImageQuantTL 1D v8.1. Protein 
lanes were manually aligned and bands was manually or automatically detected. Normalisation 
were performed by to GAPDH bands. Normalised values or Normalised volume values were 
collected for statistical analysis.  
2.5. Immunocytochemistry 
2.5.1. Immunocytofluorescence 
Cells were seeded either on a 0.1% gelatine coated black 96-well plate (BD Falcon, Ref: 
353219) or an 8-well imaging chamber (Sigma Aldrich, Ref: C7182-1PAK) and incubated for growth 
in up to 12 hours (if in imaging chamber) and 24 hours (if 96-well plate). Cells were collected and 
washed three times in cold PBS and then fixed with 100% methanol for 10-20 minutes at -20oC. After 
three washes (5 minutes/wash) in cold PBST on a shaker at a medium speed, PBST containing 10% 
serum was added to the cells to perform antigen blocking. In this blocking step, cells were incubated 
for 1 hour on a shaker at a medium speed. After blocking buffer is removed, cells were immediately 
incubated in primary antibody on a shaker in a 4oC room overnight. All antibodies were prepared in 
PBST and 1% serum and the working concentrations are stated in Table 2.2. The next day, cells were 
washed three-to-five times and incubated with secondary antibodies and DAPI for an hour on a 
shaker at room temperature and are covered by a dark chamber. Finally, cells were washed three-
to-five times with cold PBST. Cells were kept in PBST and protected from light at 4oC for microscopic 
examination. If cells were grown in imaging chamber, after incubation with secondary antibodies 
and DAPI and washing, the chamber wells were detached. Excessive water was tap dried on a paper 
towel and cells were covered with a thin layer of 20-50 μL of Fluoroshield (Sigma, F6182) followed 
by a glass coverslip.  
2.5.2. Live cell imaging 
All live cell imaging was performed under the inverted Leica DMIRB microscope. For 
examination of ROS visualisation in live cells, cells were plated at the rate of 2 x 105 cells in 100 μL 
medium in each well of an optical 96-well plate (BD Falcon #353219), coated with 0.1% gelatine. 
Similar treatments and ROS dyes were applied similarly to flow cytometry method. After that, media 
were removed, and the cells were gently washed twice with PBS and then covered in imaging buffer 
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(See section 2.3.1). Hoechst (Life Technologies, H3570) was used as per manufacturer’s procedure 
in imaging buffer. Imaging was performed under the inverted Leica DMIRB microscope. Images were 
taken by NIS v.6.4 program. 
2.6. ATP assay 
2.6.1. Enzyme and substrate preparation 
Enzyme luciferase solution  
Components Concentration 
Firefly luciferase 10 μg/ml 
DL-dithiothreitol (DTT) 75 μM 
Magnesium chloride (MgCl2) 6.25 mM 
EDTA 625 μM 
Bovine serum albumin (BSA) 1 mg/ml in 25 mM 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) buffer, pH 7.25 
 
Substrate luciferin solution 
Components Concentration 
D-luciferin 600 μM 
DTT 75 μM 
MgCl2 6.25 mM 
EDTA 625 μM 
BSA 1 mg/ml in 25 mM HEPES buffer, pH 7.25 
 
Enzyme-substrate solution:  
Enzyme and substrate solution was mixed at 1:1 ratio and incubated at room temperature 
for 10 minutes before use.  
Lysis buffer 
Components Concentration 
EDTA 4 mM 
Triton X-100   0.2 % 
 
2.6.2. ATP detection and quantitation 
Cells were seeded in a 96-well plate at 1x104 cells/well in 100 μl growth medium. After 24-
hour incubation under standard conditions, cells were washed three times in 100 μl PBS and then 
lysed in 100 μl lysis solution for 5 minutes at room temperature (RT) on an orbital shaker at medium 
speed. After that, 10 μl of cell lysate was prepared in triplicates in a white opaque U-bottom 96-well 
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plate with standard ATP samples (for standard curves). Immediately before measurement, 90 μl of 
1:1 enzyme-substrate solution was added on to each well. Luminescence produced from the ATP-
dependent oxidation of luciferin by luciferase enzyme was in the Spark 20M Tecan plate reader. An 
ATP standard curve was generated to quantitate the level of ATP (μM) produced by each sample. 
This measurement was then normalised to the total protein (see section 2.5.3) of each sample to 
allow comparation between different treatments and cell types.  
2.7. NADP/NADPH assay 
 Cells were seeded in duplicates in 24-well plates at 4x105 cells/well and incubated in 
standard conditions. After 24 hours, cells were washed 2 times in PBS and lysed in 200 μl lysis buffer 
(recipe in section 2.7.1). Lysing process was performed quickly at room temperature by vigorously 
pipetting the cells in cold lysis buffer. Then 100 μl of lysate was transferred into a fresh tube 
containing 22 μl cold perchloric acid 2M (PCA) for deproteinisation. The mixture was vortexed for 5 
second at full speed and incubated on ice for 5 minutes. The mixture was then spun at 4oC at 13000 
rcf for 2 minutes to separate precipitated protein. Then, 100 μl of the aqueous solution was 
transferred into a fresh tube containing 25 μl KOH 2M and 3 μl KOH 0.1M and shortly vortexed for 
neutralisation of PCA. No incubation was required for this step. The solution was then spun at 4oC 
for 15 minutes at 1300 rcf for the removal of precipitated PCA. After that, 100 μl of the final solution 
was transferred into a fresh tube. From this tube, 30 μl of solution was added in duplicates onto a 
black-wall, clear and flat bottom 96-well plate (BD Falcon, Ref 353219). Each well was then added 
with 30 μl of mixture of enzyme-substrate solution (Abcam, Ref: ab186033) prepared as suggested 
by the manufacturer. The plate was incubated at room temperature for 10 minutes on an orbital 
shaker at medium speed. Colours from the reaction of NAPD with the enzyme-substrate solution 
were measured at the absorbance wavelength of 460 nm every 5 minutes for 8 consecutive times 
in the Spark 20M Tecan plate reader. 
2.8. Cell proliferation assay 
 Cells were seeded in triplicates in four 24-well plates at 1x104 cells/well in 500 μl growth 
medium. After 24 hours (day 1), plate 1 was collected to set up basal number. Cells were washed 
twice and then trypsinised into 500 μl PBS. Cells were counted on a counting chamber and set up as 
a baseline. On day 2, plate 2 were collected similarly to plate 1 and cells in plate 3 and 4 were fed 
with fresh media. Similar processes were continued on day 3 and 4 until all plates were collected. 
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Collective cell counts were used to generate the proliferation curves for different cell types and 
treatments. Proliferation rate was calculated as previously described  (Sherley et al., 1995). 
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Chapter 3 Proline metabolic enzyme family is 
differentially expressed in different pluripotent states of ES 
cells 
3.1. Introduction 
  In mammalian cells, proline metabolism is a key node in the metabolic network that 
links mitochondrial activities to cytosolic redox reactions and is involved in cell programming 
and decision making (Washington et al., 2010, Casalino et al., 2011, Elia et al., 2017, Liu et al., 
2015, Liu et al., 2012). Studies of proline metabolism suggest that proline metabolism is 
variable in different cell types and the proline metabolic switch is required as the cells reach 
a particular state (Adams and Frank, 1980, Elia et al., 2017, Liu et al., 2015, Phang et al., 2012). 
However, the purposes of this variation in relation to cell growth and functioning are not well 
characterised. In cancers, metastatic cells favoured the consumption of exogenous proline 
when compared to attached cells (Elia et al., 2017). It is important for tumour cell growth and 
T lymphocyte activation to switch from free proline catabolism to proline biosynthesis using 
glutamine and ornithine resources (Wang et al., 2011, Liu et al., 2015). These studies raise the 
possibility that different proline metabolic processes are important to cell fate determination 
and can be regulated in different states of the cell development. However, the regulation of 
proline metabolic switches remains under-investigated and the precise mechanism of their 
regulatory effects go unresolved. 
Embryonic stem (ES) cell differentiation is a cell development system in which proline 
metabolism plays a regulatory role (Comes et al., 2013, Washington et al., 2010, Casalino et 
al., 2011, Tan et al., 2016a, Tan et al., 2011). Studies have shown that the differentiation of 
primed ES cells in response to proline is specific to L-proline (Washington et al., 2010, Tan et 
al., 2011). The regulation of the proline primary transporter, Snat2, was found to be higher in 
primed- compared to naïve ES cells and proline uptake was required for ES cell differentiation 
(Tan et al., 2011). The involvement of the proline oxidation enzyme, Prodh, was suggested 
(Casalino et al., 2011, Tan et al., 2016a), however, it is not known whether the regulation of 
Snat2 is correlated to Prodh activity in proline-induced ES cell differentiation. The expression 
of Snat2 is varied in different cell types and may be dependent on the condition of the 
environment (Velazquez-Villegas et al., 2014, Jones et al., 2006). In human trophoblast cells, 
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the expression of SNAT2 is regulated via the active STAT3 signalling pathway, which is 
triggered by the cytokine IL-6 (Jones et al., 2009). The reduction of SNAT2 expression was 
observed in STAT3 knockdown cells, suggesting that STAT3 is directly upstream of SNAT2 
(Jones et al., 2009, Borg et al., 2015). The decreased level of phosphorylated STAT3 and SNAT2 
expression was correlated with lower SNAT2-specific amino acid levels that were transported 
into the cells (Jones et al., 2009), which illustrates the relationship between STAT3 activation 
and SNAT2 function in cellular amino acid transport. In human ES cells, the phosphorylation 
activation of STAT3 is mediated by the LIF receptor signal via the binding to exogenous LIF 
(Daheron et al., 2004). The presence of LIF in ES cell culture is important to the cell self-
renewal, and LIF is associated with STAT3 activation in maintaining ES cells (Daheron et al., 
2004, Morgani and Brickman, 2015, Onishi and Zandstra, 2015). However, the role of LIF in ES 
cell culture and the contribution to SNAT2 expression has not been addressed. 
Carbognin et al suggested that the proliferation of ES cells, which are cultured in 2i 
conditions and LIF, required Stat3 activation that led to increased mitochondrial respiration 
(Carbognin et al., 2016), and may be a “spare capacity” in addition to the basal glycolysis 
energy supply under LIF/Stat3 signalling (Carbognin et al., 2016). It is questionable if LIF/Stat3 
signalling and Snat2 are correlated to enhance mitochondrial respiration by increasing the 
amino acid uptake into the cells.  In fact, the LIF/Stat3 pathway is important for ES cells in the 
reprograming to naïve pluripotency (van Oosten et al., 2012, Tang et al., 2012). Snat2 
expression was found to be low in naïve ES cells and upregulated in the primed state (Tan et 
al., 2016b). The observation of human embryos transcriptome revealed that SNAT2 
expression was lower in cells in the morulae state than cells in the blastocysts (Vassena et al., 
2011). In mice preimplantation embryos, Snat2 expression was lower in cells at early 
embryonic day 3.5 (E3.5i) compared to those at the later time E3.5 (E3.5ii) (Tan et al., 2016b). 
It is possible that the regulation of the proline uptake is important for pluripotent cells during 
development. Questions then arise as to whether the variation of Snat2 expression is 
correlated with the activities of proline metabolism in the cells, given that Snat2 is required 
for proline uptake in ES cells (Tan et al., 2011). That leads to the hypothesis that proline 
metabolic enzymes are also regulated in different pluripotent states of ES cells: naïve, primed 
and primed + proline. In this study, we defined primed state ES cells as the cells that were 
derived from the inner cell mass of the embryo and were released from 2i containing media. 
Chapter 3  Van T. T. Nguyen 
53 
 
This primed state must be distinguished from the primed state that is normally assigned to 
epiblast-derived stem cells (EpiSCs) or epiblast-like cells (EpiLCs), which are at the later state 
along the pluripotent lineage specification.  
The proline metabolic enzyme family has been nominated as a new target for the 
treatment of cancers and other pathological diseases such as stroke, neurodegeneration, and 
diabetes, due to the fact proline metabolic reprograming is known as a requirement for the 
cell changes in the adaptation to new functions and to support the cell growth in 
tumorigenesis (Elia et al., 2017, Liu and Phang, 2012, Liu et al., 2012, Liu et al., 2015, Wu et 
al., 2011). Understanding the regulation of proline metabolism via its enzyme family in a 
normal cell development system such as ES cells could advance future research efforts in 
cancer treatments. To examine the regulation of proline metabolic process in ES cells, this 
chapter will determine the expression of the proline enzyme family involved in proline 
transport, catabolism and biosynthesis. This will assist our understanding of the proline 
metabolic processes that are associated with ES cell pluripotency. Genes that are involved in 
these processes, including Slc38a2, Prodh, Pycr1, Pycr2, Pycrl, Oat, Aldh4a1, Aldh18a1 and 
P4ha1 (Figure 3.1.1) will be investigated for their expression in ES cells of different pluripotent 
states.  
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SNAT2 (Slc38a2): transporter sodium-dependent neutral amino acid transporter-2. PRODH 
(Prodh): proline dehydrogenase. P5CR (Pycr1): P5C reductase. P5CDH (Aldh4a1): P5C 
dehydrogenase. OAT (Oat): ornithine aminotransferase. P5CS (Aldh18a1): P5C synthase. 
P4HA1: Prolyl 4-hydroxghovbylase subunit alpha 1 (P4ha1) P5C: ∆-pyrroline-5-carboxylate. 
ROS: reactive oxygen species. GSA: glutamic-gamma-semialdehyde. 
 
  
  
Figure 3.1.1. Proline metabolic pathway in mouse ES cells.  
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3.2. Results 
3.2.1. Morphological investigation of ES cells in different pluripotent states and 
culture conditions 
 After 4 days in culture, the morphology of D3 and WA30 cells in different pluripotent 
states were observed under the microscope. Morphological heterogeneity was observed in 
all conditions and from both cell lines. However, each pluripotent state displayed distinct 
characteristics related to the major populations of those cell states (Figure 3.2.1.A and B).  ES 
cell colonies growing in 2i+LIF conditions reflected the naïve pluripotent state, which were 
round, compacted and domed with defined edges. ES cells in Serum+LIF conditions were 
partially flattened and the edge of each colony became irregular in shape. With the addition 
of proline, ES cells were more flattened and showed irregular colonies. The morphology of ES 
cells in each condition were matched to the descriptions in the literature, thus confirming 
that ES cells were at the right pluripotent state (Ying et al., 2008, Washington et al., 2010). ES 
cells in 2i conditions exhibited similar patterns of morphology between LIF and non LIF 
conditions. However, non LIF conditions appeared to supress ES cell growth in 2i. Increased 
cell death and cell float were observed in both D3 and WA30 cell lines cultured in 2i–LIF 
conditions (Figure 3.2.1.C and D), suggesting that ES cells require LIF for their maintenance 
and self-renewal. The release from 2i appeared to be stressful to WA30 ES cells, which 
resulted in increased cell death after 4 days (Figure 3.2.1.D). The addition of proline to these 
cells further stressed the cells and inflated cell death rate.  
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Cell morphology was observed after 4 days in culture. A. D3 and B. WA30 ES cell lines in 3 
conditions: 2i+LIF, Serum+LIF and Serum+LIF+Pro. C. D3 ES cells in 2i+/-LIF. D. Overlooking 
WA30 ES cells in 4 conditions showing white dead cells detached from the adhered colonies. 
In A and B, scale = 100 μm. In C and D, scale = 200 μm. 
 
 
  
 
Figure 3.2.1. Morphology of ES cells in different culture conditions 
D 
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3.2.2. The expression of proline metabolic enzymes in ES cells was subject to 
regulation in different pluripotent states and different culture conditions  
 To investigate proline metabolism in ES cells, the key enzymes of the proline metabolic 
reaction chain were separated into three different processes: biosynthesis, transportation, 
and catabolism. The primary proline transporter expression, Slc38a2, was examined in 
different ES cell states and conditions in both D3 and WA30 cell lines. Given that Slc38a2 gene 
expression is correlated with the expression of Stat3 protein (Jones et al., 2009) and Stat3 is 
affected by the presence of LIF (Liu et al., 2013, Onishi et al., 2014), it was questioned if the 
presence of LIF could affect Slc38a2 gene expression. However, only naïve ES cells could be 
maintained without the addition of LIF and therefore, to examine the effects of LIF in ES cell 
culture, only naïve ES cells were cultured with or without LIF in 2i. Examination of Slc38a2 
expression was performed in 2i+/-LIF conditions in both D3 and WA30 cell lines. In the D3 ES 
cell line, there was a small but significant increase in Slc38a2 expression in the 2i+LIF condition 
when compared to the 2i-LIF condition (Figure 3.2.2.A). However, the ratio of Slc38a2 
expression between the two conditions was not significantly different, suggesting that the 
addition of LIF only added a shift to Slc38a2 expression in 2i medium but did not create a 
major effect upon the expression of the gene. WA30 cells did not exhibit any changes in 
Slc38a2 expression in 2i+/-LIF conditions. When examined in different pluripotent states, 
Slc38a2 was expressed higher in primed, but not in the naïve state of ES cells in both D3 and 
WA30 lines (Figure 3.2.2.B). This result is consistent with previous findings in the literature 
(Tan et al., 2016b). In D3 ES cells, the addition of proline reduced Slc38a2 expression after 4 
days of culture (Figure 3.2.2.B). However, there was no significant changes in Slc38a2 
expression observed in WA30 ES cells with the addition of proline.  
The expression of the proline catabolic enzymes was investigated in different 
pluripotent states to confirm whether proline metabolism is similar in the cells of all 
pluripotent states. The proline catabolic process includes the oxidation of proline to P5C by 
Prodh. And P5C is further converted into glutamate by the enzyme P5C dehydrogenase 
(P5Cdh or Aldh4a1). After all, proline from the original source is expected to be converted to 
different metabolites and synced to other sites of cell activities. The enzyme Oat is 
bidirectional and can convert P5C into ornithine to remove proline out of the proline cycle. 
The direction of Oat catalytic activity is largely dependent on the environment; however, it 
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was suggested that Oat may have more potential in breaking down ornithine to form P5C 
(Ginguay et al., 2017). Therefore, in this study, Oat is classified as a proline biosynthetic 
enzyme for further examination. Alternatively, the incorporation of proline into peptides and 
then proline hydroxylation by prolyl-hydroxylase (P4ha1) enzyme also removed free proline 
from the reaction chain. These key enzymes: Prodh, P5Cdh and P4ha1 were examined for 
their gene expression. Both D3 and WA30 cell lines showed a higher expression of Prodh in 
the primed than naïve ES cells (around 2- to 3 folds) (Figure 3.2.2.C). There is no difference in 
the expression of Aldh4a1 in all pluripotent states. P4ha1 was highly expressed in the naïve 
state of D3 but not WA30 ES cells. No literature has suggested similar findings.  
Proline biosynthesis from ornithine and glutamate can be performed by 3 different 
reactions, including the conversion of ornithine, and glutamate to P5C/GSA, which is then 
reduced to synthesise proline. P5C/GSA can be utilised either from ornithine by the enzyme 
Oat and from glutamate by the enzyme P5C synthase (P5Cs or Aldh18a1). P5C, but not its 
interconversion form, GSA, is reduced by the P5C reductase family (P5Cr or Pycr) to form 
proline. The examination of these genes showed that naïve ES cells significantly expressed 
higher Oat (~3 folds) than primed ES cells (Figure 3.3.2.D). No difference in the expression of 
three isoforms of the Pycr enzymes, Pycr1, Pycr2 and Pycrl was observed in D3 ES cells, 
however, Pycr2 was reduced in primed WA30 ES cells. While the addition of proline into 
primed ES cells significantly decreased the expression of Aldh18a1 in D3 cells, only a minor 
reduction was observed in WA30 cells (Figure 3.2.2.D). This result has not been shown 
elsewhere in the literature.  
In summary, key proteins and enzymes of the proline metabolic reaction chain were 
found to be differentially expressed in different pluripotent states of ES cells. This was 
replicable in both D3 and WA30 cell lines. LIF only had a minor effect on the expression of 
Snat2 in 2i medium in D3 ES cells and did not have any effects on any other genes examined 
in this experiment. Except for Prodh and Oat, the expression of other proline metabolic 
enzyme genes might have been subjected to the long-term maintenance of the cells and they 
were more sensitive to the variation in culture in the WA30 cell line when compared to D3 ES 
cells. Due to the robust differential expression in naïve and primed ES cells, Prodh and Oat 
were selected for protein expression validation. These findings are novel and may need 
further validation with different cell lines and culture conditions.  
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A. Proline transporter, Slc38a2 expression in 2i+/-LIF conditions in D3 and WA30 cell lines. B. Slc38a2 
expression in different pluripotent states of ES cells. C. Proline catabolic enzyme expression. D. Proline 
biosynthesis enzyme expression. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, n=4-6. Error bar = 
SEM.  
D 
Figure 3.2.2. Gene expression of the proline metabolic enzymes. 
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3.2.3. Protein expression of Prodh and Oat confirmed their gene expression in 
different pluripotent states of ES cells 
 To confirm the gene expression results, Prodh and Oat proteins were examined by 
Western blot and immunofluorescence. In these experiments, only D3 ES cells were used. 
Western blot results illustrated that both Prodh and Oat proteins appeared with two isoforms 
in ES cells. These isoforms are here called large and small isoforms as based on their sizes. 
Only the functional isoforms of each protein (Prodh ~ 68 KDa and Oat ~ 49 KDa) provided by 
Uniprot database and also appeared in the liver and kidney samples, were used to compare 
for the differential expression of each protein. The other isoforms were unidentified by the 
Uniprot database and were not obvious in both mice liver and kidney samples (Data not 
shown). The protein expression of functional Prodh (68 KDa) was significantly higher (~ 9 
folds) in primed ES cells when compared to their naïve counterparts (Figure 3.3.3.A). There 
was no significant difference in the large Prodh isoform (93 KDa) within the pluripotent states 
(Data not shown). The functional Oat enzyme (49 KDa) was expressed at around 37-fold 
higher in naïve- than primed ES cells, either with or without proline addition (Figure 3.3.3.B). 
No significant difference was observed in any comparison with large isoform of Oat (59 KDa). 
No follow up experiment was performed to identify the isoforms of Prodh and Oat. Possibly, 
they could be the result of unspecific staining of the antibodies in ES cells. The microscopic 
examination of Prodh and Oat protein was performed to identify the subcellular location of 
the proteins. Patchy and punctate staining was observed in both Prodh and Oat 
immunocytochemistry of naïve and primed ES cells. Prodh staining did not show any 
difference in the intensity between naïve and primed ES cells (Figure 3.3.4.A). The 
colocalisation of Prodh with Cox IV, a mitochondrial membrane protein, showed that Prodh 
was present within the mitochondria (Figure 3.3.4.A).  
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A. Prodh. Column B. Oat. **p≤0.01, ***p≤0.001, n=3-6. Error bar = SEM. 
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Small Oat 
Figure 3.2.3. Protein expression of Prodh and Oat enzymes in D3 ES cells. 
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A. Prodh. B. Oat. Arrows: pointing at protein accumulation in the perinuclear/cytosolic regions of the cells. All scales = 50 μm.
50 µm 
Figure 3.2.4. Immunofluorescent images of Prodh and Oat enzymes in D3 ES cells in two pluripotent state: Naïve (2i+LIF) and Primed. 
2i+ LIF 
Primed 
B 
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3.2.4. Pilot study: Image analysis of Prodh staining 
Objectives 
The immunofluorescent examination of Prodh protein in naïve and primed ES cells 
demonstrates signs of distinguished distribution across the cell areas. As Prodh is a mitochondrial 
enzyme and localised into the mitochondria (Figure 3.3.4.A), the differences in Prodh distribution 
are potentially associated with the mitochondrial distribution in ES cells. Mitochondria are dynamic 
organelles and play an important role in regulating cellular homeostasis of PSCs (Lees et al., 2017). 
The changes in the mitochondrial functions and  distribution are known to be involved in PSC 
reprogramming and differentiation (Prowse et al., 2012, Suhr et al., 2010). The pluripotent lineage 
specification describes the natural changes of dynamic pluripotency towards the more committed 
cell states and differentiation (Savatier et al., 2017). Accordingly, there are states that are referred 
to as “no-returning points”, occuring when the cells are committed to a certain pluripotency and a 
distinct differentiation potential. Both naïve and primed ES cells have a full potential for 
differentiation and while primed ES cells are more active to respond to differentiation factors, naïve 
ES cells are distinguished with infinite self-renewal capability in culture (Ying et al., 2008, Nichols 
and Smith, 2012). Previous evidence has shown that ES cells of different pluripotent states such as 
naïve and primed ES cells have distinct metabolic states and mitochondrial profiles (Kolodziejczyk 
et al., 2015). Alterations in metabolic preferences in naïve and primed ES cells are required to 
maintain cell growth and stabilisation (Sperber et al., 2015, Wu and Izpisua Belmonte, 2015) and 
changes in metabolism accommodate ES cells to step into the definitive commitment state such as 
differentiation (Sauer et al., 2000, Schmelter et al., 2006, Kilberg et al., 2016). In a lesser definitive 
ES cell fate transition such as the exit from naïve to primed pluripotent states, no changes have been 
suggested for mitochondrial phenotypes. It is questionable whether a transition in mitochondrial 
phenotype between naïve ES and differentiated cells could be detected. As primed ES cells are ready 
for differentiation, the transition from naïve to enter the primed pluripotency illustrates a dynamic 
change in ES cells that could include some of the mitochondrial infrastructure modifications. In fact, 
perinuclear mitochondrial organisation has been reported in undifferentiated ES cells with the 
dispersion of mitochondria being associated with mitochondrial maturation a characteristic of 
differentiated cells  (Prowse et al., 2012, Lees et al., 2017), but when this event is first observed 
during the pluripotent lineage specification and differentiation process is not known. Detecting the 
transition in mitochondrial properties in different pluripotent states of ES cells will reveal presently 
unknown information about the mitochondrial maturation process in pluripotent lineage 
specification and differentiation. In this pilot study, it is hypothesised that, naïve and primed ES cells 
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have different distribution of the mitochondria enzyme, Prodh. This work aims to quantitate Prodh 
staining and determine the differences in the immunofluorescence of Prodh, in two pluripotent 
states, naïve and primed ES cells. This pilot work has not followed a commonly designated study, 
and the analysis is based on Prodh staining in the naïve and primed ES cells that had already been 
generated, thus, the purpose of this study is to describe the features of Prodh staining in ES cells.  
Materials and Methods 
Experimental design 
The immunofluorescence of Prodh was performed in naïve and primed ES cells after the cells 
were seeded on a gelatine coated imaging plate for 12 hours. The staining technique was similar to 
the protocol provided in Chapter 2, section 2.6 of this thesis. Two sets of experiments were 
performed at the same time using naïve and primed ES cells. In sample set 1 (to generate Dataset 
1), naïve and primed ES cells were stained with 1:200 concentration of Prodh (here called Ablo). In 
sample set 2 (to generate dataset 2), naïve and primed ES cells were stained with 1:100 
concentration of Prodh (Abhi). The experiment was performed once only (biological replicates, n=1). 
In each well of naïve and primed ES cells on the imaging plate, three separated areas were imaged 
(technical replicates m=3) at the 60x magnification of the Leica DMRBI microscope. The examples 
of images used for this pilot study are shown in Figure 3.2.5 
Methods 
Images of DAPI and Prodh staining in naïve and primed ES cells were analysed in Cellprofiler 
(version 2.2.0) using the provided pipelines and modules (Supp.Fig 1) as previously described 
(Gustafsdottir et al., 2013). After correcting the background, the program set up an algorithm to 
identify each cell by their positive DAPI staining (or nuclear DNA), which will be overlayed with Prodh 
staining to define the cell area. This algorithm will subtract Prodh area to DAPI area to give rise to 
the cell cytoplasm area. For each of these identified objects: cell (combined DAPI and Prodh), 
nuclear DNA (or DAPI) and cytoplasm (Prodh (or GFP)), different features of the staining such as 
intensity, shape, area, intensity location and distribution were quantitated. A list of features is 
summarised in Supp.Table 1. All data processing and analysis were performed in R studio (version 
1.1.456) and packages are available from R (version 3.5.1) using the codes that is publicly available 
online and can be found from the following site: 
https://github.com/cytomining/cytominer/blob/master/vignettes/cytominer-pipeline.Rmd.  
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A principle component analysis (or PCA) was performed to reveal if the distribution (shapes 
and area) of Prodh was mostly contributing to the separation between naïve and primed cells. Each 
step of the analysis process and codes are summarised in Supp.Fig 3 and Supp.Text 1.  Two studies 
were performed, in which, Study 1 analysed dataset 1 (samples were stained with 1:200 Prodh) and 
2 (samples were stained with 1:100 Prodh) in parallel, and Study 2 performed similar analysis to 
study 1 but to the combined dataset 1 and 2. Study design and the analytic workflow are 
summarised in Figure 3.2.6. 
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In 2 experiments using A. Low and B. High Prodh antibody concentrations [Ab]. Dataset 1 was generated from images with low [Ab] and dataset 2 was 
generated from images with high [Ab]. Scale = 50 μm.   
Figure 3.2.5: Immunofluorescent images of Prodh in naïve and primed ES cells 
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A. Structure of the pilot study. Naïve and primed ES cells were seeded for more than 6 hours before 
collecting for immunofluorescent experiment. Two experiments were performed on the same plate 
using high (1:100) and low (1:200) concentrations of Prodh antibodies. For each well of naïve and 
primed ES cells, 3 random central areas were imaged under the microscope. The total of 6 images 
from each experiment were used for analysis by CellProfiler to generate dataset 1 and 2. Study 1 
performed analysis for dataset 1 and 2 in parallel. Study 2 analysed the combined data of dataset 1 
and 2. B. An example of how algorithms in CellProfiler detected single objects (or single cells). The 
subtraction of cells to nuclei gave rise to cytoplasm. Outliners of each object were drawn by the 
programmed. All features calculated for each object were exported to dataset 1 and 2. C. Workflow 
of data analysis for study 1 and 2 in R. Data analyses revealed key features of variation in each 
dataset and in the combined data.  
 
  
Figure 3.2.6: Image analysis – Study design and analysis workflow 
 75 
 
Results 
The PCA analyses of study 1 and 2 showed a high variation among all samples, and naïve and 
primed ES cells were not separated on the first two dimensions (Figure 3.2.7), which could be due 
to the low replicate number. In study 1, six components for each dataset were generated. 
Component 1 and 2 contributed respectively to ~40% and ~30% of the variation in all samples 
(Figure 3.2.7). Twelve components were generated in study 2, in which, component 1 and 2 
contributed to ~20% and ~17% of the variation, respectively. From these PCA analyses, the 
contribution of each feature to the total variation of all samples was calculated. In study 1, the 
analysis of dataset 1 highlighted a trend of differences in the cytoplasmic and nuclear shape (total 
~30%) and the texture (total ~25%) of each cell as these features contributed mostly to the first 
component (Table 3.2.1). Specifically, cytoplasmic shape Zernike 4.2 (or astigmatism shape) 
contributed mostly to the differences in the samples of dataset 1, followed by the nuclear shape 
Zernike 7.5. The explanation of Zernike moments is shown in Figure 3.2.8. Cell and nuclear texture 
contributed to the total of ~38% of the variation in the second components (Table 3.2.1.A). Samples 
in dataset 2 were mostly separated by the nuclear (Zernike 5.5) and cytoplasmic (Zernike 6.0 or 
spherical) shapes. These features contributed to the total of ~50% of the first component of the 
variation in all samples (Table 3.2.1.B). The second component show that distances exist between 
cells, and the cell texture is different in dataset 2 (Table 3.2.1.B). Based on the CellProfiler’s manual 
about the measurements that are performed by the program, these features might describe the 
heterogeneity in each sample. In study 2, with the combined data of dataset 1 and 2, ten features 
of each component were examined. The first component displayed cell and cytoplasmic shapes 
(total ~6.2%), nuclear texture (~6.1%), cell correlated DNA (~4.5%) and heterogeneity (~4.3%). The 
second component mostly illustrated the variations in cell and cytoplasm shape (~11.9%), nuclear 
texture (~6.5%) and heterogeneity (~4.5%) (Table 3.2.1.C).  
In conclusion, study 1 showed that trends in sample variation are represented by the 
astigmatism and spherical shapes of the cells and cytoplasm. Nuclear shapes, nuclear texture, cell 
texture and heterogeneity also contributed to the differences of all samples, however, there is no 
significant difference in the measurements of these features between naïve and primed ES cells 
(data not shown). Study 2 showed similar results to study 1, that cell and nuclear shapes of the cells 
are more variable than other features. However, these features were slightly different from those 
in study 1. In addition, the correlation between cells and DNA are the features of variation in all 
samples in study 2 and no significant difference between naïve and primed ES cells were detected 
in these features (data not shown)
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Principle component analysis showed the clustering of A. Dataset 1, C. Dataset 2 and E. 
Combined dataset of dataset 1 and 2. Contribution of each cluster (or dimension) to the 
variation of the samples in each dataset were shown in Scree plots B, D and F, respectively.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.2.7 Clustering of samples in relation to each feature and the contribution of each cluster 
to the variation of all samples. 
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Table 3.2.1. Statistic contribution of all features to the variation of each dimension in 
Study 1 and 2 
 
A. The contribution of each feature to the variation of different dimensions (or 
components) in dataset 1. All features contribute to the total of 100% variation of 
each dimension. The highest contributions from each dimension are highlighted. 
  Dim.1 Dim.2 Dim.3 Dim.4 Dim.5 Dim.6 
Cytoplasm_AreaShape_Zernike_4_2 15.09 0.97 4.52 1.52 4.30 29.56 
Nuclei_AreaShape_Zernike_7_5 14.71 1.13 2.91 8.36 1.52 10.57 
Cells_Texture_InfoMeas2_DNA_5_02 12.89 4.48 1.41 7.20 2.24 12.02 
Nuclei_Texture_Correlation_DNA_10_00 11.24 2.06 3.02 23.26 10.74 2.06 
Cells_Neighbors_SecondClosestObjectNumber_Adjacent 10.67 0.00 18.65 0.81 1.05 0.83 
Nuclei_Texture_Correlation_DNA_5_00 9.12 11.53 0.01 1.27 0.02 1.49 
Cells_Texture_DifferenceEntropy_DNA_5_00 7.38 0.55 21.21 5.69 23.05 11.47 
Nuclei_AreaShape_Zernike_8_2 5.83 11.93 8.12 0.18 0.52 16.63 
Nuclei_AreaShape_Zernike_5_3 5.53 14.54 1.96 3.37 4.67 8.22 
Cells_Texture_Correlation_DNA_20_03 5.16 0.58 25.68 3.65 37.99 2.40 
Cells_Texture_Correlation_DNA_5_00 1.20 20.22 2.28 0.98 10.04 2.22 
Nuclei_AreaShape_Zernike_5_5 0.78 14.00 0.05 43.72 1.53 2.28 
Nuclei_Texture_InfoMeas1_DNA_5_03 0.40 17.99 10.18 0.00 2.34 0.25 
 
B. The contribution of each feature to the variation of different dimensions (or 
components) in dataset 2.  
  Dim.1 Dim.2 Dim.3 Dim.4 Dim.5 Dim.6 
Nuclei_AreaShape_Zernike_5_5 25.65 5.19 1.40 0.75 0.02 42.58 
Cytoplasm_AreaShape_Zernike_6_0 24.65 0.02 1.93 12.88 8.39 0.11 
Cells_Intensity_MassDisplacement_GFP 17.27 0.80 28.32 0.06 21.10 21.25 
Cells_Texture_InverseDifferenceMoment_GFP_20_00 13.08 17.22 0.04 17.27 5.19 8.60 
Cells_Texture_Correlation_DNA_20_03 9.92 10.49 20.21 16.07 17.22 15.01 
Cells_Neighbors_FirstClosestDistance_Adjacent 6.14 30.20 1.23 0.00 17.14 5.91 
Nuclei_Texture_DifferenceVariance_GFP_20_01 3.12 13.54 41.10 0.64 30.82 6.13 
Cells_Texture_AngularSecondMoment_GFP_20_02 0.17 22.53 5.77 52.34 0.12 0.42 
 
C. The top 10 features (out of 176 features) contributing most to the first three 
dimensions (or components) to the combined dataset 1 and 2.  
  Dim.1 
Cells_AreaShape_Zernike_9_5 2.49 
Cells_RadialDistribution_FracAtD_GFP_1of4 2.49 
Nuclei_Texture_Correlation_DNA_5_02 2.39 
Cells_Texture_Correlation_DNA_5_03 2.38 
Cells_Texture_Correlation_DNA_10_00 2.08 
Cytoplasm_AreaShape_Zernike_4_2 1.99 
Nuclei_Texture_Correlation_DNA_5_01 1.91 
Cytoplasm_Intensity_MassDisplacement_GFP 1.86 
Cytoplasm_AreaShape_Zernike_5_3 1.83 
Nuclei_Texture_Correlation_DNA_5_03 1.79 
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  Dim.2 
Cells_AreaShape_Zernike_7_3 2.63 
Cells_AreaShape_Orientation 2.43 
Cytoplasm_AreaShape_Orientation 2.41 
Nuclei_Neighbors_SecondClosestDistance_Adjacent 2.40 
Cells_Neighbors_SecondClosestDistance_Adjacent 2.35 
Nuclei_Texture_DifferenceEntropy_DNA_20_03 2.25 
Cytoplasm_AreaShape_Zernike_8_6 2.23 
Cytoplasm_AreaShape_Area 2.23 
Nuclei_Texture_SumEntropy_DNA_20_01 2.16 
Nuclei_Texture_DifferenceEntropy_DNA_20_01 2.14 
 
  Dim.3 
Cells_Texture_SumVariance_DNA_20_02 2.90 
Cells_AreaShape_Zernike_6_0 2.75 
Nuclei_AreaShape_Solidity 2.49 
Nuclei_AreaShape_FormFactor 2.44 
Nuclei_Texture_Contrast_DNA_20_03 2.29 
Nuclei_Texture_Contrast_DNA_10_02 2.25 
Nuclei_Texture_Correlation_DNA_20_01 2.23 
Cells_Texture_SumEntropy_DNA_20_01 2.18 
Nuclei_Texture_Correlation_DNA_10_01 2.13 
Cells_Texture_DifferenceEntropy_DNA_20_01 2.09 
Cells_Texture_SumEntropy_DNA_20_03 2.06 
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The fundamentals of Zernike wavefronts (A) were used to define 2D Zernike shapes and 
distribution (B) of the staining in CellProfiler. Zernike moments are vertically arranged in 
radial order and horizontally arranged in angular meridional frequency. In this pilot study, 
polar distribution Zernike (4,2) (astigmatism shape) and Zernike (6,0) (spherical) (in blue 
circles) were specifically highlighted as contributing the most to the variation of objects in 
all samples. The above images can be accessed via the links:  
http://bme240.eng.uci.edu/students/08s/ticenogl/Wavefront-Guided%20LASIK/Wavefront.html (A) 
and https://en.wikipedia.org/wiki/Zernike_polynomials (B). 
  
Figure 3.2.8: Zernike polynomials 
 
Figure 3.2.9: Proliferation rate of 
naïve and primed ES cells.Figure 
3.2.10: Zernike polynomials 
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Conclusion 
Image-based profiling of cell phenotypes have been previously described (Boutros et 
al., 2015, Caicedo et al., 2017). Image analysis of Prodh reveals that there is a trend of 
variation in Prodh staining in the cells of all samples. Particularly, astigmatism and spherical 
shapes of the cells and cytoplasm, which were marked by Prodh staining, contributing mostly 
to the variation in all samples. Due to the small sample size, the data were inconclusive as to 
what shape of Prodh distribution was correlated with the naïve or primed ES cells. Prodh was 
localised into the mitochondrial in chapter 3 of this thesis, the suggestion of different Prodh 
distribution may also reflect the distribution of mitochondria in ES cells. How this is related to 
the cell functions and physiology will need further validation, but perhaps, the changes in 
mitochondrial distribution may be initiated during the early pluripotent transition of ES cells. 
Whether these cells were a part of the differentiated population of ES cells and how far they 
are in the differentiation process will warrant future examination which will clarify how early 
on in the pluripotent lineage specification process that mitochondrial dispersion occurs for 
the first time.  
Prodh has been shown to be differentially expressed in naïve and primed ES cells, 
however, the intensity of Prodh was not suggested to be a factor of variation in different 
samples based on data resulting from this work. If Prodh is correlated with mitochondria, the 
question remains that, whether the distribution of mitochondria is the cause behind the 
differential transcription of Prodh. Naïve ES cells are known to have homogenous 
mitochondria of round shape, that are immature and arranged perinuclearly, while primed ES 
cells possess heterogeneous mitochondria of both round and elongated shapes (Mandal et 
al., 2011, Mathieu and Ruohola-Baker, 2017). It would be interesting to discover if the 
difference in mitochondrial numbers or morphology are correlated with Prodh expression in 
naïve and primed ES cells and if that is a sign for differentiation initiation. In fact, 
mitochondrial DNA (mtDNA) copy numbers were reported to increase during ES cell 
differentiation, however, mitochondrial replication was not observed in D3 ES cells in the 
transition to neuronal differentiation (Facucho-Oliveira et al., 2007). Accordingly, the increase 
in mtDNA copy number was only observed in D3 ES cells at day 6 post-differentiation and the 
change in mtDNA copy numbers was associated with cell expansion (Facucho-Oliveira et al., 
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2007). Therefore, it is likely that the modification of Prodh distribution suggested in this pilot 
study could have reflected a small population of the differentiated cells.  
Nuclear shape and texture were mentioned as the contributing factors to the variation 
of all samples in both study 1 and 2, suggesting that ES cells could have different nuclear 
contents such as DNA, nucleoli and bar bodies (Coronado et al., 2013, Takahashi et al., 2018). 
These differences could potentially originate from the different cell cycles and cell states, 
which could contribute to the variation in DNA condensation and nuclear contents. A 
measurement of proliferation between naïve and primed ES cells showed that the average 
division rates of naïve and primed ES cells are 18 and 21.5 hours respectively (Figure 3.2.9), 
suggesting that the ES cells of different pluripotent states have different division rates and 
different cells may stay in different phases of the cell cycle. Furthermore, the results revealed 
that cells in different samples have different textures, which reflected the heterogeneity of 
the cell populations. This is consistent with previous reports that ES cells are heterogeneous, 
and cells of a particular pluripotent states may have different subpopulations due to 
spontaneous differentiation (Kolodziejczyk et al., 2015, Hayashi et al., 2008, Tanaka, 2009). In 
addition, the results in study 2 showed that cell and DNA are correlated in ES cells. The 
definition of this feature in the Cellprofiler’s manual describes the relationship between 
Prodh and DNA staining, which could reflect the differences of the intensity of Prodh and DNA 
staining across samples or even the colocalisation of these staining. This may be caused by 
different antibody concentrations that were applied and the heterogeneous characteristics 
of ES cells because heterogeneity could potentially introduce bias effects on the profiling of 
ES cells of different states (Hayashi et al., 2008, Osorno and Chambers, 2011, Godwin et al., 
2017, Neupane et al., 2015, Tanaka, 2009). Further replications could support and confirm 
these findings. In studies using small sample sizes, as with this particular pilot study, using 
each cell in the population as a replicate, which is also called single cell profiling, could help 
to reduce the bias artefact and would provide useful information on the cell subpopulations. 
In fact, single cell analysis has also been suggested in image-based cell profiling for 
heterogeneous populations (Caicedo et al., 2017). Finally, to correlate the staining of Prodh 
with mitochondria, co-staining of Prodh with mitochondrial marker would give a more 
definitive conclusion on the mitochondrial distribution in ES cells. At the same time, a more 
consistent standard of Prodh staining in a less crowded population will be useful to provide 
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images of a better resolution and therefore, will create a more precise quantitation of the 
data. Overall, the use of image analysis will be useful for adding information into the research 
database of ES cell biology. The integration of cell imaging data and other -omics data will 
provide a more precise picture on cell phenotyping and will enhance the ability to profile 
different cell types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Naïve and primed ES cells were seeded at the same rate. The cells were counted on a counting 
chamber every 24 hours for 4 days. The first count for each cell type was used as day 0 
reference. An exponential equation: y = Ntx was generated based on the count data, where y 
is the total number of cells on day x. Division rate r (days/division) was calculated based on 
previously published method (Sherley et al., 1995) and is equal 1/t. Division rate in hours h is 
calculated as h = r*24 (hours/division). 
 
 
 
y = 4.1871e1.1114x
R² = 0.9598
y = 7.3777e1.3285x
R² = 0.9926
days/division hours/division
naïve 0.90 21.54
Primed 0.75 18.07
Figure 3.2.11: Proliferation rate of naïve and primed ES cells. 
 
Figure 3.2.12. Proline metabolic models in different pluripotent states 
of ES cells based on the expression of proline metabolic enzyme 
family.Figure 3.2.13: Proliferation rate of naïve and primed ES cells. 
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3.3. Discussion 
3.3.1. The gene expression of the proline metabolic enzymes is differentially 
regulated in different pluripotent states and is affected by long term culture 
conditions 
In mammalian cells, the expression of the proline metabolic enzyme family, including Prodh, 
Aldh18a1, Aldh4a1, Pycr1, and Oat, is regulated by the master transcription regulators p53 
and Myc (Rivera and Maxwell, 2005, Donald et al., 2001, Wang et al., 2011, Liu et al., 2012). 
It is suggested that within cancer cells, P53 is responsible for activating the expression of 
PRODH and leads to the increase in proline metabolism (Rivera and Maxwell, 2005, Donald et 
al., 2001). Furthermore, MYC might act as a suppressor for PRODH expression via miR-23b 
(Liu et al., 2012). However, in T cells, the reduction of MYC is correlated with the decreased 
expression of PRODH, OAT and ALDH18A1 (Wang et al., 2011). It is possible that P53 and MYC 
may exert a reversed regulation on the proline metabolic enzyme family and P53 could 
repress the regulatory effect of MYC (Puzio-Kuter, 2011, Liang et al., 2013). Recent data have 
found that P53 and MYC also control the expression of other proline metabolic enzymes 
(Wang et al., 2011, Liu et al., 2012, Yoon et al., 2004). Particularly, P53 activates the 
expression of P5CDH gene (ALDH4A1) and MYC is reported to regulate the expression of P5C 
synthase (ALDH18A1), P5C reductase (PYCRs) and OAT genes(Yoon et al., 2004, Wang et al., 
2011, Liu et al., 2012), thus, it is possible for MYC and P53 to coordinate the expression of the 
proline metabolic enzyme family depending on the physiological conditions, which generate 
metabolic switches between proline catabolism and biosynthesis in mammalian cells.  
Here it is shown that proline metabolic switches also occurred during the pluripotent lineage 
specification of ES cell growth, particularly, the gene of proline metabolic enzyme family is 
regulated and differentially expressed in different pluripotent states. Similar results are 
observed in both ES cell lines, D3 and WA30, indicating that this is a robust metabolic change 
during the pluripotent lineage specification. The increase in Prodh when ES cells are released 
from 2i into the primed state occurred at the same time with the increase in the proline 
primary transporter Slc38a2 (encoding Snat2 protein) in the cells. This result is consistent with 
previous data in the literature (Tan et al., 2016b). Moreover, this is not limited to ES cell 
culture. It has been reported that the regulation of Slc38a2 recapitulates the in vivo 
development of the pluripotent cells in mice embryo (Tan et al., 2016b). The observation of 
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the human embryonic data also showed evidence that blastocyst cells show higher expression 
of Slc38a2 when compared to the morula cells, the earlier state of blastocyst cells (Vassena 
et al., 2011). Therefore, the increase of Slc38a2 is a requirement for pluripotent cells at the 
primed state, but not the naïve state. The inhibition of Erk1/2 pathway in T cells is known to 
affect the expression of MYC, a regulator of Prodh (Wang et al., 2011), thus, the inhibition of 
Erk1/2 in naïve ES cells may produce an effect on the expression of Prodh via suppressing 
MYC. The combination of increased expression of the transporter, Slc38a2, and the key 
enzyme, Prodh, suggested that when moving from naïve to primed state, ES cells switch on 
proline uptake and proline catabolism. It is hypothesised that this switch may be needed for 
ES cells in this transition to prepare ES cells to utilise proline metabolism for differentiation 
into the later pluripotent states, thus more investigation is required to confirm this possibility.  
In contrast, primed ES cells expressed lower levels of Oat compared to naïve ES cells. As Oat 
plays a role in proline biosynthesis, a decrease in Oat expression predicts a reduction in P5C 
synthesis, while the increased levels of Prodh expression is expected to increase P5C levels 
from proline. It is possible that the reduction in Oat may act to compensate the increase of 
Prodh in primed ES cells by stopping P5C synthesis from ornithine as high levels of P5C has 
been shown to inhibit cell respiration in yeast (Nishimura et al., 2012). However, as Oat is a 
bidirectional enzyme, it is uncertain if any direction was favoured in ES cells and if it is subject 
to the changes in ES cell programming. It is also possible that the reduction of Oat may retain 
P5C in the proline cycle to support ES cell maintenance by preventing P5C escaping via Oat 
catalytic activity. This hypothesis will require investigation of the P5C levels within the cells. 
The robust changes in gene expression of Slc38a2, Prodh and Oat shows that the proline 
metabolic shift is more likely to correlate with the release of ES cells from 2i to serum because 
other modifications of the culture conditions did not provide additional effects to this shift. 
This is the first data that highlights the shift in proline metabolism in naïve and primed ES 
cells, which could potentially be used to perform the discrimination of these ES cells. The 
examination of various naïve and primed ES cell expression data will be useful for further 
validation of this finding. 
It was noted that the proline-induced differentiated ES cells showed a reduction of the P5C 
synthase (Aldh18a1) expression in both ES cell lines, but this effect was clearer in D3 cells 
when compared to WA30 cells. This is in agreement with the recent study that Aldh18a1 is 
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reduced early after the addition of L-proline into ES cells (D'Aniello et al., 2015), however, it 
disagrees with the earlier report that Aldh18a1 was not changed with proline treatment 
(Comes et al., 2013). This suggests that Aldh18a1 gene may be subject to variation in different 
ES cell lines and different culture conditions, similarly to the variation of other proline 
metabolic genes that were examined in cancers (Phang et al., 2008a, Phang et al., 2012, Phang 
et al., 2015, Phang et al., 2008b, Elia et al., 2017). The expression of Snat2 gene, Slc38a2, also 
decreased in D3, but not in WA30 ES cells in the addition of proline. This result is in contrast 
with the previous findings whereby Slc38a2 was not affected by the differentiation process 
(Comes et al., 2013). The reduction of Snat2 and P5C synthase is expected to decrease the 
proline uptake and thus preventing its precursor from glutamate to be fed back to the 
catabolic process. This regulation may provide protection to the cells by limiting proline 
availability for oxidation given proline oxidation could lead to ROS production (Donald et al., 
2001) and ROS-induced apoptosis in cancer cells (Rivera and Maxwell, 2005). The data 
suggests that D3 ES cells were more responsive to the proline addition than WA30 ES cells in 
regulating key genes of the proline metabolic enzyme family. In contrast, the variation 
observed with Pycr2 and P4ha1 genes between the naïve and primed pluripotent states was 
only found in WA30, but not in D3 ES cells (Figure 3.3.2.C and D), suggesting that WA30 may 
be more sensitive to the pluripotent lineage specification than D3 ES cells, which led to 
increased variation in the gene expression. This result could be correlated with the differences 
in the long term cultivation of these cell lines because the long term suppression of Mek1/2 
in 2i medium was reported to impact upon ES cell development and differentiation (Choi et 
al., 2017), thus, WA30 ES cells may be more sensitive to the developmental changes induced 
by proline, which resulted in the increased cell death in proline addition. 
In conclusion, the data suggested that the proline metabolic enzyme expression in ES cells 
was subjected to regulation by changes to different pluripotent states, but possibly not by the 
variation in the culture conditions. WA30 ES cells were more responsive to the release from 
2i than D3 ES cells and that led to increased WA30 cell death in serum. It is suspected that the 
long-term cultivation of different ES cell lines contributes to the enhanced effects upon 
proline metabolic enzymes. In other words, as the WA30 cell line is maintained in 2i and D3 
cells are maintained in serum, their original media could lead to different responses to the 
same culture conditions. In fact, naïve and primed state ES cells have distinguished metabolic 
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processes that serve their stability in defined conditions (Sperber et al., 2015, Wu and Izpisua 
Belmonte, 2015). The pluripotency of different ES cell lines are unstable in different 
conditions and can be affected by the extrinsic factors within the environment, this allowing 
the interconversion of naïve and primed ES cells (Hanna et al., 2010). Moreover, the 
difference in pluripotent cell states could result in different responses to amino acid 
availability in the environment (Kilberg et al., 2016, Shan et al., 2013). Therefore, the different 
cultivation conditions in different ES cell lines could result in the unstable achievement of 
naïve and primed states and the oscillation of gene expression signatures (Guo et al., 2009), 
which could include proline metabolism. More studies are required to fully describe the 
precise mechanisms of the changes in proline metabolic enzyme expression.  
3.3.2. Differential expression of the proline enzyme genes is correlated with the 
functional proteins 
 Validation of the gene expression data in D3 ES cells proposed two isoforms of Prodh 
and Oat, one of which was not seen in the literature and were not obvious within the liver 
and kidney controls. Even though the result was consistent across all independent 
experiments and with different lytic techniques, however, it did not exclude the possibility of 
unspecific binding of the antibodies in D3 ES cell line and the chance that these unspecific 
proteins are more abundant in ES cells than in livers and kidneys. The quantitation of protein 
expression of the functional Prodh and Oat enzymes confirms the gene expression data in 
naïve and primed ES cells but at a much higher magnitude of differences. This result confirms 
the proline metabolic switch in naïve and primed ES cells, which could be used to perform as 
a metabolic discrimination between the two pluripotent states. Naïve and primed ES cells are 
generally distinguished by their metabolic profiles (Sperber et al., 2015) and naïve ES cells 
showed an increase in metabolic activity with a higher respiration rate and lower glycolysis 
when compared to its primed counterparts (Kilens et al., 2018, Takashima et al., 2014, Gu et 
al., 2016). The differences in amino acid and fatty acid metabolism have been demonstrated 
by the metabolomic data of naïve and primed ES cells (Sperber et al., 2015), evidence that 
methionine and nicotinamide levels were downregulated in naïve ES cells and S-adenosyl 
methionine (SAM) levels were increased in primed ES cells (Sperber et al., 2015). The 
examination of single-cell RNA sequencing found that basic metabolism such as glycolysis and 
glutathione metabolism are key differences separating between the two pluripotent states 
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(Kolodziejczyk et al., 2015). Therefore, with this finding of the proline metabolic switch in 
naïve and primed ES cells, proline metabolism is a potential metabolic marker to distinguish 
these pluripotent states. A precise mechanism of proline metabolic regulation, thus warrants 
further investigation to unravel the correlation between ES cell development and proline 
metabolic needs.  
 Prodh and Oat are mitochondrial enzymes and are functional within the mitochondria 
(Adams and Frank, 1980, Hancock et al., 2016, Ginguay et al., 2017). The correlation between 
Prodh enzyme and mitochondrial activities has been reported (Hancock et al., 2016, Liu et al., 
2009), confirming Prodh activities within the mitochondria. Localisation examination of Prodh 
in D3 ES cells illustrated that the protein is located within the mitochondria while it is 
circulating the nuclei. This is further supported by the previous findings that ES cells and other 
highly proliferative cells have punctate and perinuclear mitochondria (Kuroda et al., 2006, 
Prowse et al., 2012, Cho et al., 2006a), which may be important for cell proliferation and self-
renewal (Lees et al., 2017).  
 Oat enzymes in naïve and primed ES cells appeared to be distinguished in their 
expression levels. The accumulation of Oat protein was observed in both naïve and primed ES 
cells, and when compared to naïve ES cells, Oat accumulated at a higher level in primed cells. 
Additionally, Oat accumulation appeared to mismatch the expression of Cox IV protein, a 
mitochondrial membrane protein, indicating that Oat may have a different cell location other 
than the mitochondrial matrix. Previous studies suggest that OAT can interact with ATF2 
protein in human skin cells and could be located in the mitochondrial outer membrane (Lau 
et al., 2012) and precursors of Oat were found to be bound to the mitochondrial membrane 
before they were translocated into the mitochondria (Ono and Tuboi, 1986). However, Oat 
protein was also suggested to localise into the nuclei with an unknown function (Ginguay et 
al., 2017). In ES cells, the proline transporters Snat1 and Snat2 were found to accumulate in 
the perinuclear area, which is potentially used to back up the cells in nutrition restricted 
conditions (Tan et al., 2016b), and possibly the accumulation of Oat in order to support cells 
in devastating conditions. The examination of Oat proteins in relation to other cell 
compartments under a high-performance microscope will help to determine and confirm Oat 
accumulation and further study is required to understand the other biological functions of 
the Oat enzymes and the role of Oat accumulation in ES cells.  
Chapter 3  Van T. T. Nguyen 
90 
 
 In conclusion, the protein expression and localisation of Prodh and Oat confirm their 
differential gene expression in the naïve and primed ES cells, which is correlated with their 
functional isoforms and their sites of activities. Therefore, Prodh and Oat are expected to 
perform their catalytic functions in ES cells. The increase of Prodh in primed, but not naïve ES 
cells suggest that proline catabolism is higher in these cells. Given that primed ES cells can 
differentiate in the presence of proline, the question remains as to whether the upregulation 
of Prodh in primed ES cells is required for the initiation of the differentiation process, thus it 
is possible that the proline metabolic switch is required for ES cells in different pluripotent 
states, not only to support the cell needs, but also to prepare the cells for a cell response to 
differentiation cues. More research into this hypothesis is required in order to establish the 
role of the proline metabolic switch in ES cell programming.  
  
 
 
 
 
 
 
 
 
 
Naïve state of ES cells expressed low levels of Snat2 and Prodh, and high levels of Oat, which 
reduces the intake and breakdown of proline and increases the breakdown of ornithine to 
form P5C. In primed ES cells, Snat2 and Prodh expression is increased and the cells were more 
Figure 3.3.1. Proline metabolic models in different pluripotent states of ES cells based on 
the expression of proline metabolic enzyme family. 
 
Figure 3.3.2. Proline metabolic models in different pluripotent states of ES cells based on 
the expression of proline metabolic enzyme family. 
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active in proline uptake and transport. Primed ES cells also express the gene that potentially 
increased the synthesis of proline from glutamate. However, Oat is reduced in primed ES cells, 
which would potentially sync proline out of the cycle. Thus, this would keep the proline cycle 
high in primed state. In the addition of proline, Snat2 is reduced and P5Cs reduced to prevent 
the uptake and the synthesis of proline. Therefore, the central reactions of the proline cycle 
are maintained. 
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Chapter 4 The production of reactive oxygen species 
(ROS) in ES cells in response to proline is regulated in 
different pluripotent states of ES cells and is correlated 
with differentiation 
4.1. Introduction 
Reactive oxygen species (ROS) have long been considered as a sign of cellular stress and 
damages that are associated with pathological conditions and aging. In recent years, ROS has 
been raised as an interest in research for its biological role in cell signalling and programming 
(Covarrubias et al., 2008, Murphy et al., 2011), indicating the important involvement of ROS 
in development. Mitochondria is the major sites of ROS production (Murphy, 2009).  The 
generation of ROS is often correlated with the mitochondrial membrane potential (MMP) and 
mitochondrial functions (Balaban et al., 2005). ROS is mainly produced from mitochondrial 
activities, which comprise a complex network of metabolism and redox balancing systems 
(Murphy, 2009, Balaban et al., 2005). In the field of stem cell research, mitochondrial 
functions including metabolic activities and ROS production were found to play an important 
role in regulating PCS growth and differentiation, which contribute to the control of cell fates 
(Bukowiecki et al., 2014, Suhr et al., 2010, Jeong et al., 2009, Schmelter et al., 2006, Ji et al., 
2010, Ronn et al., 2017, Song et al., 2014, Birket et al., 2013, Crespo et al., 2010, Zhou et al., 
2016, Schieke et al., 2008, Birket et al., 2011, Chung et al., 2007, Mandal et al., 2011). 
Metabolic regulation of ROS signalling has been shown in stem cell growth and 
differentiation (Kubli and Sussman, 2017, Ryu et al., 2015). The regulation of ROS production 
involves multiple mitochondrial activities, in which, metabolism is an important factor 
(Lushchak, 2014, Murphy, 2009). An example of metabolic regulation of ROS in PSC function 
is indicated by Crespo and colleagues (2010), who investigated the correlation between high 
glucose content in the culture media and the increase in ROS production and suggesting that 
this correlation was required for cardiomyocyte differentiation from ES cells (Crespo et al., 
2010). Glutamine metabolism mediated ROS production was also found to have a role in PSC 
differentiation, where ROS-regulated redox homeostasis in human ES cells was associated 
with the oxidation of the transcription factor OCT4 to mediate the cell changes (Marsboom 
et al., 2016). However, the link between mitochondrial metabolic regulation of ROS and PSC 
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decision making is not well characterised. The correlation of metabolic ROS regulation in 
different pluripotent states of the cells is also poorly understood. Sperber et al., 2015 found 
that naïve and primed ES cells are distinct in their metabolic profiles and suggested that 
mitochondrial respiration was higher in naïve, compared to primed, ES cells (Sperber et al., 
2015). Naïve ES cells were previously shown to have high metabolic rate (Kilens et al., 2018, 
Taleahmad et al., 2015); however, comparing to primed ES cells, naïve ES cells were suggested 
to have lower glycolytic activities and higher oxidative phosphorylation (Gu et al., 2016), 
predicting that naïve ES cells may produce higher mitochondrial ROS than primed ES cells. No 
study has investigated the production of ROS in ES cells in different pluripotent states, making 
it challenging to address the origin of ROS and its involvement in cellular signalling. 
Understanding the basal production of ROS will provide information for studying ES cell 
metabolism in the correlation to pluripotent states, culture conditions and their 
differentiation potential.  
There is increasing evidence for a role of proline metabolism and mitochondrial ROS 
production in ES cell differentiation (Tan et al., 2016a, Casalino et al., 2011, Tan et al., 2016b, 
Tan et al., 2011). Findings in chapter 3 of this thesis revealed that the expression of proline 
metabolic enzymes was regulated in different pluripotent states of ES cells in the way that 
favoured proline metabolism (or proline breakdown) in primed, but not naïve, state of 
pluripotency. Increased ROS production by proline metabolic enzyme, Prodh, and proline 
availability has been shown to regulate mitochondrial respiration (Hancock et al., 2016). As 
mitochondrial regulation of ROS is a determining factor of cell fates and plays a role in cellular 
redox signalling (Prigione and Adjaye, 2010, Chen et al., 2008, Varum et al., 2009, Crespo et 
al., 2010), proline metabolic regulation of ROS may suggest a role in ES cell development via 
redox homeostasis. Even though it was recently argued that redox homeostasis might not be 
the primary effect of proline induced differentiation in ES cells (D'Aniello et al., 2017), the 
involvement of ROS signalling pathways was suggested (Tan et al., 2016a). Given the results 
in chapter 3 that naïve ES cells have lower Prodh expression compared to primed 
counterparts, it is hypothesised that they will respond differently to exogenous proline to 
produce different levels of ROS. Specifically, it is hypothesised that ROS production will be 
higher in primed ES cells compared naïve ES cells with proline addition.   
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To address this hypothesis, mitochondrial ROS was examined in ES cells in a controlled 
(non-treated) condition to define the standard ROS levels in different pluripotent states: naïve 
and primed ES cells. The detection of ROS was validated by the antioxidant, ascorbic acid or 
vitamin C was used to neutralise ROS generation. The production of ROS in response to 
proline was also investigated in these states to examine the involvement of ROS upon 
differentiation. Understanding ROS production in ES cells at different pluripotent states would 
enhance the current knowledge of metabolic regulation of ROS and support the 
discrimination of ES cell fates.  
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4.2. Results 
4.2.1. ES cells have distinct subpopulations of proline-induced ROS 
To investigate the role of proline induced ROS production in ES cell differentiation, 
ROS was measured in D3 ES cells by flow cytometry using a mitochondrial superoxide dye, 
MitoSOX Red, 24 hours after the cells were seeded into new plates. ES cells formed two 
distinct populations with different ROS profiles, here called low and high ROS populations: 
ROSlo and ROShi (Figure 4.3.1.A). Analysis of the data have revealed that low-ROS producing 
cells accounted for ~65% of the total ES cell population. To further understand if the 
production of ROS in response to proline was correlated with mitochondrial activities and 
respiration, mitochondria membrane potential (MMP) was measure for each population of 
ROS in D3 ES cells in a randomly selected untreated sample of five different replicates. It was 
found that ES cells were homogenous for MMP, but ROSlo and ROShi populations were 
associated with low and high MMP respectively (Figure 4.3.1.B and C), which reflects different 
mitochondrial activities in these populations.  
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D3 ES cells were grown on a gelatine coated 24-well plate for 24 hours before collection. Cells 
were measure with A. MitoSOX Red, B. MitoSOX Red and Mitotracker Green. C. ROSlo and 
ROShi populations were gated as in (B) to examine the levels of Mitotracker Green 
fluorescence. n=5, **p≤0.01 
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Figure 4.2.2. ROS measurement by flow cytometry in ES cells in a control (untreated or 
Serum + LIF) condition. 
 
Figure 4.2.3. Real time ROS production measured by flow cytometry in ES cells in response 
to proline at different time points.Figure 4.2.4. ROS measurement by flow cytometry in ES 
cells in a control (untreated or Serum + LIF) condition. 
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4.2.2. Dynamics of ROS production in the addition of proline in primed ES cells 
It was previously reported that ROS production, both total hydrogen peroxide and 
mitochondrial superoxide, increased in primed ES cells in the addition of proline (Tan et al., 
2016a). However, how quickly ES cells respond to proline to produce ROS was not 
investigated. To examine the dynamics of ROS production and subpopulations of ROS 
producing cells in response to proline, ROS was measured at different time points: 0.5, 1, 3, 
6, 12 and 24 hours after proline addition. It appears that total ROS levels increased 
significantly at 1, 6, 12 and 24 hours after 200 μM proline was added to the medium (Figure 
4.3.2). It was observed that the peak of ROS production, which identify the point where most 
of ES cells produced the same level of ROS, significantly increased at 1 hour in both high and 
low ROS populations and at 6 hours in ROSlo population, which then returned to the original 
levels (Figure 4.3.3.A). This demonstrates that most of ES cells have a stable point of ROS 
production in response to proline. Aside the significant spike of ROS immediately after proline 
addition at 0.5 hours, which was the maximal level of ROS production at this time, no other 
significant changes in the lowest and highest ROS production points were detected for 24 
hours responding to proline (Figure 4.3.3.B), suggesting that ES cells have a defined range of 
ROS production.  
When looking at ROS levels in ROSlo and ROShi populations, ROS production increased 
at 1 hour in ROShi population and at 6 hours in ROSlo population, which returned to the control 
level after 24 hours (Figure 4.3.3.D). This is explained by the fact that in the long term 
responding to proline, low-ROS producing cells significantly shifted to producing high ROS at 
1, 12 and 24 hours (Figure 4.3.3.C). Live imaging of ROS (Figure 4.3.4) confirmed this result at 
24 hours after proline addition. This suggests that ES cells have a controlled production of 
ROS in response to proline and the increased in ROS production occurred by shifting ROS 
production within a defined range of ROS in individual cells. No changes in nuclear staining by 
DAPI, an indication of cell death, was obtained in this experiment. These data showed that 
the addition of proline to ES cells activated ROS production while maintaining the 
physiological level of ROS, and ROS production was not a response to cell stress or a sign of 
apoptosis.  
The antioxidant, ascorbic acid (or vitamin C), was used to reduce ROS level. ROS 
production increased in response to proline (Figure 4.3.4), and vitamin C reduced ROS in ES 
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cells to the same level either with or without proline addition (Figure 4.3.5), which is 
consistent with previous findings (Tan et al., 2016a). The reduced ROS level in the present of 
vitamin C was significantly lower than the basal ROS level in the untreated ES cells. Compared 
to other treatments, ROS level detected in ES cells treated with vitamin C has appeared to be 
the lowest level that could be detected. Microscopic examination showed that ES cells had 
no signs of stress or apoptosis in the addition of vitamin C or both proline and vitamin C, 
suggesting that the decreased or increased ROS production was not a response to 
environmental stress. 
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A. Histogram of MitoSOX Red intensity (ROS production). B. Total ROS production in ES cells 
in response to proline at different time points. n=3-6, *p≤0.05. 
 
  
Figure 4.2.5. Real time ROS production measured by flow cytometry in ES cells in response 
to proline at different time points. 
 
Figure 4.2.6. Real time ROS production measured by flow cytometry in ES cells in response 
to proline at different time points. 
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ROS production in ROS-high and ROS-low population of ES cells was accessed for A. The point of where most of the cells produced the same 
level of ROS. B. The highest points of ROS levels produced. C.  Percentages of cell counts. D. Total ROS levels in each population. n=5, *p≤0.05. 
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Figure 4.2.8. ROS production of heterogeneous populations of ES cells in response to proline at different time points. 
 
Figure 4.2.9. ROS production of heterogeneous populations of ES cells in response to proline at different time points. 
Chapter 4  Van T. T. Nguyen 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ES cells were grown on gelatine coated 96-well plates and treated with 200 μM proline for 24 
hours and vitamin C for 4 hours. 30 minutes imaging, cells were stained with 7.5 μM MitoSOX 
Red dyes for 30 minutes at 37oC. Cells were in imaging buffer during the imaging process. 
Scale = 50 μm. 
 
    
  
Primed 
Primed +Pro 
Figure 4.2.11. Live cell ROS imaging in D3 ES cells. 
 
Fig re 4.2.12. Live cell ROS imaging in D3 ES cells. 
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ROS production in ES cells was validated with the addition of Vitamin C by A. 
Immunofluorescence and B. Flow cytometry. n=3, *p≤0.05.  
 
  
Figure 4.2.14. ROS production in ES cells in response to ascorbic acid (or vitamin 
C). 
 
Figure 4.2.15. ROS production in ES cells in response to ascorbic acid (or vitamin 
C). 
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4.2.3. ROS production in response to proline is regulated in naïve and primed ES cells 
Given that ROS production is a direct product of proline oxidation by the enzyme 
Prodh and naïve and primed ES cells have differential expression of this enzyme, it was 
hypothesised that this could lead to different proline metabolism in different ES cell states 
and only primed ES cells with high level of Prodh will increase ROS in the addition of proline. 
Therefore, ROS production in the mitochondria was measured by flow cytometry in naïve and 
primed D3 ES cells in response to proline. First, the level of ROS production in naïve ES cells 
was compared to that of primed ES cells. It was found that the total ROS production was 
similar in naïve and primed ES cells. However, in naïve ES cells, ROSlo population produced 
significantly lower ROS than those of primed counterparts (Figure 4.3.6.B), most probably 
because naïve-ROSlo cells sit in a lower range of ROS compared to primed ES cells (Figure 
4.3.6.A). Different constitution of ROSlo and ROShi populations was also observed in naïve and 
primed ES cells. Particularly, there was a tendency that naïve state of ES cells had higher 
percentages of ROShi and lower percentages of ROSlo cells compared to primed state (in all 5 
replicates with p = 0.053), suggesting that ES cells of different pluripotent states may have 
distinguished ROS profiles. As ROS profiles were different in different pluripotent states: 
naïve, primed and primed + proline ES cells, it was hypothesised that this ROS was correlated 
with the production of ATP in these cells and that cells with higher ROS production generate 
higher ATP levels. ATP assay was performed in these cells to examine this question. 
Interestingly, naïve ES cells produced significantly higher ATP than primed ES cells (Figure 
4.3.7). Primed ES cells treated with proline showed a trend of increased ATP synthesis (in 4 
out of 5 experiments) compared to control cells (Figure 4.3.7). This has not been shown before 
in the literature even though it was shown that ATP level is higher in naïve ES cells cultured in 
2i+LIF compared to EpiSC cells cultured on KOSR and MEF (Zhou et al., 2012).  
Based on the ROS profiles, naïve and primed ES cells were then examined for their 
ROS production in response to proline. After 3 hours of proline addition to the culture media 
(at the concentration of 200μM), only primed but not naïve ES cells, significantly increased 
the production of ROS (Figure 4.3.8). Morphological investigation of naïve ES cells in response 
to proline informed that naïve ES cells were not able to obtain differentiated morphology in 
proline addition (Figure 4.3.9), confirming that proline-induced differentiation only occurs in 
primed ES cells and is correlated with the ROS production. Due to time restrain, WA30 ES cells 
were not investigated f or ROS production. 
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D3 ES cells grown in 2i+LIF and Serum+LIF conditions for at least 2 passages were used for 
ROS measurement by flow cytometry. A. Flow cytometry histogram of MitoSOX Red intensity 
(ROS production) in naïve and primed ES cells. B. Comparison of ROSlo production and the 
lowest or minimal (Min) levels of ROS detected in naïve and primed ES cells. n=5, *p≤0.05, 
**p≤0.01. 
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Figure 4.2.17. ROS production in naïve (2i+LIF) compared to primed (Serum+LIF) D3 ES 
cells. 
 
Figure 4.2.18. ATP measurement in ES cells in different pluripotent states.Figure 4.2.19. 
ROS production in naïve (2i+LIF) compared to primed (Serum+LIF) D3 ES cells. 
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Cells were grown in coat-free 96-well plate 24 hours before harvest. ATP measurement (μM) 
were normalised to the protein content (mg/mL) of the cells. 
  
Figure 4.2.20. ATP measurement in ES cells in different pluripotent states. 
 
Figure 4.2.21. ATP measurement in ES cells in different pluripotent states. 
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Histogram of MitoSOX Red intensity (ROS production) of naïve (2i+LIF) (A) and primed 
(Serum+LIF) (B) D3 ES cells. C. ROS production in response to 3 hr proline addition (200 μM) 
in naïve and primed D3 ES cells. The cells were grown for 24 hours before collection for 
analysis. 30 minutes before collection, MitoSOX Red dye was added to detect ROS production 
in the cells. *p≤0.05, n=6-9.   
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Figure 4.2.23. Reactive oxygen species production in D3 ES cells in response to 200μM 
proline. 
 
Figure 4.2.24. Morphological investigation of naïve (2i+LIF) and primed (Serum+LIF) D3 ES 
cells in response to proline for 4 days.Figure 4.2.25. Reactive oxygen species production in 
D3 ES ll  in response to 200μM proline. 
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Scale = 50 μm. 
 
  
Figure 4.2.26. Morphological investigation of naïve (2i+LIF) and primed (Serum+LIF) D3 ES 
cells in response to proline for 4 days. 
 
Figure 4.2.27. ROS production in ES cells in response to A. Ornithine (200 μM) and B. Low 
proline concentration (40 μM).Figure 4.2.28. Morphological investigation of naïve (2i+LIF) 
and primed (Serum+LIF) D3 ES cells in response to proline for 4 days. 
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4.3. Discussions 
4.3.1. ROS production revealed ES cell heterogeneity 
ES cell heterogeneity has been studied from different molecular aspects including 
epigenetics, DNA property, and transcriptomic and metabolomic diversity, which 
demonstrated the common presence of different ES cell subpopulations in culture (Hayashi 
et al., 2008, Wang et al., 2017, Turco et al., 2012, Singer et al., 2014, Tanaka, 2009, Herberg 
et al., 2016). In this chapter, the data show that D3 ES cell subpopulations could be defined 
by mitochondrial ROS production, adding a new parameter to determining ES cell 
heterogeneity. Many studies have investigated ROS production in ES cells using MitoSOX Red, 
which measure mitochondrial superoxide levels as the major source of ROS in the cell 
microenvironment (Prowse et al., 2012, Heo et al., 2016, Varum et al., 2009). None of these 
studies have mentioned the heterogeneous profile of ROS in their ES cell lines, even though 
the signs of ROS heterogeneity could be observed in the data of some experiments (Prowse 
et al., 2012, Heo et al., 2016, Marsboom et al., 2016). As a major product from mitochondrial 
activities, it is questionable whether the separation of ROS populations could link ES cell 
heterogeneity to their mitochondrial function.  
Spontaneous reversible differentiation occurring during cell growth appears to promote 
heterogeneity in ES cell in vitro (Nair et al., 2015, MacArthur et al., 2012). The transcription 
regulation network including Nanog, Oct4, Sox2 and Zfp42 forms a pluripotent circuity to 
govern ES cell fates (Masui et al., 2007, Mitsui et al., 2003). The changes in mitochondrial 
function were known to be associated with the changes in the pluripotent circuit that defines 
embryonic development (Harvey et al., 2011), somatic cell reprograming (Suhr et al., 2010) 
and ES cell differentiation (Cho et al., 2006a, Chung et al., 2007). Understanding the origin of 
ROS heterogeneity would be useful to confirm the role of mitochondrial activities in ES cell 
growth and help to predict potential ES cell fate.  
Physiological regulation of ROS is required to maintain genomic integrity in ES cells as 
the excessive ROS production of ROS could lead to oxidative damage to DNA content (Li and 
Marban, 2010, Saretzki et al., 2008) and the extreme suppression of ROS could affect the 
efficiency of DNA repair (Li and Marban, 2010). In the conversion of mice embryonic 
fibroblasts (MEFs) to mice induced pluripotent stem cells (iPSCs), physiological level of ROS 
was reported to be required for efficient nuclear reprograming, in which, both the decreased 
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and increased levels of ROS in MEFs resulted in the low iPSC yield (Zhou et al., 2016). In 
contrast, other data have documented that the use of antioxidants was efficient to reduce 
DNA damage in iPSC reprograming and support cell survival during the reprogramming 
process (Ji et al., 2014, Esteban et al., 2010). Indeed, ROS signalling has a range for optimal 
effects in ES cell growth. The data show that ROS production range is stable around the lowest 
points but not the highest points and vitamin C reduced ROS production by shifting the total 
population towards ROSlo position. It is suggestive that ES cell may have a minimal 
maintenance of ROS production and this may reflect the basic activities of the mitochondria 
to sustain the cell function.  
The need of minimal ROS production has been described in a model that was used for 
examinating mitochondrial uncoupling protein (UCPs) functions and was reviewed by Echtay 
and Brand (Echtay and Brand, 2007), but no study has examined the roles of minimal ROS 
requirement in PSCs. In fact, as ROS populations were associated with different MMP, it is 
possible that ROS heterogeneity could originate from cells with different mitochondrial 
properties. Ascorbic acid, which is commonly called vitamin C, is a strong antioxidant and is 
effective in reducing mitochondrial ROS by interacting with other mitochondrial enzyme 
activities (Valdecantos et al., 2010). It is questionable if low ROS level in vitamin C treatment 
is correlated with minimal MMP of the cells, and how vitamin C neutralise mitochondrial 
superoxide from the cells, or how cothe remaining ROS was still detectable. Further validation 
is needed to identify the relationship between ROS production and MMP as Mitotracker 
Green was observed to be affected by the presence of ROS or may be insensitive of MMP 
(Pendergrass et al., 2004, Xiao et al., 2016). At the same time, Mitotracker Green may also 
stain other organelles at high concentration as stated by the producers. The use of other MMP 
dyes may be informative and perhaps, the detection of mitochondrial features using electron 
microscope may be useful to understand mitochondrial profile of ES cell subpopulations 
during differentiation.  
In this experiment, no correlation was made for ROS production, MMP and ATP 
production in naïve and primed ES cells, however, as naïve ES cells appear to have a higher 
percentage of ROShi cells, they also produce significant higher levels of ATP when compared 
to primed ES cells. This, perhaps, is in the agreement with the previous finding that ES cells 
leaving naïve pluripotency show a reduction in glycolysis and OXPHOS (Kalkan et al., 2017), 
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and that ATP generation in naïve ES cells is higher than primed and differentiated ES cells 
(Zhou et al., 2012). This is also supported by the data in the literature, which suggests that 
naïve ES cells as grown in 2i, possess higher mitochondrial respiration and oxygen 
consumption rate compaired to primed ES cells, which are grown in MEF feeder and knock-
out serum (Guo et al., 2016, Zhou et al., 2012, Takashima et al., 2014). With the 
acknowledgement that media contents can contribute bias to the metabolic changes of ES 
cells (Rathjen et al., 2014, Zhang et al., 2016), the results in the literature are still consistent 
with the data in this thesis, where the culture media contents are more comparable, in that 
naïve ES cells are more active in energy generation compared to primed ES cells. In conclusion, 
the evidence suggests that high energy requirement is likely to be the characteristic of naïve 
ES cells cultured in 2i.  
The results also show a sign of increased ATP requirement in the transition of primed 
ES cells toward proline-induced differentiated cells. This is contrast with the data in human 
PSCs, which indicate that undifferentiated cells rely on glycolysis for energy production and 
produce more ATP than the differentiated counterparts, which are less dependent on 
glycolysis (Zhang et al., 2011a, Birket et al., 2011). However, compared to the differentiated 
cells from other types of differentiation, proline-induced differentiation generates 
pluripotent stem cells at a different commitment state of cell fate determination, and thus, 
more examination is required to confirm the increase in ATP level in proline-induce 
differentiated ES cells.  
4.3.2. Proline-induced ROS production is regulated in different pluripotent states 
Given that proline metabolic enzymes, including Prodh and Oat, were differentially 
expressed in naïve and primed ES cells, these cells may perform different mechanisms to 
respond to proline and thus, the dynamics of proline metabolism could be regulated in 
different pluripotent states. As ROS is a product from proline metabolism catalysed by Prodh 
(Donald et al., 2001), ROS could be controlled in different pluripotent states in ES cells by 
different response to proline. Recent studies have shown that metabolic profiles of naïve and 
primed ES cells are distinguished by different glycolytic gene expression (Kolodziejczyk et al., 
2015), lipid oxidation and amino acid metabolism (Sperber et al., 2015). These differences 
were correlated with the inhibition of GSK3 and MEK/ERK pathways (Kolodziejczyk et al., 
2015, Sperber et al., 2015), however, proline metabolism is not mediated by this inhibition, 
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but instead, by the expression of p53 and Myc (Donald et al., 2001, Yoon et al., 2004, Rivera 
and Maxwell, 2005, Liu et al., 2012). Myc plays a role in the proliferation and biogenesis of 
naïve ES cells cultured in 2i conditions (Scognamiglio et al., 2016) and proline metabolism was 
not mentioned to be involved in the biogenesis process of these cells. No changes in ROS 
production or morphology of naïve ES cells in response to proline were detected, suggesting 
that naïve ES cells did not have similar mechanism to produce ROS and to differentiate when 
being compared to primed ES cells. Previous data have shown that the inhibition of MEK by 
PD0325901 did not affect ES cell differentiation in MEDII media (Tan et al., 2016a). Perhaps, 
forcing the conversion of primed ES cells back to naïve state by 2i could be correlated with 
the inhibition of proline-induced ROS production and the differentiation potential in these 
cells. In other words, releasing inhibition of GSK3 and MEK/ERK pathways may activate proline 
response via proline metabolism and Prodh induced ROS production to prime ES cells for 
differentiation. More investigations into this hypothesis is required to understand the 
correlation of proline metabolism and ROS production in ES cell differentiation. 
Previous studies have reported that mitochondrial activities are regulated during the 
differentiation process, which results in the increased expression of the metabolic genes 
associated with oxidative metabolism and the decreased expression of stress defences 
(Saretzki et al., 2008, Chung et al., 2007). The question remains as of whether the changes in 
mitochondrial activities, including proline metabolism, could provide a signal for 
differentiation or are a consequence of differentiation initiation. Perhaps the production of 
ROS is likely to be an effect of differentiation process as the cells increase mitochondrial 
biogenesis upon differentiation initiation (Saretzki et al., 2008), but is not the requirement for 
differentiation. More investigations are required to clarify this posibility. However, the 
increased ROS production is observed in primed, but not naïve ES cells, and occurs early after 
proline addition and prolongs until 24 hours afterwards. In a time manner, the effect of ROS 
on nuclear reprograming occurred at the early state of reprograming and the later stage 
inhibition of ROS was found to have no effects on inhibiting MEFs reprograming (Zhou et al., 
2016). As pluripotent stem cells rely on glycolysis (Folmes et al., 2011, Prigione et al., 2010), 
which produces less ROS than OXPHOS to protect their DNA content (Li and Marban, 2010), 
a robust increase in ROS production in ES cells at the early stage of proline addition indicates 
that ROS production could be a requirement for the differentiation process of ES cells. 
Considering increased ROS production as a response of proline metabolism (Donald et al., 
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2001), and that ROS could be involved in ES cell differentiation via proline metabolism (Tan 
et al., 2016b, Tan et al., 2016a), the data in this chapter suggest that mitochondrial ROS could 
be induced by proline metabolism and provide signals to initiate the differentiation process.  
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Chapter 5 The involvement of Prodh activities and 
proline-induced reactive oxygen species in ES cell 
differentiation  
5.1. Introduction 
 Mitochondrial metabolism provides a source of active biochemicals that are involved 
in the regulation of pluripotent stem cells (PSCs), (Prigione and Adjaye, 2010, Lisowski et al., 
2018). The mitochondrial reshaping is achieved as the cells escape or enter pluripotency (Suhr 
et al., 2010, Bukowiecki et al., 2014) along with the cell metabolic programming, which can 
be observed in glycolysis, OXPHOS, and amino acid metabolism (Panopoulos et al., 2012). For 
programming, the cells need to adjust the mitochondrial activities and control the expression 
of the key metabolic enzymes, such as the oxidant and antioxidant factors (Saretzki et al., 
2008, Armstrong et al., 2010), which promotes the balance in the cell redox homeostasis and 
supports cell maintenance (Lisowski et al., 2018). As a result, modifications occur to the cell 
pluripotent circuit transcription and the epigenetics (Tatapudy et al., 2017). Given that the 
mitochondrial metabolism is critical to the cell response to the environment and is 
contributing to the determination of PSC fate, little is known about the links between the 
mitochondrial metabolic factors and their mechanisms of action on PSC programming. It 
remains unclear as to how the metabolism and metabolites interact with PSC developmental 
cues.  
Proline metabolism is known to play an important role in redox homeostasis of the 
mammalian cells to protect the cells from oxidative stress (Krishnan et al., 2008, Liu and 
Phang, 2012). The proline cycle, including proline catabolism and proline biosynthesis, was 
found to be required in the regulation of proline mediated tumour cell growth (Liu et al., 
2015). Not only are the products of proline catabolism important for cell programming, but 
the synchronised effects of generating and feeding P5C, a proline precursor, back to the cycle 
are also required for the cell proliferation (Liu et al., 2015). The proline cycle includes multiple 
reactions that create a pool of metabolites and redox molecules such as NAD(P)+ and 
NAD(P)H, which are linked to glutamine metabolism and aerobic glycolysis (Hagedorn and 
Phang, 1986, Liu et al., 2015). Moreover, proline metabolism is positioned in the middle of 
the mitochondrial activities and its metabolites could be fed to the tricarboxylic (TCA) thus, 
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proline metabolism is proposed as a key node in the regulation of cell function via the 
interaction with other metabolisms and mitochondrial activities.  
The proline oxidation enzyme, Prodh, is a p53-dependent protein that is required for 
the proline-driven ROS production to initiate apoptosis in a variety of cancer cells (Donald et 
al., 2001, Rivera and Maxwell, 2005). Prodh is also found to play a protective role against 
hydrogen peroxide induced cell death in melanoma and prostate carcinoma cells (Natarajan 
et al., 2012). Depending on environmental factors, Prodh may play a different role in 
mediating cell responses via ROS production, which includes the interaction with other 
metabolic pathways to maintain redox homeostasis in cancer cells (Phang et al., 2012). 
Multiple downstream regulators have been investigated in relation to Prodh and proline, 
reporting their functions in activating key proteins via phosphorylation such as Akt, p38-MAPK 
and Src (Natarajan et al., 2012, Tan et al., 2016a). In contrast, the increased expression of 
Prodh without additional exogenous proline results in the reduced phosphorylation of MAPK 
and MEK/ERK (Liu et al., 2006). It is questionable whether proline is involved in other redox 
regulatory roles rather than its own metabolism. The production of mitochondrial ROS has 
been documented to cause the phosphorylative and oxidative activation of proteins (Ito et 
al., 2006, Ding et al., 2008). However, there is a missing connection that links Prodh activity 
and proline metabolism to the generation of ROS and redox signalling. In proline-induced ES 
cell differentiation, exogenous proline is known to generate ROS production, and the use of 
Prodh inhibitors prevents both ROS and the differentiation process (Tan et al., 2016a). The 
use of antioxidants inhibited the morphological differentiation of ES cells with the addition of 
proline (Casalino et al., 2011) and the activation of ROS signalling pathways was suggested 
(Tan et al., 2016a). However, the link from proline catabolism to ROS activation during the 
differentiation process has not been discovered. In this thesis, the regulation of proline 
metabolic enzyme expression and the dynamic ROS production following proline addition 
have been examined, and the correlation of ROS production with the differentiation of ES 
cells has been suggested. The mechanism of proline-induced ROS production in ES cell 
differentiation remains unknown. It is hypothesised that the proline oxidation reaction 
catalysed by Prodh is correlated with ROS production and this ROS is required for ES cell 
differentiation.  
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To address this hypothesis, ROS production was measured in D3 ES cells with the addition 
of Prodh inhibitors in the presence of proline. This would create a correlation of ROS 
production with the proline oxidation. ES cells in this treatment were also examined for the 
differentiated phenotype and pluripotent gene expression to confirm if the inhibition of 
Prodh and proline catabolism is associated with the differentiation process. To access the role 
of ROS in differentiation, multiple antioxidants were used to keep ROS at low levels, where 
after, the phenotypic and transcriptional investigation of ES cells was performed to validate 
whether ROS was required for differentiation. In addition, NADP+/NADPH ratio was quantified 
to demonstrate the changes to the redox status within the cells following the proline 
treatment and to confirm the role of ROS via redox homeostasis. The results would establish 
the link between Prodh activity and ROS production to the differentiation of ES cells.  
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5.2. Results 
5.2.1. Proline-induced ROS production is dose dependent and is correlated with ES 
cell differentiation 
The data in the previous chapter showed that ROS production increased in response to 
200 μM proline, which was efficient enough to induce ES cell differentiation. However, at a 
lower concentration, 40 μM proline has been shown to be ineffective to induce ES cell 
differentiation (Washington et al., 2010). The question remains as to whether ES cells increase 
ROS production as a response to proline at this low concentration. Therefore, ROS was 
measured in ES cells 24 hours after 40 μM proline was added, which showed no significant 
increase in ROS production in ES cells, and ROS production was significantly lower in ES cells 
that were treated with 200 μM proline (Figure 5.2.1.B), suggesting that ROS production is 
dependent on the concentration of proline and is correlated with ES cell differentiation.  
Proline metabolism involves the conversion of ornithine to proline via the activity of Oat 
enzyme (Adams and Frank, 1980). In this conversion, the production of the intermediate, P5C, 
was suggested to be involved in the differentiation process (Casalino et al., 2011). It is 
unknown whether the conversion of ornithine to proline by Oat enzyme can raise the cellular 
concentrations of proline, which increases proline oxidation by Prodh to produce ROS in ES 
cells as a consequence. Previous observations suggested that ornithine did not lead to ES cell 
differentiation (data not shown). It raises the hypothesis that the addition of ornithine does 
not lead to the production of ROS and therefore does not lead to ES cell differentiation. To 
test this hypothesis, ROS was measured in response to 200 μM ornithine and ES cell 
differentiation was examined via the morphological changes and gene expression. At the 
same concentration to proline, 200 μM ornithine was not sufficient to increase ROS 
production and induce ES cell differentiation (Figure 5.2.1 and 5.2.4.D.). This was ten-fold 
lower than the concentration that was used successfully in the literature to induce 
differentiation (Casalino et al., 2011), but reflected the physiological range of ornithine amino 
acid in mammals (Kwon et al., 2003, Wu et al., 2008, Ginguay et al., 2017). Thus, the 
biosynthesis of proline from ornithine was not sufficient to replace proline in inducing ROS 
production and in driving ES cell differentiation, at least with the addition of ornithine at the 
physiological level. 
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ES cells were treated with 200 μM ornithine and 40 μM proline concentration for 24 hours 
before collection. 30 minutes before collection, cells were stained with 7.5 μM MitoSox Red 
in complete media in the incubator. Cells were then visualised by flow cytometry. Non-treated 
ES cells and ES cells treated with 200 μM proline were included for controls. *p ≤ 0.05, n=3-5. 
 
 
  
Figure 5.2.1. ROS production in ES cells in response to A. Ornithine (200 μM) and B. Low 
proline concentration (40 μM). 
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5.2.2. Prodh inhibitors were not sufficient to prevent proline-induced ROS 
production and differentiation 
To evaluate whether proline oxidation is correlated with ROS production and differentiation, 
the Prodh inhibitors, 3, 4- Dehydroproline (DHP) and L- tetrahydro-2-furoic acid (THFA) were 
used to compete with proline for the binding on Prodh as previously described (Smith et al., 
1962, Natarajan et al., 2012). After 24-hours of treatment with 200 μM DHP and THFA, none 
of the inhibitors were effective to prevent ROS production in ES cells in response to proline 
(Figure 5.2.2.B). Furthermore, the addition of DHP increased ROS production significantly 
when compared with both proline treated and untreated control ES cells (Figure 5.2.2.B), and 
this is the highest ROS level that could be detected in ES cells during this study. However, 
when DHP was added to ES cells treated with proline, ROS production was returned to the 
same level as proline treatment alone (Figure 5.2.2.B), suggesting that proline inhibited the 
effect of DHP in inducing extreme ROS production. At the same time, the morphological 
examination of Prodh inhibitors showed that DHP led to growth arrested in ES cells, which 
was rescued by the addition of proline (Figure 5.2.3.C). The addition of proline not only 
restored the growth arrested condition, but also induced ES cell differentiation, suggesting 
that DHP was not efficient enough to inhibit the proline effect on ES cell differentiation (Figure 
5.2.3.C). This contrasts with the previous findings that DHP can inhibit proline-induced 
differentiation and ROS production (Tan et al., 2016a, Casalino et al., 2011), possibly due to 
different types of measurements and different use of the proline/DHP ratios. However, even 
when the similar proline/DHP ratios were applied, ROS production did not alter (data not 
shown). When compared to control ES cells, the addition of DHP alone to ES cells significantly 
reduced the expression of Dnmt3b while Otx2 expression increased (Figure 5.2.4.B), which is 
significantly different from both the controlled and proline-induced differentiated ES cells, 
suggesting that DHP produced different effects to ES cells and is not related to proline. 
Similarly, even though TFHA did not create any alterations to ES cell pluripotency and ROS 
production, it was not efficient to reduce proline-induced ROS after 24 hours and was not 
effective in preventing proline-induced ES cell differentiation after 4 days (Figure 5.2.2.B and 
5.2.4.B).  
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A. Antioxidants. B. Prodh inhibitors. GSH (1mM), NAC (50 μM), DHP (200 μM) and THFA (200 
μM). n=3, * or # p ≤ 0.05, ** or ## p ≤ 0.01 *compared to ES control, # compared to ES+ 200 
μM Pro. Bar: SEM 
 
  
Figure 5.2.2. ROS production in ES cells with the addition of antioxidants and Prodh 
inhibitors. 
 
Figure 5.2.3. Morphology examination of ES cellsFigure 5.2.4. ROS production in ES cells 
with the addition of antioxidants and Prodh inhibitors. 
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5.2.3. The coeffect of ROS production and mTOR activation did not lead to ES cell 
differentiation 
Given that mTOR is activated by a number of amino acids such as proline, leucine and 
glycine (Washington et al., 2010), the question remains whether ROS production and mTOR 
activation are both required in order to initiate ES cell differentiation. Since DHP could 
increase ROS production, but not necessarily activate mTOR, leucine was also used to 
contribute the additional mTOR signal (Washington et al., 2010) thus, DHP and leucine (1mM) 
were added to ES cells to examine if this combination would be sufficient enough to activate 
the differentiation process. DHP (200 μM) and leucine (1mM) were added to ES cells for 24 
hours, which showed that the co-activation of ROS production and mTOR was insufficient to 
cause ES cell morphology toward proline-induced differentiation (Figure 5.2.2.B and 5.2.4.B). 
In addition, DHP still caused arrested cell growth and leucine could not restore this effect 
(Figure 5.2.3.C). It then raised the question, of whether the pluripotency of ES cells was 
changed by the addition of DHP, and thus, led to the arrested growth observed in the 
experiment. To confirm this possibility, the gene expression of Oct4 (or Pou5) and Nanog was 
examined in DHP treated ES cells. The resulting data showed that Oct4 and Nanog expression 
in ES cells was not altered in DHP treatment (Figure 5.2.4.C). Similar results were observed in 
ES cells treated with both DHP and leucine (Figure 5.2.4.C), confirming that leucine was 
insufficient to overcome the effects of DHP.  
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ES cells were treated with Ornithine (panel A), Antioxidants (panel B), and Prodh inhibitors (panel C). D3 ES cells were treated with different 
components at fixed concentrations: 200 μM proline, 200 μM ornithine, 50 μM Vitamin C, 500 μM NAC, 1 mM GSH, 200 μM THFA, 200 μM 
DHP and 1 mM Leucine. The cells were grown for 4 days with new media replaced every 24 hours. Images were taken at the end of day 4. All 
scales = 100 μm. 
 
 
Figure 5.2.5. Morphology examination of ES cells 
 
Figure 5.2.6. Morphology examination of ES cells 
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5.2.4. Antioxidants were insufficient to reduce proline-induced ROS production and 
ES cell differentiation 
When addressing whether ROS production in ES cells in response to proline is required 
for ES cell differentiation, popular antioxidants including N-acetyl-cysteine (NAC) and 
glutathione (GSH) were used to prevent the production of ROS in ES cells. The cells were then 
collected to investigate the effects of the antioxidants on the differentiation of ES cells via the 
morphological changes and the pluripotent marker gene expression. There was no significant 
reduction of ROS in the treatment with either NAC or GSH (Figure 5.2.2.A). The less popular 
antioxidants such as vitamin E and Trolox were also tested but none of them were effective 
in reducing ROS production in ES cells in response to proline (data not shown). None of the 
antioxidants were effective in preventing the morphological differentiation of ES cells in 
response to proline (Figure 5.2.3.B). The examination of the pluripotent marker expression 
indicated that Vitamin C had a mild effect on preventing ES cell differentiation (Figure 5.2.4.A). 
However, none of other antioxidants were effective in inhibiting the activity of proline (Figure 
5.2.4.A), suggesting that the use of antioxidants, apart from Vitamin C, was not sufficient 
enough to reduce ROS and prevent the differentiation of ES cells. Vitamin C, even though 
exerting a strong effect on reducing ROS production in ES cells, was not able to fully reduce 
the effects of proline on ES cell differentiation. This confirms that ES cell differentiation was 
not solely driven by ROS but also by other factors from the addition of proline. It should be 
noted, that the cells were collected for the gene expression examination at the 96-hour time 
point and 24 hours after fresh antioxidants were replaced. As the measurement of ROS was 
only taken at the 24-hour time intervals, and 4 hours after the antioxidants were added to 
the cells, it remains unclear as to whether the half-life of each antioxidant in the cell 
environment was sufficient to overcome the effects of proline.  
 
 
 
 
 
 
 
 
 
 
Chapter 5  Van T. T. Nguyen 
124 
 
 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pluripotent markers in ES cells treated by Prodh inhibitors 
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C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ES cells treated with Antioxidants (A) and Prodh inhibitors (B, C) and Ornithine (D). D3 ES cells 
were treated with different components as stated in Figure 5.2.3. The expression fold change 
was calculated by dividing the normalised expression values from each treatment by ES cell 
control’s (or ES (Ctrl) as marked). Paired t test based on the ratio of expression to ES cells (p 
values in *) or to ES + Pro cells (+Pro as marked, p values in #) were performed. The presence 
of a * shows that the expression of the gene was significantly different from ES cells, or more 
similar to EPL cells. The presence of a # shows that the expression was significantly different 
from EPL cells, or more similar to ES cells. The presence of both a * and a # shows that the 
expression of the gene was significantly different from both ES and EPL cells. n=3, * or #p ≤ 
0.05, ** or ## p ≤ 0.01, *** or ### p ≤ 0.001. 
  
D. 
 
Fi
g
ur
e 
5.
2.
7. 
G
e
n
e 
e
x
pr
es
si
o
n 
of 
k
y 
pl
ur
ip
ot
e
nt 
m
ar
k
er
s 
fr
o
m 
D
3 
E
S 
Figure 5.2.8. Gene expression of key pluripotent markers from D3 ES cells 
 
Figure 5.2.9. Gene expression of key pluripotent markers from D3 ES cells 
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5.2.5. The increase in ROS production was not associated with the changes in 
NADP/NADPH ratio 
 Given the robust increase in ROS production in ES cells in response to proline, it was 
hypothesised that these changes in ROS levels were associated with the changes in the redox 
status of the cells. To address this question, nicotinamide adenine dinucleotide phosphate 
(NADP+) and its reduced form, NADPH, was measured in ES cells in response to the addition 
of proline. The conversion of NADP/NADPH was also suggested to illustrate the proline 
biosynthesis process by P5C reductase as shown in intact mitochondria (Hagedorn and Phang, 
1986) thus, the increase in NADP/NADPH levels could indicate that proline completes a 
catalytic cycle and P5C is reversed back to proline. This conversion may play a role in proline-
induced differentiation given that P5C is suggested to be involved (Casalino et al., 2011). The 
measurement of the total cell lysates showed no significant difference in the NADP/NADPH 
ratios in ES cells between the untreated controls and proline treated cells (Figure 5.2.5), 
suggesting that ROS was not involved in the redox balance of the total NADP/NADPH levels. 
However, in this experiment, NADP/NADPH ratio was measured at the cellular, but not, the 
mitochondrial levels and the dynamics of proline catalysis within the mitochondria, and thus 
inconclusive. 
 
 
 
 
 
 
 
 
ES cells were grown in non-coated 24-well plate at the density of 4x105 cells/well/500 μL 
media for 24 hours in Serum+LIF or Serum+LIF+Proline media before they were collected for 
NADP/NADPH assay. The absorbance at 460 nm wavelength reflected the concentration of 
NADPH concentration inside the cells. The concentration of NADPH (μM) was then normalised 
to the total protein concentration (mg/ml). Bar: SEM.  
Figure 5.2.10. NADP/NADPH measurement in D3 ES cells in response to proline. 
 
Figure 5.2.11: Possible sites of future investigation for the proline-induced 
differentiation in ES cellsFigure 5.2.12. NADP/NADPH measurement in D3 ES 
cells in respo se to proline.
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5.3. Discussion 
5.3.1. Proline oxidation is not primarily required for proline-induced ROS production 
and ES cell differentiation 
 Proline oxidation that is catalysed by Prodh was suggested as a source of 
mitochondrial superoxide and hydrogen peroxide production in insects and human cell lines 
(Goncalves et al., 2014). Without the presence of the enzyme Prodh, proline itself is 
insufficient to increase ROS production in cancer cells (Donald et al., 2001), indicating that 
proline-induced ROS production is associated with proline oxidation catalysed by Prodh. In 
this study, the use of Prodh inhibitors, DHP and L-THFA showed no effects in reducing proline-
induced ROS production in ES cells or preventing ES cell differentiation, suggesting two 
possibilities: a/ the mitochondrial ROS production that was measured in ES cells, was not a 
product from proline metabolism but  was a result of other effects of proline-induced 
differentiation in ES cells and/or b/ DHP and L-THFA were not sufficient, at least at the 1:1 
ratio to proline, in inhibiting Prodh and proline oxidation.  
Proline metabolism can be linked to multiple cell metabolic processes such as the TCA 
and urea cycles (Liu and Phang, 2012). The presence of Prodh and Prodh activity are known 
to increase the levels of α-ketoglutarate (α-KG) and decrease the levels of succinate, fumarate 
and lactate (Liu et al., 2009). In addition, proline was found to increase the levels of  NAD(P)H 
reduction in the presence of rotenone (Goncalves et al., 2014). This evidence suggests that 
proline and proline metabolism both play a multiple role in regulating mitochondrial 
functions. It is possible that the detection of mitochondrial superoxide with the addition of 
proline in ES cells came from the summary effect of this regulation. The sources of proline-
induced ROS production were investigated in mammalian cells (Hancock et al., 2016, 
Goncalves et al., 2014). Prodh is known to provide electrons to the electron transport chain 
(ETC) and is an indirect source of superoxide and H2O2 production in intact mitochondria 
(Goncalves et al., 2014). Prodh was also shown to transfer electrons directly to the Coenzyme 
Q1 and the expression of Prodh directly down-regulated proteins of the ETC, leading to a 
decreased respiratory rate (Hancock et al., 2016). The data raise the possibility that the 
production of ROS in response to proline could be generated from different sites of the 
mitochondria. In addition, the use of the Prodh inhibitor, DHP, alone could inhibit the 
suppression effect of Prodh on ETC proteins which results in an increase in mitochondrial 
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respiration (Hancock et al., 2016). It is thus suspected that the use of DHP may not be effective 
in preventing mitochondrial ROS production but may provide an effect upon ETC proteins and 
mitochondrial respiration. As L-THFA should inhibit Prodh oxidation similarly to DHP, the use 
of L-THFA is expected to increase mitochondrial respiration. However, this was not supported 
by the ROS measurement data, which showed that L-THFA itself did not change ROS 
production in ES cells. It is also noticed that ES cells or PSCs do not have mature mitochondrial 
features and low mitochondrial functions (Suhr et al., 2010, Bukowiecki et al., 2014). This 
makes it challenging to study the efficiency of the mitochondrial transport. The understanding 
of immature mitochondria and their roles in ES cells is poorly understood, thus the effect of 
DHP and L-THFA as an inhibitor of Prodh in ES cells may be inconclusive based on ROS 
production. It was found that DHP inhibited the formation of hydrogen peroxide H2O2 in ES 
cells with the addition of proline (Tan et al., 2016a).  DHP and L-THFA may provide different 
outcomes in ES cells and none of those outcomes directly affect the proline-induced 
mitochondrial superoxide production. ROS production could be the total sum effect of cell 
responses to proline rather than an effect of proline metabolism, and therefore, the 
conversion of proline to P5C may be more useful to study DHP and L-THFA in Prodh inhibition 
(Hagedorn and Phang, 1986, Nishimura et al., 2012, Hancock et al., 2016). 
DHP has been previously used for preventing proline-induced differentiated 
morphology in ES cells at the three to one ratio with proline (150 μM DHP and 50 μM proline) 
(Casalino et al., 2011). The addition of DHP was reported to prevent the differentiation of ES 
cells by decreasing the expression of Dnmt3b and Otx2, key markers of proline-induced 
differentiated cells (Tan et al., 2016a). However, the morphology of ES cells in response to 
DHP reflected the growth arrested condition at the concentration of 200 μM, in which, the 
cell colonies appeared in a similar shape to the undifferentiated populations. The addition of 
proline restored this effect, and at the same time, induced differentiation. The restoration of 
the DHP-induced growth arrested morphology in ES cells was only specific to proline and was 
independent from mTOR activation due to the use of leucine which was ineffective. Together, 
these data suggest that the combination of mTOR activation and ROS production were not 
involved in ES cell differentiation and that the differentiation process was only specific to 
proline, confirming the previous finding on proline-induce differentiation (Washington et al., 
2010). While DHP has shown adverse effects on cell growth, the addition of DHP on its own 
did not affect ES cell key pluripotent markers Oct4 and Nanog. However, DHP reduced the 
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DNA methylation enzyme Dnmt3b expression and increased the differentiation marker Otx2. 
Previous studies have reported that Dnmt3b plays a role in DNA methylation and the reduced 
expression of Dnmt3b can result in the decrease of global DNA methylation in ES cells (Liao et 
al., 2015, Chen et al., 2003). Otx2 is known to play a role in the transition of ES cells to EpiSCs 
and in the maintenance of EpiSCs (Acampora et al., 2013). Therefore, DHP may serve a 
function in regulating ES cell methylation via the downregulation of Dnmt3b without affecting 
the cell pluripotency (Liao et al., 2015), while at the same time, inducing ES cell transition to 
the later primed state of pluripotency. To understand the role of DHP in ES cell programming 
and the regulation upon the pluripotent circuit, more investigation of DHP in ES cell function 
and pluripotency are required.  However, given the extreme increase of ROS production in 
the addition of DHP, DHP effects may be more associated to the decrease in cell maintenance 
by increasing apoptosis in ES cells. This is supported by previous studies that DHP could inhibit 
collagen synthesis and the use of DHP was found to be toxic to bacterial cells (Kerwar, 1979, 
Smith et al., 1962). As the use of L-THFA did not affect ES cell growth, L-THFA may be safer 
than DHP in inhibiting the function of Prodh. Given that these inhibitors were not effective in 
reducing proline-induced ROS production and ES cell differentiation, the evidence proposes 
that ROS production in response to proline was not generated from the oxidation of proline 
and proline metabolism was not involved in the differentiation of ES cells. To confirm this 
finding, a cell system to track Prodh activity, and or, to effectively inhibit Prodh, may include 
the regulation of Prodh gene expression in ES cells, which may provide more opportunities to 
study the role of Prodh and proline metabolism in ES cell differentiation. 
5.3.2. ROS production in ES cells is correlated with proline responses but is not 
primarily required for ES cell differentiation 
 Given that low concentrations of proline is ineffective in driving ES cell differentiation 
(Washington et al., 2010), and did not induce the production of ROS, it appears that the 
proline response is a dose dependent effect and proline may have a concentration  threshold 
to generate ROS and regulate differentiation. At the same time, the biosynthesis of proline 
from ornithine did not produce ROS and did not lead to differentiation, demonstrating that 
there may be a correlation between proline-induced ROS production and ES cell 
differentiation. In fact, as primed ES cells did not express high levels of Oat, it was uncertain 
if the conversion of ornithine to proline was effective in primed ES cells or a high 
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concentration of ornithine may be required to initiate similar effects to proline (Casalino et 
al., 2011), which may fall out of the cell physiological range and may not recapitulate the 
natural pool of amino acids in mammals. It is known that the concentration of ornithine during 
the embryonic development does not exceed 600 μM, moreover, in adult humans a plasma 
concentration of 400 μM is considered to be toxic and damaging (Tanzer et al., 2011, Kwon 
et al., 2003, Ginguay et al., 2017). It is important to understand the transport and uptake of 
ornithine in ES cells in order to evaluate the role of ornithine in relation to the proline 
metabolic role in ES cell differentiation. 
As none of the antioxidants used were effective in reducing ROS production or ES cell 
differentiation, except for vitamin C, it suggests that ROS production in response to proline 
and the differentiation process may be correlated. The addition of vitamin C reduced ROS to 
the lowest levels that could be detected in ES cells but only generated a minor effect in 
preventing ES cell differentiation, suggesting that ROS may be involved but is not a primary 
requirement for the differentiation process. In fact, proline was reported to play a role in the 
methylation of ES cell DNA that resulted in ES cells being primed towards epiblast stem cells 
(EpiSCs) and vitamin C reversed this effect and converted ES cells back to the naïve state of 
pluripotency (D'Aniello et al., 2017). ROS could be a response of the proline-induced 
differentiation, which provides the possibility that it is correlated with the differentiation 
initiation process rather than being a driven factor. Depending on the environmental factors 
and cell states, the expression of Prodh may support the withdrawal of proline from other 
sites that are contributing to the cell redox status. Specifically, proline and vitamin C are 
involved in the catalytic activities of the enzyme family prolyl-4-hydroxylase (P4H), which can 
function in collagen synthesis and the regulation of the hypoxia-inducible transcription factor 
HIF (Gorres and Raines, 2010, Myllyharju, 2013). P4H enzyme reaction requires 2-
oxoglutarate (2-OG), which is also known as α-ketoglutarate (or α-KG), and ascorbate to bind 
to the catalytic site (Myllyharju, 2013). Furthermore, α-KG is a product of the TCA cycle that 
has been reported to correlate with the expression of Prodh to regulate the HIF-1α pathway 
(Liu et al., 2009). Even though it remains unclear as to the role of proline and vitamin C in the 
regulation of HIF-1α pathway of ES cells, the expression of HIF-1α downstream elements has 
been observed (D'Aniello et al., 2017), given that HIF-1α itself plays a role in regulating PSC 
metabolism and differentiation (Prigione et al., 2014, Zhou et al., 2012). More investigation 
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into this hypothesis is required in order to establish the mechanisms of proline-induced 
differentiation.  
It should be noted that the measurement of ROS was limited to mitochondrial 
superoxide, which cannot be presented as the total ROS of the cells. Therefore, the use of 
antioxidants, GSH and NAC may be more effective in reducing hydrogen peroxide (H2O2) and 
hydroxyl radical (OH-) levels rather than superoxide (Murphy et al., 2011). In addition, 
questions remain about the cell transport of these antioxidants into the mitochondria to 
suppress the production of ROS, as well as the half-life of each antioxidant, including vitamin 
C. For example, in this study the effects of vitamin C in reducing ROS was measured at a 4 
hour interval and after being added to the cells, but the effect upon differentiation was 
examined at day 4 of the proline addition with media to be replaced every 24 hours. Thus, it 
may be inconclusive that these antioxidants were effective in preventing mitochondrial ROS 
production and proline-induced differentiation. In other words, proline may have exerted a 
longer half-life than vitamin C and regained its control after the antioxidant effects had 
ceased. It is possible that as vitamin C was sufficient to reduce mitochondrial superoxide and 
prevent differentiation to a small extent, it is possible that the differentiation may be partially 
dependent upon proline-induced mitochondrial superoxide. Furthermore, the conversion of 
superoxide into other types of ROS such as hydrogen peroxide can be performed by the 
mitochondrial enzyme manganese-dependent SOD (MnSOD) (Brand, 2016). The examination 
of different types of antioxidants such as MnSOD and different types of ROS could elucidate 
the active involvement of ROS in ES cell programming.  
The redox pair NADPH/NADP+ is an important metabolic factor of the mitochondrial 
homeostatic regulation system (Agledal et al., 2010, Xiao et al., 2018). The amount of oxidised 
NADPH was reported in the catalytic activity of proline metabolism by using the mitochondrial 
protein pool (Hagedorn and Phang, 1986). The conversion of NADP+ and NADPH is also known 
to link proline to glucose metabolism via the pentose phosphate pathway (PPP) (Phang et al., 
2012) however, it is unknown if the changes in NADP+/NADPH ratios in the intact 
mitochondria can be generated into the changes within the whole cells. Given that no changes 
in the NADP+/NADPH levels were observed after the 24 hour addition of proline to ES cells, it 
suggests that the redox balance could have been achieved at this time point, thus, this result 
may not be used to conclude the redox status of the cells, and it is suspected that the 
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measurement of other redox couples may provide similar outcomes as the redox balance is 
an immediate response. In fact, the global cell redox couple GSH/GSSG ratios was shown to 
remain unchanged in ES cells in response to proline (D'Aniello et al., 2017). Given that redox 
homeostasis in the cells is interchangeable, various time points and multiple redox targets 
should be considered for future investigation. Indeed, the downstream targets of these redox 
changes of ES cells would be useful to highlight the role of ROS in cell signalling, for example, 
protein oxidation may be more stable for quantitation and would provide a more reliable 
indicator for understanding the mechanism of ROS signalling in response to proline. This can 
be achieved by investigating different types of ROS-induced protein modifications such as 
thiol oxidation, disulfides and s-glutathionylation (Cai and Yan, 2013, Grimsrud et al., 2008). 
To finalise the role of proline metabolism and ROS production in the proline-induced 
differentiation of ES cells, effective neutralisation of ROS must be considered. Previously, 
superoxide dismutase (SOD) was used to effectively target mitochondrial ROS (Murphy et al., 
2011, Fridovich, 1997) and thus, SOD can be used alternatively to reduce ROS production in 
ES cells. The effective inhibition of ROS production would be useful to investigate the role of 
ROS in ES cell programming, however, it should be considered that low ROS levels may 
potentially affect  cell stability (Li and Marban, 2010). Therefore, the efficient manipulation 
of the Prodh-induced ROS production system may be more effective in addressing these 
issues, which again, highlights the need for a regulatory system of the Prodh expression in ES 
cells. 
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Chapter 6 Discussion and Future work 
6.1. Overview of findings 
Proline metabolism is conserved in multiple species including plants and mammals. 
Proline metabolism and its metabolites have been investigated in several cell models to 
elucidate their roles in cell programming. However, none of these studies have successfully 
identified those mechanisms which produce proline metabolically induced cell changes. As 
proline metabolism is a complex network which involves multi-reactions in the cell the 
environment, it is critical to understand the cross-talk between proline metabolism and cell 
modifications. This thesis is the first to study the relationship between the expression of the 
proline metabolic enzyme family and the production of proline-induced ROS in ES cell 
differentiation, which has been discussed in chapter 3 and 4. This is also the first study looking 
at ROS levels in different pluripotent states of ES cells, which confirms the distinguished 
proline metabolic dynamics in naïve and primed ES cells and suggests the roles of proline 
induced ROS in differentiation. The data in chapter 5 of this thesis have shown that proline 
metabolism may not be the source of ROS production and ROS may not be the key active 
component in proline-induced differentiation. However, the evidence could not completely 
exclude the involvement of Prodh and ROS in ES cell differentiation as their activities were 
inconclusive. Different approaches into the functions of Prodh and ROS should be considered 
for future investigation. For example, using Prodh-/- cell lines or the controlled knockdown of 
Prodh translation could potentially suggest if the change in Prodh expression influence 
changes in the spectrum of ES cell differentiation. The detection of other ROS types could 
possibly offer an opportunity to examine the overall pool of ROS within ES cells and its 
potentially significant role in the cell programming. Future work also warrants the 
involvement of P5C and the further investigation of other possible sites of proline acceptors 
within the cells.  
6.2. The novel role of the proline metabolic switch in pluripotent lineage 
specification 
Proline metabolic switches have been investigated in a number of cancer cells and 
were suggested to be involved in cancer development (Elia et al., 2017, Liu et al., 2012). The 
increase in proline biosynthesis from glutamine is required to support prostate cancer cell 
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growth and proliferation (Liu et al., 2012). However, in lung cancer cells, the gain of metastatic 
characteristics was associated with increased proline oxidation (Elia et al., 2017). The 
inhibition of Prodh, known as the key enzyme responsible for proline oxidation, was effective 
to prevent the growth and metastasis of cancer cells both in vitro and in vivo (Elia et al., 2017). 
Perhaps the proline metabolic switch is important for cell programming in high proliferative 
cells as it is also found in ES cells.  
There have been debates in the literature about how ES cells of different pluripotent 
states can be best profiled. The data in chapter 3 of this thesis propose that proline 
metabolism may be an important indicator of the moving from naïve to primed pluripotency, 
although the possibility of using proline metabolism to identify ES cells of different pluripotent 
states will require further validation. A systematic review of the data of expression arrays in 
the literature may be useful for future investigation, thus, it is important to develop an 
algorithmic pipeline that can analyse expression data across multiple platforms. The 
integration of the gene expression and metabolomic data may potentially unravel and reveal 
new characteristics and cell pathways to better define the pluripotent lineages of ES cells 
based on their metabolism.  
6.3. Mitochondrial superoxide production and mitochondrial activities 
Mitochondrial superoxide production reflects mitochondrial activities, and this study 
is the first to suggest that ES cell heterogeneity can be detected by the measurement of 
mitochondrial ROS production in live ES cells. The origins of the heterogeneous populations 
are not known, and ES cell heterogeneity, in which, key pluripotent transcription factors 
fluctuate in spontaneous differentiation (Graf and Stadtfeld, 2008), still remain an unresolved 
question in stem cell biology. What cellular factors contribute to the phenomenon and how 
they cross-talk to cell changes are largely unknown. Therefore, it requires further examination 
to determine whether the heterogeneous ROS population are in correlation with the 
oscillatory expression of the pluripotent circuit and different metabolic signatures in ES cells. 
The increased mitochondrial superoxide production in primed ES cells soon after the addition 
of proline indicates that proline is an active supplement that can quickly accelerate ES cell 
response. It would be interesting to examine if the addition of other amino acids that are 
transported by Snat2 would give rise to similar responses in ES cells. Snat2 and mTOR have 
been shown to provide signals to mammalian cells in response to exogenous nutrients (Hyde 
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et al., 2007, Sahu et al., 2016). Examination of whether Snat2 or mTOR may be responsible 
for the increased mitochondrial ROS production in response to proline or other amino acids 
would clarify the role of nutrients in the culture of ES cells and how they cross-talk to the 
changes in the cell mitochondrial activities.  
When considering ES cells with heterogenous ROS populations, questions are raised 
around what intrinsically defines these ROS levels and if the mitochondrial membrane 
potential is associated with ROS production, and as to whether these ROS populations have 
different metabolic properties or are in distinguished pluripotency or cell states. This 
knowledge may be beneficial in therapeutical application, given pluripotent stem cells are the 
key element necessary for regenerative medicine. The understanding that ES cells have 
different metabolic states and ROS production will also aid in the decision as to whether the 
use of low or high metabolic cells would be more beneficial in different types of treatments. 
With the understanding that the origins of different ROS profiles need validation and 
investigation, it is hypothesised that the use of a single population of ROS profile will be more 
stable and more predictable in justifying the outcomes of applying PSCs as a treatment. 
Perhaps the increase in ROS production in ES cells treated with proline is a direct result of the 
differentiation process as being suggested in chapter 5. It has been shown that the level of 
ROS production in ES cells and differentiated cells can be dependent on the cell size 
(Lyublinskaya et al., 2017). The question remains, as to whether this is correlated with 
mitochondrial function and will require further research.  
6.4. The role of vitamin C and proline in ROS production in ES cells 
Findings of the ROS measurement indicated that only vitamin C was efficient enough 
to reduce mitochondrial superoxide in both control and proline treated conditions. The role 
of vitamin C in mammalian cells and in ES cells specifically remains questionable, however, 
vitamin C and proline were reported to perform opposite effects on ES cell programming and 
plasticity as vitamin C reprogramed  ES cells back towards the naïve state of pluripotency, 
while proline primed ES cells towards the epiblast stem cell state (D'Aniello et al., 2017). There 
possibly is a threshold for vitamin C activities as high Vitamin C/proline ratio which was 
effective in preventing ES cell differentiation (D'Aniello et al., 2017). Understanding the 
spectrum of Vitamin C and the proline effects in ES cells will contribute to our understanding 
of the role of these metabolites in cell programming.  
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6.5. Other preliminary findings that still require validation 
6.5.1. Protein expression of Prodh and Oat and their cellular translocation 
Different Prodh and Oat isoforms were detected in ES cells using the Western Blot 
technique. Even though it has been concluded that these isoforms could be a result of 
unspecific binding of the polyclonal antibodies, there is a possibility that these proteins could 
be isoforms of Prodh and Oat that are specific in ES cells. Different protein isoforms and 
protein splicing were shown to be involved in ES cell programming and differentiation 
(Buszczak et al., 2014, Gabut et al., 2011). The presence of the larger Oat isoform displayed a 
sign of differential expression in different pluripotent states, particularly, this was higher in 
primed and lower in naïve ES cells. It is suspected that this isoform may be regulated in 
different pluripotent states and may reflect the aggregation of the protein observed in the 
immunofluorescent experiment in chapter 3 as there is more Oat accumulation in the primed 
cells than there is in the naïve ES cells. 
In image analysis pilot study with Prodh staining, the results suggested that there is a 
correlation between Prodh and DNA staining in all samples of the naïve and primed ES cells. 
The possible explanation for this result is the translocation of Prodh into the nuclei. The 
nuclear translocation of several metabolic enzymes has been reported in the literature 
(Snaebjornsson and Schulze, 2018, Boukouris et al., 2016). A study of the crystal structure of 
the PutA699 protein in Escherichia coli, which is the first structure of Prodh, shows evidence 
that Prodh is a multifunctional enzyme, which possesses a DNA-binding domain and is capable 
of performing transcription regulation (Lee et al., 2003). However, this has never been found 
in mammals. A question then arises as to whether this function has been lost during evolution 
or has evolved into different regulatory processes. Further investigation into this question 
would involve the isolation of the mitochondrial and nuclear proteins in ES cells, which would 
help to confirm if Prodh is present in the nuclei and mitochondria. Additionally, the painting 
of the cells with different organelle markers would possibly reveal the presence and location 
of Prodh and Oat in the cells. 
6.5.2. Possible sites of proline-induced ES cell differentiation 
Proline metabolism has been proposed as a potential mechanism for ES cell 
differentiation and has been studied in different mammalian cell models, which suggested a 
regulatory role in controlling cell fates. The involvement of proline metabolism in cell 
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programming and development is yet to be established. This thesis suggests that other sites 
of proline acceptors within the cells should also be considered in future investigation, 
specifically, prolyl hydroxylases, including P4Hs and prolyl hydroxylase domains (PHD), which 
hydroxylate proline residues in collagen synthesis and for the regulation of HIF-1α 
respectively. It is shown that proline and proline peptides are specific for the activation of ES 
cell differentiation (Washington et al., 2010). Free amino acid proline is not hydroxylated by 
P4Hs or PHDs, but they can interfere with the enzyme activity and the uncoupled 2-OG 
decarboxylation reactions (Gorres and Raines, 2010, Myllyharju, 2013). Any disruption of 
these enzymes could lead to the stabilisation of HIF-1α (Myllyharju, 2008, Myllyharju, 2013), 
which has been shown to play a role in ES cell differentiation (Bino et al., 2016). It is shown in 
this thesis that P4ha1, which encodes a subunit of P4Hs, are expressed in ES cells, suggesting 
that the system is present in these cells (as shown in chapter 3). The examination of PHDs in 
ES cells would potentially confirm whether these enzymes and the system play a role in the 
differentiation process. In fact, the Prodh inhibitor, DHP, is known to disrupt normal reactions 
catalysed by P4Hs and is a potential substrate for PHDs when replacing proline residues on 
HIF peptides (Kerwar and Felix, 1976, Li et al., 2004), moreover, DHP increases the rate of 2-
OG decarboxylation reactions. Ascorbate, a derivative of vitamin C, is required for the 
uncoupled 2-OG decarboxylation reaction, which is catalysed by both P4Hs and PHDs. Given 
that both DHP and proline generate high ROS production and only Vitamin C reduces ROS in 
the proline treated ES cells, it is suggested that ROS production and these metabolites might 
be correlated with the uncoupled decarboxylation of 2-OG, and this effect may be separated 
from ES differentiation (as described in chapter 5). It is possible that these metabolites have 
different spectrums to contribute to ES cell programming and pluripotency as previously 
described (D'Aniello et al., 2017). This does not exclude the role of Prodh and proline 
metabolism in ES cell differentiation, and a Prodh knock-out cell line would be useful to 
confirm these conclusions. 
6.6. Conclusion 
This thesis is the first to produce data related to the proline metabolic enzyme family 
and the immediate cellular responses to proline that has been determined within ES cells, 
which revealed that proline metabolism and proline induced-ROS production are regulated in 
different pluripotent states. This thesis has further confirmed the critical role of proline and 
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proline metabolism in regulating ES cell fate at the early states of pluripotency. Even though 
the precise mechanisms of how proline induces the differentiation in ES cells still requires 
future research, the data in this thesis has largely proven that the proline metabolic switch is 
important in ES cells during the pluripotent lineage specification process, following which, ES 
cells responded differently to the addition of the exogeneous proline which produced 
different levels of ROS. How this metabolic switch supports ES cells in the different pluripotent 
states, and how it supports different metabolic outcomes requires further research and 
validation. This data suggests that the proline-induced differnetiation of ES cells may not 
originate from the proline metabolism process, and to confirm this possibility, the knock-out 
of Prodh is essential. Through the data it is proposed that the other proline receptor sites 
should be further examined in future research to fully clarify the specific role of proline in ES 
cell programing.  
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Future work into proline-induced differentiation in ES cells would include the manipulation of 
Prodh gene expression, the conversion of proline into ornithine and glutamate, and the 
involvement of P4Hs and PHDs as well as α-KG and HIF-1α. 
 
 
 
Figure 6.6.1: Possible sites of future investigation for the proline-induced differentiation in 
ES cells 
 
Supp. Fig 1: Summary of 13 modules in CellProfiler that were used for image analysis.Figure 
6.6.2: Possible sites of future investigation for the proline-induced differentiation in ES cells 
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Appendix 1. Cell profiler module setup. 
 
Module 1: Identify Primary Objects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supp. Fig 2: Summary of 13 modules in CellProfiler that were used for image analysis.  
 
Supp. Fig 3: Summary of 13 modules in CellProfiler that were used for image analysis.  
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Module 2: Identify Secondary Objects 
 
 
 
 
 
 
 
 
 
 
 
Module 3: Identify Teritiary Objects 
 
 
 
 
 
 
 
 
Module 4: Measure Object Intensity 
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Module 5: Measure Object Intensity 
 
 
 
 
 
 
 
 
Module 6: Measure Object Neighbors 
 
 
 
 
 
 
 
Module 7: Measure Object Neighbors 
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Module 8: Measure Object Intensity Distribution 
 
 
 
 
 
 
 
 
 
 
 
 
Module 9: Measure Object Intensity Distribution 
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Module 10: Measure Object Size Shape 
 
 
 
 
 
 
 
 
 
 
Module 11: Measure Texture 
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Module 12: Measure Image Intensity  
 
 
 
 
 
 
Module 13: Export To Database 
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Supp.Table 1: List of features remained after data clean up and processing. 
 
Cells_AreaShape_Area Cells_Intensity_LowerQuartileIntensity_GFP 
Cells_AreaShape_Center_X Cells_Intensity_MADIntensity_GFP 
Cells_AreaShape_Center_Y Cells_Intensity_MassDisplacement_GFP 
Cells_AreaShape_Compactness Cells_Intensity_MaxIntensityEdge_GFP 
Cells_AreaShape_Eccentricity Cells_Intensity_MaxIntensity_GFP 
Cells_AreaShape_EulerNumber Cells_Intensity_MeanIntensityEdge_GFP 
Cells_AreaShape_Extent Cells_Intensity_MeanIntensity_GFP 
Cells_AreaShape_FormFactor Cells_Intensity_MedianIntensity_GFP 
Cells_AreaShape_MajorAxisLength Cells_Intensity_MinIntensityEdge_GFP 
Cells_AreaShape_MaxFeretDiameter Cells_Intensity_MinIntensity_GFP 
Cells_AreaShape_MaximumRadius Cells_Intensity_StdIntensityEdge_GFP 
Cells_AreaShape_MeanRadius Cells_Intensity_StdIntensity_GFP 
Cells_AreaShape_MedianRadius Cells_Intensity_UpperQuartileIntensity_GFP 
Cells_AreaShape_MinFeretDiameter Cells_Location_CenterMassIntensity_X_GFP 
Cells_AreaShape_MinorAxisLength Cells_Location_CenterMassIntensity_Y_GFP 
Cells_AreaShape_Orientation Cells_Location_Center_X 
Cells_AreaShape_Perimeter Cells_Location_Center_Y 
Cells_AreaShape_Solidity Cells_Location_MaxIntensity_X_GFP 
Cells_AreaShape_Zernike_0_0 Cells_Location_MaxIntensity_Y_GFP 
Cells_AreaShape_Zernike_1_1 Cells_Neighbors_AngleBetweenNeighbors_Adjacent 
Cells_AreaShape_Zernike_2_0 Cells_Neighbors_FirstClosestDistance_Adjacent 
Cells_AreaShape_Zernike_2_2 Cells_Neighbors_FirstClosestObjectNumber_Adjacent 
Cells_AreaShape_Zernike_3_1 Cells_Neighbors_NumberOfNeighbors_Adjacent 
Cells_AreaShape_Zernike_3_3 Cells_Neighbors_PercentTouching_Adjacent 
Cells_AreaShape_Zernike_4_0 Cells_Neighbors_SecondClosestDistance_Adjacent 
Cells_AreaShape_Zernike_4_2 Cells_Neighbors_SecondClosestObjectNumber_Adjacent 
Cells_AreaShape_Zernike_4_4 Cells_Parent_Nuclei 
Cells_AreaShape_Zernike_5_1 Cells_RadialDistribution_FracAtD_GFP_1of4 
Cells_AreaShape_Zernike_5_3 Cells_RadialDistribution_FracAtD_GFP_2of4 
Cells_AreaShape_Zernike_5_5 Cells_RadialDistribution_FracAtD_GFP_3of4 
Cells_AreaShape_Zernike_6_0 Cells_RadialDistribution_FracAtD_GFP_4of4 
Cells_AreaShape_Zernike_6_2 Cells_RadialDistribution_MeanFrac_GFP_1of4 
Cells_AreaShape_Zernike_6_4 Cells_RadialDistribution_MeanFrac_GFP_2of4 
Cells_AreaShape_Zernike_6_6 Cells_RadialDistribution_MeanFrac_GFP_3of4 
Cells_AreaShape_Zernike_7_1 Cells_RadialDistribution_MeanFrac_GFP_4of4 
Cells_AreaShape_Zernike_7_3 Cells_RadialDistribution_RadialCV_GFP_1of4 
Cells_AreaShape_Zernike_7_5 Cells_RadialDistribution_RadialCV_GFP_2of4 
Cells_AreaShape_Zernike_7_7 Cells_RadialDistribution_RadialCV_GFP_3of4 
Cells_AreaShape_Zernike_8_0 Cells_RadialDistribution_RadialCV_GFP_4of4 
Cells_AreaShape_Zernike_8_2 Cells_Texture_AngularSecondMoment_DNA_10_00 
Cells_AreaShape_Zernike_8_4 Cells_Texture_AngularSecondMoment_DNA_10_01 
Cells_AreaShape_Zernike_8_6 Cells_Texture_AngularSecondMoment_DNA_10_02 
Cells_AreaShape_Zernike_8_8 Cells_Texture_AngularSecondMoment_DNA_10_03 
Cells_AreaShape_Zernike_9_1 Cells_Texture_AngularSecondMoment_DNA_20_00 
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Cells_AreaShape_Zernike_9_3 Cells_Texture_AngularSecondMoment_DNA_20_01 
Cells_AreaShape_Zernike_9_5 Cells_Texture_AngularSecondMoment_DNA_20_02 
Cells_AreaShape_Zernike_9_7 Cells_Texture_AngularSecondMoment_DNA_20_03 
Cells_AreaShape_Zernike_9_9 Cells_Texture_AngularSecondMoment_DNA_5_00 
Cells_Intensity_IntegratedIntensityEdge_GFP Cells_Texture_AngularSecondMoment_DNA_5_01 
Cells_Intensity_IntegratedIntensity_GFP Cells_Texture_AngularSecondMoment_DNA_5_02 
Cells_Texture_AngularSecondMoment_DNA_5_03 Cells_Texture_Correlation_GFP_10_01 
Cells_Texture_AngularSecondMoment_GFP_10_00 Cells_Texture_Correlation_GFP_10_02 
Cells_Texture_AngularSecondMoment_GFP_10_01 Cells_Texture_Correlation_GFP_10_03 
Cells_Texture_AngularSecondMoment_GFP_10_02 Cells_Texture_Correlation_GFP_20_00 
Cells_Texture_AngularSecondMoment_GFP_10_03 Cells_Texture_Correlation_GFP_20_01 
Cells_Texture_AngularSecondMoment_GFP_20_00 Cells_Texture_Correlation_GFP_20_02 
Cells_Texture_AngularSecondMoment_GFP_20_01 Cells_Texture_Correlation_GFP_20_03 
Cells_Texture_AngularSecondMoment_GFP_20_02 Cells_Texture_Correlation_GFP_5_00 
Cells_Texture_AngularSecondMoment_GFP_20_03 Cells_Texture_Correlation_GFP_5_01 
Cells_Texture_AngularSecondMoment_GFP_5_00 Cells_Texture_Correlation_GFP_5_02 
Cells_Texture_AngularSecondMoment_GFP_5_01 Cells_Texture_Correlation_GFP_5_03 
Cells_Texture_AngularSecondMoment_GFP_5_02 Cells_Texture_DifferenceEntropy_DNA_10_00 
Cells_Texture_AngularSecondMoment_GFP_5_03 Cells_Texture_DifferenceEntropy_DNA_10_01 
Cells_Texture_Contrast_DNA_10_00 Cells_Texture_DifferenceEntropy_DNA_10_02 
Cells_Texture_Contrast_DNA_10_01 Cells_Texture_DifferenceEntropy_DNA_10_03 
Cells_Texture_Contrast_DNA_10_02 Cells_Texture_DifferenceEntropy_DNA_20_00 
Cells_Texture_Contrast_DNA_10_03 Cells_Texture_DifferenceEntropy_DNA_20_01 
Cells_Texture_Contrast_DNA_20_00 Cells_Texture_DifferenceEntropy_DNA_20_02 
Cells_Texture_Contrast_DNA_20_01 Cells_Texture_DifferenceEntropy_DNA_20_03 
Cells_Texture_Contrast_DNA_20_02 Cells_Texture_DifferenceEntropy_DNA_5_00 
Cells_Texture_Contrast_DNA_20_03 Cells_Texture_DifferenceEntropy_DNA_5_01 
Cells_Texture_Contrast_DNA_5_00 Cells_Texture_DifferenceEntropy_DNA_5_02 
Cells_Texture_Contrast_DNA_5_01 Cells_Texture_DifferenceEntropy_DNA_5_03 
Cells_Texture_Contrast_DNA_5_02 Cells_Texture_DifferenceEntropy_GFP_10_00 
Cells_Texture_Contrast_DNA_5_03 Cells_Texture_DifferenceEntropy_GFP_10_01 
Cells_Texture_Contrast_GFP_10_00 Cells_Texture_DifferenceEntropy_GFP_10_02 
Cells_Texture_Contrast_GFP_10_01 Cells_Texture_DifferenceEntropy_GFP_10_03 
Cells_Texture_Contrast_GFP_10_02 Cells_Texture_DifferenceEntropy_GFP_20_00 
Cells_Texture_Contrast_GFP_10_03 Cells_Texture_DifferenceEntropy_GFP_20_01 
Cells_Texture_Contrast_GFP_20_00 Cells_Texture_DifferenceEntropy_GFP_20_02 
Cells_Texture_Contrast_GFP_20_01 Cells_Texture_DifferenceEntropy_GFP_20_03 
Cells_Texture_Contrast_GFP_20_02 Cells_Texture_DifferenceEntropy_GFP_5_00 
Cells_Texture_Contrast_GFP_20_03 Cells_Texture_DifferenceEntropy_GFP_5_01 
Cells_Texture_Contrast_GFP_5_00 Cells_Texture_DifferenceEntropy_GFP_5_02 
Cells_Texture_Contrast_GFP_5_01 Cells_Texture_DifferenceEntropy_GFP_5_03 
Cells_Texture_Contrast_GFP_5_02 Cells_Texture_DifferenceVariance_DNA_10_00 
Cells_Texture_Contrast_GFP_5_03 Cells_Texture_DifferenceVariance_DNA_10_01 
Cells_Texture_Correlation_DNA_10_00 Cells_Texture_DifferenceVariance_DNA_10_02 
Cells_Texture_Correlation_DNA_10_01 Cells_Texture_DifferenceVariance_DNA_10_03 
Cells_Texture_Correlation_DNA_10_02 Cells_Texture_DifferenceVariance_DNA_20_00 
Cells_Texture_Correlation_DNA_10_03 Cells_Texture_DifferenceVariance_DNA_20_01 
Cells_Texture_Correlation_DNA_20_00 Cells_Texture_DifferenceVariance_DNA_20_02 
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Cells_Texture_Correlation_DNA_20_01 Cells_Texture_DifferenceVariance_DNA_20_03 
Cells_Texture_Correlation_DNA_20_02 Cells_Texture_DifferenceVariance_DNA_5_00 
Cells_Texture_Correlation_DNA_20_03 Cells_Texture_DifferenceVariance_DNA_5_01 
Cells_Texture_Correlation_DNA_5_00 Cells_Texture_DifferenceVariance_DNA_5_02 
Cells_Texture_Correlation_DNA_5_01 Cells_Texture_DifferenceVariance_DNA_5_03 
Cells_Texture_Correlation_DNA_5_02 Cells_Texture_DifferenceVariance_GFP_10_00 
Cells_Texture_Correlation_DNA_5_03 Cells_Texture_DifferenceVariance_GFP_10_01 
Cells_Texture_Correlation_GFP_10_00 Cells_Texture_DifferenceVariance_GFP_10_02 
Cells_Texture_DifferenceVariance_GFP_10_03 Cells_Texture_InfoMeas1_GFP_20_01 
Cells_Texture_DifferenceVariance_GFP_20_00 Cells_Texture_InfoMeas1_GFP_20_02 
Cells_Texture_DifferenceVariance_GFP_20_01 Cells_Texture_InfoMeas1_GFP_20_03 
Cells_Texture_DifferenceVariance_GFP_20_02 Cells_Texture_InfoMeas1_GFP_5_00 
Cells_Texture_DifferenceVariance_GFP_20_03 Cells_Texture_InfoMeas1_GFP_5_01 
Cells_Texture_DifferenceVariance_GFP_5_00 Cells_Texture_InfoMeas1_GFP_5_02 
Cells_Texture_DifferenceVariance_GFP_5_01 Cells_Texture_InfoMeas1_GFP_5_03 
Cells_Texture_DifferenceVariance_GFP_5_02 Cells_Texture_InfoMeas2_DNA_10_00 
Cells_Texture_DifferenceVariance_GFP_5_03 Cells_Texture_InfoMeas2_DNA_10_01 
Cells_Texture_Entropy_DNA_10_00 Cells_Texture_InfoMeas2_DNA_10_02 
Cells_Texture_Entropy_DNA_10_01 Cells_Texture_InfoMeas2_DNA_10_03 
Cells_Texture_Entropy_DNA_10_02 Cells_Texture_InfoMeas2_DNA_20_00 
Cells_Texture_Entropy_DNA_10_03 Cells_Texture_InfoMeas2_DNA_20_01 
Cells_Texture_Entropy_DNA_20_00 Cells_Texture_InfoMeas2_DNA_20_02 
Cells_Texture_Entropy_DNA_20_01 Cells_Texture_InfoMeas2_DNA_20_03 
Cells_Texture_Entropy_DNA_20_02 Cells_Texture_InfoMeas2_DNA_5_00 
Cells_Texture_Entropy_DNA_20_03 Cells_Texture_InfoMeas2_DNA_5_01 
Cells_Texture_Entropy_DNA_5_00 Cells_Texture_InfoMeas2_DNA_5_02 
Cells_Texture_Entropy_DNA_5_01 Cells_Texture_InfoMeas2_DNA_5_03 
Cells_Texture_Entropy_DNA_5_02 Cells_Texture_InfoMeas2_GFP_10_00 
Cells_Texture_Entropy_DNA_5_03 Cells_Texture_InfoMeas2_GFP_10_01 
Cells_Texture_Entropy_GFP_10_00 Cells_Texture_InfoMeas2_GFP_10_02 
Cells_Texture_Entropy_GFP_10_01 Cells_Texture_InfoMeas2_GFP_10_03 
Cells_Texture_Entropy_GFP_10_02 Cells_Texture_InfoMeas2_GFP_20_00 
Cells_Texture_Entropy_GFP_10_03 Cells_Texture_InfoMeas2_GFP_20_01 
Cells_Texture_Entropy_GFP_20_00 Cells_Texture_InfoMeas2_GFP_20_02 
Cells_Texture_Entropy_GFP_20_01 Cells_Texture_InfoMeas2_GFP_20_03 
Cells_Texture_Entropy_GFP_20_02 Cells_Texture_InfoMeas2_GFP_5_00 
Cells_Texture_Entropy_GFP_20_03 Cells_Texture_InfoMeas2_GFP_5_01 
Cells_Texture_Entropy_GFP_5_00 Cells_Texture_InfoMeas2_GFP_5_02 
Cells_Texture_Entropy_GFP_5_01 Cells_Texture_InfoMeas2_GFP_5_03 
Cells_Texture_Entropy_GFP_5_02 Cells_Texture_InverseDifferenceMoment_DNA_10_00 
Cells_Texture_Entropy_GFP_5_03 Cells_Texture_InverseDifferenceMoment_DNA_10_01 
Cells_Texture_InfoMeas1_DNA_10_00 Cells_Texture_InverseDifferenceMoment_DNA_10_02 
Cells_Texture_InfoMeas1_DNA_10_01 Cells_Texture_InverseDifferenceMoment_DNA_10_03 
Cells_Texture_InfoMeas1_DNA_10_02 Cells_Texture_InverseDifferenceMoment_DNA_20_00 
Cells_Texture_InfoMeas1_DNA_10_03 Cells_Texture_InverseDifferenceMoment_DNA_20_01 
Cells_Texture_InfoMeas1_DNA_20_00 Cells_Texture_InverseDifferenceMoment_DNA_20_02 
Cells_Texture_InfoMeas1_DNA_20_01 Cells_Texture_InverseDifferenceMoment_DNA_20_03 
Cells_Texture_InfoMeas1_DNA_20_02 Cells_Texture_InverseDifferenceMoment_DNA_5_00 
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Cells_Texture_InfoMeas1_DNA_20_03 Cells_Texture_InverseDifferenceMoment_DNA_5_01 
Cells_Texture_InfoMeas1_DNA_5_00 Cells_Texture_InverseDifferenceMoment_DNA_5_02 
Cells_Texture_InfoMeas1_DNA_5_01 Cells_Texture_InverseDifferenceMoment_DNA_5_03 
Cells_Texture_InfoMeas1_DNA_5_02 Cells_Texture_InverseDifferenceMoment_GFP_10_00 
Cells_Texture_InfoMeas1_DNA_5_03 Cells_Texture_InverseDifferenceMoment_GFP_10_01 
Cells_Texture_InfoMeas1_GFP_10_00 Cells_Texture_InverseDifferenceMoment_GFP_10_02 
Cells_Texture_InfoMeas1_GFP_10_01 Cells_Texture_InverseDifferenceMoment_GFP_10_03 
Cells_Texture_InfoMeas1_GFP_10_02 Cells_Texture_InverseDifferenceMoment_GFP_20_00 
Cells_Texture_InfoMeas1_GFP_10_03 Cells_Texture_InverseDifferenceMoment_GFP_20_01 
Cells_Texture_InfoMeas1_GFP_20_00 Cells_Texture_InverseDifferenceMoment_GFP_20_02 
Cells_Texture_InverseDifferenceMoment_GFP_20_03 Cells_Texture_SumEntropy_GFP_5_01 
Cells_Texture_InverseDifferenceMoment_GFP_5_00 Cells_Texture_SumEntropy_GFP_5_02 
Cells_Texture_InverseDifferenceMoment_GFP_5_01 Cells_Texture_SumEntropy_GFP_5_03 
Cells_Texture_InverseDifferenceMoment_GFP_5_02 Cells_Texture_SumVariance_DNA_10_00 
Cells_Texture_InverseDifferenceMoment_GFP_5_03 Cells_Texture_SumVariance_DNA_10_01 
Cells_Texture_SumAverage_DNA_10_00 Cells_Texture_SumVariance_DNA_10_02 
Cells_Texture_SumAverage_DNA_10_01 Cells_Texture_SumVariance_DNA_10_03 
Cells_Texture_SumAverage_DNA_10_02 Cells_Texture_SumVariance_DNA_20_00 
Cells_Texture_SumAverage_DNA_10_03 Cells_Texture_SumVariance_DNA_20_01 
Cells_Texture_SumAverage_DNA_20_00 Cells_Texture_SumVariance_DNA_20_02 
Cells_Texture_SumAverage_DNA_20_01 Cells_Texture_SumVariance_DNA_20_03 
Cells_Texture_SumAverage_DNA_20_02 Cells_Texture_SumVariance_DNA_5_00 
Cells_Texture_SumAverage_DNA_20_03 Cells_Texture_SumVariance_DNA_5_01 
Cells_Texture_SumAverage_DNA_5_00 Cells_Texture_SumVariance_DNA_5_02 
Cells_Texture_SumAverage_DNA_5_01 Cells_Texture_SumVariance_DNA_5_03 
Cells_Texture_SumAverage_DNA_5_02 Cells_Texture_SumVariance_GFP_10_00 
Cells_Texture_SumAverage_DNA_5_03 Cells_Texture_SumVariance_GFP_10_01 
Cells_Texture_SumAverage_GFP_10_00 Cells_Texture_SumVariance_GFP_10_02 
Cells_Texture_SumAverage_GFP_10_01 Cells_Texture_SumVariance_GFP_10_03 
Cells_Texture_SumAverage_GFP_10_02 Cells_Texture_SumVariance_GFP_20_00 
Cells_Texture_SumAverage_GFP_10_03 Cells_Texture_SumVariance_GFP_20_01 
Cells_Texture_SumAverage_GFP_20_00 Cells_Texture_SumVariance_GFP_20_02 
Cells_Texture_SumAverage_GFP_20_01 Cells_Texture_SumVariance_GFP_20_03 
Cells_Texture_SumAverage_GFP_20_02 Cells_Texture_SumVariance_GFP_5_00 
Cells_Texture_SumAverage_GFP_20_03 Cells_Texture_SumVariance_GFP_5_01 
Cells_Texture_SumAverage_GFP_5_00 Cells_Texture_SumVariance_GFP_5_02 
Cells_Texture_SumAverage_GFP_5_01 Cells_Texture_SumVariance_GFP_5_03 
Cells_Texture_SumAverage_GFP_5_02 Cells_Texture_Variance_DNA_10_00 
Cells_Texture_SumAverage_GFP_5_03 Cells_Texture_Variance_DNA_10_01 
Cells_Texture_SumEntropy_DNA_10_00 Cells_Texture_Variance_DNA_10_02 
Cells_Texture_SumEntropy_DNA_10_01 Cells_Texture_Variance_DNA_10_03 
Cells_Texture_SumEntropy_DNA_10_02 Cells_Texture_Variance_DNA_20_00 
Cells_Texture_SumEntropy_DNA_10_03 Cells_Texture_Variance_DNA_20_01 
Cells_Texture_SumEntropy_DNA_20_00 Cells_Texture_Variance_DNA_20_02 
Cells_Texture_SumEntropy_DNA_20_01 Cells_Texture_Variance_DNA_20_03 
Cells_Texture_SumEntropy_DNA_20_02 Cells_Texture_Variance_DNA_5_00 
Cells_Texture_SumEntropy_DNA_20_03 Cells_Texture_Variance_DNA_5_01 
Cells_Texture_SumEntropy_DNA_5_00 Cells_Texture_Variance_DNA_5_02 
Appendix 1  Van T. T. Nguyen 
150 
 
Cells_Texture_SumEntropy_DNA_5_01 Cells_Texture_Variance_DNA_5_03 
Cells_Texture_SumEntropy_DNA_5_02 Cells_Texture_Variance_GFP_10_00 
Cells_Texture_SumEntropy_DNA_5_03 Cells_Texture_Variance_GFP_10_01 
Cells_Texture_SumEntropy_GFP_10_00 Cells_Texture_Variance_GFP_10_02 
Cells_Texture_SumEntropy_GFP_10_01 Cells_Texture_Variance_GFP_10_03 
Cells_Texture_SumEntropy_GFP_10_02 Cells_Texture_Variance_GFP_20_00 
Cells_Texture_SumEntropy_GFP_10_03 Cells_Texture_Variance_GFP_20_01 
Cells_Texture_SumEntropy_GFP_20_00 Cells_Texture_Variance_GFP_20_02 
Cells_Texture_SumEntropy_GFP_20_01 Cells_Texture_Variance_GFP_20_03 
Cells_Texture_SumEntropy_GFP_20_02 Cells_Texture_Variance_GFP_5_00 
Cells_Texture_SumEntropy_GFP_20_03 Cells_Texture_Variance_GFP_5_01 
Cells_Texture_SumEntropy_GFP_5_00 Cells_Texture_Variance_GFP_5_02 
Cells_Texture_Variance_GFP_5_03 Cytoplasm_Intensity_IntegratedIntensity_GFP 
Cytoplasm_AreaShape_Area Cytoplasm_Intensity_LowerQuartileIntensity_GFP 
Cytoplasm_AreaShape_Center_X Cytoplasm_Intensity_MADIntensity_GFP 
Cytoplasm_AreaShape_Center_Y Cytoplasm_Intensity_MassDisplacement_GFP 
Cytoplasm_AreaShape_Compactness Cytoplasm_Intensity_MaxIntensityEdge_GFP 
Cytoplasm_AreaShape_Eccentricity Cytoplasm_Intensity_MaxIntensity_GFP 
Cytoplasm_AreaShape_EulerNumber Cytoplasm_Intensity_MeanIntensityEdge_GFP 
Cytoplasm_AreaShape_Extent Cytoplasm_Intensity_MeanIntensity_GFP 
Cytoplasm_AreaShape_FormFactor Cytoplasm_Intensity_MedianIntensity_GFP 
Cytoplasm_AreaShape_MajorAxisLength Cytoplasm_Intensity_MinIntensityEdge_GFP 
Cytoplasm_AreaShape_MaxFeretDiameter Cytoplasm_Intensity_MinIntensity_GFP 
Cytoplasm_AreaShape_MaximumRadius Cytoplasm_Intensity_StdIntensityEdge_GFP 
Cytoplasm_AreaShape_MeanRadius Cytoplasm_Intensity_StdIntensity_GFP 
Cytoplasm_AreaShape_MedianRadius Cytoplasm_Intensity_UpperQuartileIntensity_GFP 
Cytoplasm_AreaShape_MinFeretDiameter Cytoplasm_Location_CenterMassIntensity_X_GFP 
Cytoplasm_AreaShape_MinorAxisLength Cytoplasm_Location_CenterMassIntensity_Y_GFP 
Cytoplasm_AreaShape_Orientation Cytoplasm_Location_Center_X 
Cytoplasm_AreaShape_Perimeter Cytoplasm_Location_Center_Y 
Cytoplasm_AreaShape_Solidity Cytoplasm_Location_MaxIntensity_X_GFP 
Cytoplasm_AreaShape_Zernike_0_0 Cytoplasm_Location_MaxIntensity_Y_GFP 
Cytoplasm_AreaShape_Zernike_1_1 Cytoplasm_Parent_Cells 
Cytoplasm_AreaShape_Zernike_2_0 Cytoplasm_Parent_Nuclei 
Cytoplasm_AreaShape_Zernike_2_2 Nuclei_AreaShape_Area 
Cytoplasm_AreaShape_Zernike_3_1 Nuclei_AreaShape_Center_X 
Cytoplasm_AreaShape_Zernike_3_3 Nuclei_AreaShape_Center_Y 
Cytoplasm_AreaShape_Zernike_4_0 Nuclei_AreaShape_Compactness 
Cytoplasm_AreaShape_Zernike_4_2 Nuclei_AreaShape_Eccentricity 
Cytoplasm_AreaShape_Zernike_4_4 Nuclei_AreaShape_Extent 
Cytoplasm_AreaShape_Zernike_5_1 Nuclei_AreaShape_FormFactor 
Cytoplasm_AreaShape_Zernike_5_3 Nuclei_AreaShape_MajorAxisLength 
Cytoplasm_AreaShape_Zernike_5_5 Nuclei_AreaShape_MaxFeretDiameter 
Cytoplasm_AreaShape_Zernike_6_0 Nuclei_AreaShape_MaximumRadius 
Cytoplasm_AreaShape_Zernike_6_2 Nuclei_AreaShape_MeanRadius 
Cytoplasm_AreaShape_Zernike_6_4 Nuclei_AreaShape_MedianRadius 
Cytoplasm_AreaShape_Zernike_6_6 Nuclei_AreaShape_MinFeretDiameter 
Cytoplasm_AreaShape_Zernike_7_1 Nuclei_AreaShape_MinorAxisLength 
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Cytoplasm_AreaShape_Zernike_7_3 Nuclei_AreaShape_Orientation 
Cytoplasm_AreaShape_Zernike_7_5 Nuclei_AreaShape_Perimeter 
Cytoplasm_AreaShape_Zernike_7_7 Nuclei_AreaShape_Solidity 
Cytoplasm_AreaShape_Zernike_8_0 Nuclei_AreaShape_Zernike_0_0 
Cytoplasm_AreaShape_Zernike_8_2 Nuclei_AreaShape_Zernike_1_1 
Cytoplasm_AreaShape_Zernike_8_4 Nuclei_AreaShape_Zernike_2_0 
Cytoplasm_AreaShape_Zernike_8_6 Nuclei_AreaShape_Zernike_2_2 
Cytoplasm_AreaShape_Zernike_8_8 Nuclei_AreaShape_Zernike_3_1 
Cytoplasm_AreaShape_Zernike_9_1 Nuclei_AreaShape_Zernike_3_3 
Cytoplasm_AreaShape_Zernike_9_3 Nuclei_AreaShape_Zernike_4_0 
Cytoplasm_AreaShape_Zernike_9_5 Nuclei_AreaShape_Zernike_4_2 
Cytoplasm_AreaShape_Zernike_9_7 Nuclei_AreaShape_Zernike_4_4 
Cytoplasm_AreaShape_Zernike_9_9 Nuclei_AreaShape_Zernike_5_1 
Cytoplasm_Intensity_IntegratedIntensityEdge_GFP Nuclei_AreaShape_Zernike_5_3 
Nuclei_AreaShape_Zernike_5_5 Nuclei_RadialDistribution_FracAtD_DNA_4of4 
Nuclei_AreaShape_Zernike_6_0 Nuclei_RadialDistribution_MeanFrac_DNA_1of4 
Nuclei_AreaShape_Zernike_6_2 Nuclei_RadialDistribution_MeanFrac_DNA_2of4 
Nuclei_AreaShape_Zernike_6_4 Nuclei_RadialDistribution_MeanFrac_DNA_3of4 
Nuclei_AreaShape_Zernike_6_6 Nuclei_RadialDistribution_MeanFrac_DNA_4of4 
Nuclei_AreaShape_Zernike_7_1 Nuclei_RadialDistribution_RadialCV_DNA_1of4 
Nuclei_AreaShape_Zernike_7_3 Nuclei_RadialDistribution_RadialCV_DNA_2of4 
Nuclei_AreaShape_Zernike_7_5 Nuclei_RadialDistribution_RadialCV_DNA_3of4 
Nuclei_AreaShape_Zernike_7_7 Nuclei_RadialDistribution_RadialCV_DNA_4of4 
Nuclei_AreaShape_Zernike_8_0 Nuclei_Texture_AngularSecondMoment_DNA_10_00 
Nuclei_AreaShape_Zernike_8_2 Nuclei_Texture_AngularSecondMoment_DNA_10_01 
Nuclei_AreaShape_Zernike_8_4 Nuclei_Texture_AngularSecondMoment_DNA_10_02 
Nuclei_AreaShape_Zernike_8_6 Nuclei_Texture_AngularSecondMoment_DNA_10_03 
Nuclei_AreaShape_Zernike_8_8 Nuclei_Texture_AngularSecondMoment_DNA_20_00 
Nuclei_AreaShape_Zernike_9_1 Nuclei_Texture_AngularSecondMoment_DNA_20_01 
Nuclei_AreaShape_Zernike_9_3 Nuclei_Texture_AngularSecondMoment_DNA_20_02 
Nuclei_AreaShape_Zernike_9_5 Nuclei_Texture_AngularSecondMoment_DNA_20_03 
Nuclei_AreaShape_Zernike_9_7 Nuclei_Texture_AngularSecondMoment_DNA_5_00 
Nuclei_AreaShape_Zernike_9_9 Nuclei_Texture_AngularSecondMoment_DNA_5_01 
Nuclei_Intensity_IntegratedIntensityEdge_DNA Nuclei_Texture_AngularSecondMoment_DNA_5_02 
Nuclei_Intensity_IntegratedIntensity_DNA Nuclei_Texture_AngularSecondMoment_DNA_5_03 
Nuclei_Intensity_LowerQuartileIntensity_DNA Nuclei_Texture_AngularSecondMoment_GFP_10_00 
Nuclei_Intensity_MADIntensity_DNA Nuclei_Texture_AngularSecondMoment_GFP_10_01 
Nuclei_Intensity_MassDisplacement_DNA Nuclei_Texture_AngularSecondMoment_GFP_10_02 
Nuclei_Intensity_MaxIntensityEdge_DNA Nuclei_Texture_AngularSecondMoment_GFP_10_03 
Nuclei_Intensity_MaxIntensity_DNA Nuclei_Texture_AngularSecondMoment_GFP_20_00 
Nuclei_Intensity_MeanIntensityEdge_DNA Nuclei_Texture_AngularSecondMoment_GFP_20_01 
Nuclei_Intensity_MeanIntensity_DNA Nuclei_Texture_AngularSecondMoment_GFP_20_02 
Nuclei_Intensity_MedianIntensity_DNA Nuclei_Texture_AngularSecondMoment_GFP_20_03 
Nuclei_Intensity_MinIntensityEdge_DNA Nuclei_Texture_AngularSecondMoment_GFP_5_00 
Nuclei_Intensity_MinIntensity_DNA Nuclei_Texture_AngularSecondMoment_GFP_5_01 
Nuclei_Intensity_StdIntensityEdge_DNA Nuclei_Texture_AngularSecondMoment_GFP_5_02 
Nuclei_Intensity_StdIntensity_DNA Nuclei_Texture_AngularSecondMoment_GFP_5_03 
Nuclei_Intensity_UpperQuartileIntensity_DNA Nuclei_Texture_Contrast_DNA_10_00 
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Nuclei_Location_CenterMassIntensity_X_DNA Nuclei_Texture_Contrast_DNA_10_01 
Nuclei_Location_CenterMassIntensity_Y_DNA Nuclei_Texture_Contrast_DNA_10_02 
Nuclei_Location_Center_X Nuclei_Texture_Contrast_DNA_10_03 
Nuclei_Location_Center_Y Nuclei_Texture_Contrast_DNA_20_00 
Nuclei_Location_MaxIntensity_X_DNA Nuclei_Texture_Contrast_DNA_20_01 
Nuclei_Location_MaxIntensity_Y_DNA Nuclei_Texture_Contrast_DNA_20_02 
Nuclei_Neighbors_AngleBetweenNeighbors_Adjacent Nuclei_Texture_Contrast_DNA_20_03 
Nuclei_Neighbors_FirstClosestDistance_Adjacent Nuclei_Texture_Contrast_DNA_5_00 
Nuclei_Neighbors_FirstClosestObjectNumber_Adjacent Nuclei_Texture_Contrast_DNA_5_01 
Nuclei_Neighbors_NumberOfNeighbors_Adjacent Nuclei_Texture_Contrast_DNA_5_02 
Nuclei_Neighbors_PercentTouching_Adjacent Nuclei_Texture_Contrast_DNA_5_03 
Nuclei_Neighbors_SecondClosestDistance_Adjacent Nuclei_Texture_Contrast_GFP_10_00 
Nuclei_Neighbors_SecondClosestObjectNumber_Adjacent Nuclei_Texture_Contrast_GFP_10_01 
Nuclei_RadialDistribution_FracAtD_DNA_1of4 Nuclei_Texture_Contrast_GFP_10_02 
Nuclei_RadialDistribution_FracAtD_DNA_2of4 Nuclei_Texture_Contrast_GFP_10_03 
Nuclei_RadialDistribution_FracAtD_DNA_3of4 Nuclei_Texture_Contrast_GFP_20_00 
Nuclei_Texture_Contrast_GFP_20_01 Nuclei_Texture_DifferenceEntropy_GFP_20_03 
Nuclei_Texture_Contrast_GFP_20_02 Nuclei_Texture_DifferenceEntropy_GFP_5_00 
Nuclei_Texture_Contrast_GFP_20_03 Nuclei_Texture_DifferenceEntropy_GFP_5_01 
Nuclei_Texture_Contrast_GFP_5_00 Nuclei_Texture_DifferenceEntropy_GFP_5_02 
Nuclei_Texture_Contrast_GFP_5_01 Nuclei_Texture_DifferenceEntropy_GFP_5_03 
Nuclei_Texture_Contrast_GFP_5_02 Nuclei_Texture_DifferenceVariance_DNA_10_00 
Nuclei_Texture_Contrast_GFP_5_03 Nuclei_Texture_DifferenceVariance_DNA_10_01 
Nuclei_Texture_Correlation_DNA_10_00 Nuclei_Texture_DifferenceVariance_DNA_10_02 
Nuclei_Texture_Correlation_DNA_10_01 Nuclei_Texture_DifferenceVariance_DNA_10_03 
Nuclei_Texture_Correlation_DNA_10_02 Nuclei_Texture_DifferenceVariance_DNA_20_00 
Nuclei_Texture_Correlation_DNA_10_03 Nuclei_Texture_DifferenceVariance_DNA_20_01 
Nuclei_Texture_Correlation_DNA_20_00 Nuclei_Texture_DifferenceVariance_DNA_20_02 
Nuclei_Texture_Correlation_DNA_20_01 Nuclei_Texture_DifferenceVariance_DNA_20_03 
Nuclei_Texture_Correlation_DNA_20_02 Nuclei_Texture_DifferenceVariance_DNA_5_00 
Nuclei_Texture_Correlation_DNA_20_03 Nuclei_Texture_DifferenceVariance_DNA_5_01 
Nuclei_Texture_Correlation_DNA_5_00 Nuclei_Texture_DifferenceVariance_DNA_5_02 
Nuclei_Texture_Correlation_DNA_5_01 Nuclei_Texture_DifferenceVariance_DNA_5_03 
Nuclei_Texture_Correlation_DNA_5_02 Nuclei_Texture_DifferenceVariance_GFP_10_00 
Nuclei_Texture_Correlation_DNA_5_03 Nuclei_Texture_DifferenceVariance_GFP_10_01 
Nuclei_Texture_Correlation_GFP_10_00 Nuclei_Texture_DifferenceVariance_GFP_10_02 
Nuclei_Texture_Correlation_GFP_10_01 Nuclei_Texture_DifferenceVariance_GFP_10_03 
Nuclei_Texture_Correlation_GFP_10_02 Nuclei_Texture_DifferenceVariance_GFP_20_00 
Nuclei_Texture_Correlation_GFP_10_03 Nuclei_Texture_DifferenceVariance_GFP_20_01 
Nuclei_Texture_Correlation_GFP_20_00 Nuclei_Texture_DifferenceVariance_GFP_20_02 
Nuclei_Texture_Correlation_GFP_20_01 Nuclei_Texture_DifferenceVariance_GFP_20_03 
Nuclei_Texture_Correlation_GFP_20_02 Nuclei_Texture_DifferenceVariance_GFP_5_00 
Nuclei_Texture_Correlation_GFP_20_03 Nuclei_Texture_DifferenceVariance_GFP_5_01 
Nuclei_Texture_Correlation_GFP_5_00 Nuclei_Texture_DifferenceVariance_GFP_5_02 
Nuclei_Texture_Correlation_GFP_5_01 Nuclei_Texture_DifferenceVariance_GFP_5_03 
Nuclei_Texture_Correlation_GFP_5_02 Nuclei_Texture_Entropy_DNA_10_00 
Nuclei_Texture_Correlation_GFP_5_03 Nuclei_Texture_Entropy_DNA_10_01 
Nuclei_Texture_DifferenceEntropy_DNA_10_00 Nuclei_Texture_Entropy_DNA_10_02 
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Nuclei_Texture_DifferenceEntropy_DNA_10_01 Nuclei_Texture_Entropy_DNA_10_03 
Nuclei_Texture_DifferenceEntropy_DNA_10_02 Nuclei_Texture_Entropy_DNA_20_00 
Nuclei_Texture_DifferenceEntropy_DNA_10_03 Nuclei_Texture_Entropy_DNA_20_01 
Nuclei_Texture_DifferenceEntropy_DNA_20_00 Nuclei_Texture_Entropy_DNA_20_02 
Nuclei_Texture_DifferenceEntropy_DNA_20_01 Nuclei_Texture_Entropy_DNA_20_03 
Nuclei_Texture_DifferenceEntropy_DNA_20_02 Nuclei_Texture_Entropy_DNA_5_00 
Nuclei_Texture_DifferenceEntropy_DNA_20_03 Nuclei_Texture_Entropy_DNA_5_01 
Nuclei_Texture_DifferenceEntropy_DNA_5_00 Nuclei_Texture_Entropy_DNA_5_02 
Nuclei_Texture_DifferenceEntropy_DNA_5_01 Nuclei_Texture_Entropy_DNA_5_03 
Nuclei_Texture_DifferenceEntropy_DNA_5_02 Nuclei_Texture_Entropy_GFP_10_00 
Nuclei_Texture_DifferenceEntropy_DNA_5_03 Nuclei_Texture_Entropy_GFP_10_01 
Nuclei_Texture_DifferenceEntropy_GFP_10_00 Nuclei_Texture_Entropy_GFP_10_02 
Nuclei_Texture_DifferenceEntropy_GFP_10_01 Nuclei_Texture_Entropy_GFP_10_03 
Nuclei_Texture_DifferenceEntropy_GFP_10_02 Nuclei_Texture_Entropy_GFP_20_00 
Nuclei_Texture_DifferenceEntropy_GFP_10_03 Nuclei_Texture_Entropy_GFP_20_01 
Nuclei_Texture_DifferenceEntropy_GFP_20_00 Nuclei_Texture_Entropy_GFP_20_02 
Nuclei_Texture_DifferenceEntropy_GFP_20_01 Nuclei_Texture_Entropy_GFP_20_03 
Nuclei_Texture_DifferenceEntropy_GFP_20_02 Nuclei_Texture_Entropy_GFP_5_00 
Nuclei_Texture_Entropy_GFP_5_01 Nuclei_Texture_InfoMeas2_GFP_5_03 
Nuclei_Texture_Entropy_GFP_5_02 Nuclei_Texture_InverseDifferenceMoment_DNA_10_00 
Nuclei_Texture_Entropy_GFP_5_03 Nuclei_Texture_InverseDifferenceMoment_DNA_10_01 
Nuclei_Texture_InfoMeas1_DNA_10_00 Nuclei_Texture_InverseDifferenceMoment_DNA_10_02 
Nuclei_Texture_InfoMeas1_DNA_10_01 Nuclei_Texture_InverseDifferenceMoment_DNA_10_03 
Nuclei_Texture_InfoMeas1_DNA_10_02 Nuclei_Texture_InverseDifferenceMoment_DNA_20_00 
Nuclei_Texture_InfoMeas1_DNA_10_03 Nuclei_Texture_InverseDifferenceMoment_DNA_20_01 
Nuclei_Texture_InfoMeas1_DNA_20_00 Nuclei_Texture_InverseDifferenceMoment_DNA_20_02 
Nuclei_Texture_InfoMeas1_DNA_20_01 Nuclei_Texture_InverseDifferenceMoment_DNA_20_03 
Nuclei_Texture_InfoMeas1_DNA_20_02 Nuclei_Texture_InverseDifferenceMoment_DNA_5_00 
Nuclei_Texture_InfoMeas1_DNA_20_03 Nuclei_Texture_InverseDifferenceMoment_DNA_5_01 
Nuclei_Texture_InfoMeas1_DNA_5_00 Nuclei_Texture_InverseDifferenceMoment_DNA_5_02 
Nuclei_Texture_InfoMeas1_DNA_5_01 Nuclei_Texture_InverseDifferenceMoment_DNA_5_03 
Nuclei_Texture_InfoMeas1_DNA_5_02 Nuclei_Texture_InverseDifferenceMoment_GFP_10_00 
Nuclei_Texture_InfoMeas1_DNA_5_03 Nuclei_Texture_InverseDifferenceMoment_GFP_10_01 
Nuclei_Texture_InfoMeas1_GFP_10_00 Nuclei_Texture_InverseDifferenceMoment_GFP_10_02 
Nuclei_Texture_InfoMeas1_GFP_10_01 Nuclei_Texture_InverseDifferenceMoment_GFP_10_03 
Nuclei_Texture_InfoMeas1_GFP_10_02 Nuclei_Texture_InverseDifferenceMoment_GFP_20_00 
Nuclei_Texture_InfoMeas1_GFP_10_03 Nuclei_Texture_InverseDifferenceMoment_GFP_20_01 
Nuclei_Texture_InfoMeas1_GFP_20_00 Nuclei_Texture_InverseDifferenceMoment_GFP_20_02 
Nuclei_Texture_InfoMeas1_GFP_20_01 Nuclei_Texture_InverseDifferenceMoment_GFP_20_03 
Nuclei_Texture_InfoMeas1_GFP_20_02 Nuclei_Texture_InverseDifferenceMoment_GFP_5_00 
Nuclei_Texture_InfoMeas1_GFP_20_03 Nuclei_Texture_InverseDifferenceMoment_GFP_5_01 
Nuclei_Texture_InfoMeas1_GFP_5_00 Nuclei_Texture_InverseDifferenceMoment_GFP_5_02 
Nuclei_Texture_InfoMeas1_GFP_5_01 Nuclei_Texture_InverseDifferenceMoment_GFP_5_03 
Nuclei_Texture_InfoMeas1_GFP_5_02 Nuclei_Texture_SumAverage_DNA_10_00 
Nuclei_Texture_InfoMeas1_GFP_5_03 Nuclei_Texture_SumAverage_DNA_10_01 
Nuclei_Texture_InfoMeas2_DNA_10_00 Nuclei_Texture_SumAverage_DNA_10_02 
Nuclei_Texture_InfoMeas2_DNA_10_01 Nuclei_Texture_SumAverage_DNA_10_03 
Nuclei_Texture_InfoMeas2_DNA_10_02 Nuclei_Texture_SumAverage_DNA_20_00 
Appendix 1  Van T. T. Nguyen 
154 
 
Nuclei_Texture_InfoMeas2_DNA_10_03 Nuclei_Texture_SumAverage_DNA_20_01 
Nuclei_Texture_InfoMeas2_DNA_20_00 Nuclei_Texture_SumAverage_DNA_20_02 
Nuclei_Texture_InfoMeas2_DNA_20_01 Nuclei_Texture_SumAverage_DNA_20_03 
Nuclei_Texture_InfoMeas2_DNA_20_02 Nuclei_Texture_SumAverage_DNA_5_00 
Nuclei_Texture_InfoMeas2_DNA_20_03 Nuclei_Texture_SumAverage_DNA_5_01 
Nuclei_Texture_InfoMeas2_DNA_5_00 Nuclei_Texture_SumAverage_DNA_5_02 
Nuclei_Texture_InfoMeas2_DNA_5_01 Nuclei_Texture_SumAverage_DNA_5_03 
Nuclei_Texture_InfoMeas2_DNA_5_02 Nuclei_Texture_SumAverage_GFP_10_00 
Nuclei_Texture_InfoMeas2_DNA_5_03 Nuclei_Texture_SumAverage_GFP_10_01 
Nuclei_Texture_InfoMeas2_GFP_10_00 Nuclei_Texture_SumAverage_GFP_10_02 
Nuclei_Texture_InfoMeas2_GFP_10_01 Nuclei_Texture_SumAverage_GFP_10_03 
Nuclei_Texture_InfoMeas2_GFP_10_02 Nuclei_Texture_SumAverage_GFP_20_00 
Nuclei_Texture_InfoMeas2_GFP_10_03 Nuclei_Texture_SumAverage_GFP_20_01 
Nuclei_Texture_InfoMeas2_GFP_20_00 Nuclei_Texture_SumAverage_GFP_20_02 
Nuclei_Texture_InfoMeas2_GFP_20_01 Nuclei_Texture_SumAverage_GFP_20_03 
Nuclei_Texture_InfoMeas2_GFP_20_02 Nuclei_Texture_SumAverage_GFP_5_00 
Nuclei_Texture_InfoMeas2_GFP_20_03 Nuclei_Texture_SumAverage_GFP_5_01 
Nuclei_Texture_InfoMeas2_GFP_5_00 Nuclei_Texture_SumAverage_GFP_5_02 
Nuclei_Texture_InfoMeas2_GFP_5_01 Nuclei_Texture_SumAverage_GFP_5_03 
Nuclei_Texture_InfoMeas2_GFP_5_02 Nuclei_Texture_SumEntropy_DNA_10_00 
Nuclei_Texture_SumEntropy_DNA_10_01 Nuclei_Texture_SumVariance_GFP_10_01 
Nuclei_Texture_SumEntropy_DNA_10_02 Nuclei_Texture_SumVariance_GFP_10_02 
Nuclei_Texture_SumEntropy_DNA_10_03 Nuclei_Texture_SumVariance_GFP_10_03 
Nuclei_Texture_SumEntropy_DNA_20_00 Nuclei_Texture_SumVariance_GFP_20_00 
Nuclei_Texture_SumEntropy_DNA_20_01 Nuclei_Texture_SumVariance_GFP_20_01 
Nuclei_Texture_SumEntropy_DNA_20_02 Nuclei_Texture_SumVariance_GFP_20_02 
Nuclei_Texture_SumEntropy_DNA_20_03 Nuclei_Texture_SumVariance_GFP_20_03 
Nuclei_Texture_SumEntropy_DNA_5_00 Nuclei_Texture_SumVariance_GFP_5_00 
Nuclei_Texture_SumEntropy_DNA_5_01 Nuclei_Texture_SumVariance_GFP_5_01 
Nuclei_Texture_SumEntropy_DNA_5_02 Nuclei_Texture_SumVariance_GFP_5_02 
Nuclei_Texture_SumEntropy_DNA_5_03 Nuclei_Texture_SumVariance_GFP_5_03 
Nuclei_Texture_SumEntropy_GFP_10_00 Nuclei_Texture_Variance_DNA_10_00 
Nuclei_Texture_SumEntropy_GFP_10_01 Nuclei_Texture_Variance_DNA_10_01 
Nuclei_Texture_SumEntropy_GFP_10_02 Nuclei_Texture_Variance_DNA_10_02 
Nuclei_Texture_SumEntropy_GFP_10_03 Nuclei_Texture_Variance_DNA_10_03 
Nuclei_Texture_SumEntropy_GFP_20_00 Nuclei_Texture_Variance_DNA_20_00 
Nuclei_Texture_SumEntropy_GFP_20_01 Nuclei_Texture_Variance_DNA_20_01 
Nuclei_Texture_SumEntropy_GFP_20_02 Nuclei_Texture_Variance_DNA_20_02 
Nuclei_Texture_SumEntropy_GFP_20_03 Nuclei_Texture_Variance_DNA_20_03 
Nuclei_Texture_SumEntropy_GFP_5_00 Nuclei_Texture_Variance_DNA_5_00 
Nuclei_Texture_SumEntropy_GFP_5_01 Nuclei_Texture_Variance_DNA_5_01 
Nuclei_Texture_SumEntropy_GFP_5_02 Nuclei_Texture_Variance_DNA_5_02 
Nuclei_Texture_SumEntropy_GFP_5_03 Nuclei_Texture_Variance_DNA_5_03 
Nuclei_Texture_SumVariance_DNA_10_00 Nuclei_Texture_Variance_GFP_10_00 
Nuclei_Texture_SumVariance_DNA_10_01 Nuclei_Texture_Variance_GFP_10_01 
Nuclei_Texture_SumVariance_DNA_10_02 Nuclei_Texture_Variance_GFP_10_02 
Nuclei_Texture_SumVariance_DNA_10_03 Nuclei_Texture_Variance_GFP_10_03 
Nuclei_Texture_SumVariance_DNA_20_00 Nuclei_Texture_Variance_GFP_20_00 
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Nuclei_Texture_SumVariance_DNA_20_01 Nuclei_Texture_Variance_GFP_20_01 
Nuclei_Texture_SumVariance_DNA_20_02 Nuclei_Texture_Variance_GFP_20_02 
Nuclei_Texture_SumVariance_DNA_20_03 Nuclei_Texture_Variance_GFP_20_03 
Nuclei_Texture_SumVariance_DNA_5_00 Nuclei_Texture_Variance_GFP_5_00 
Nuclei_Texture_SumVariance_DNA_5_01 Nuclei_Texture_Variance_GFP_5_01 
Nuclei_Texture_SumVariance_DNA_5_02 Nuclei_Texture_Variance_GFP_5_02 
Nuclei_Texture_SumVariance_DNA_5_03 Nuclei_Texture_Variance_GFP_5_03 
Nuclei_Texture_SumVariance_GFP_10_00  
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Appendix 2: R codes for the analysis of Study 1 and 2 
 
# Clean the data for each object using cytominer 
# 1. clean the data 
# 2. normalize the features so that they are comparable across experiments 
# 3. transform the features so that their distributions are well-behaved (i.e., 
bring them in line with assumptions we want to make about their disributions) 
# 4. select features based on their quality 
# 5. aggregate the single-cell data, if needed 
## The cytominer package makes these steps fast and easy. 
 
## Load data 
 
## read packages 
library(dbplyr) 
library(dplyr) 
library(stringr) 
library(magrittr) 
library(cytominer) 
library(lattice) 
library(ggplot2) 
 
 
# Read objective files and image files 
do <-read.csv("Van_Per objectives.csv", header = TRUE, sep = ",") 
df<- read.csv("Van_Per image.csv", header = TRUE, sep=",")hi_df<- 
read.csv("hi_Per_image.csv", header = TRUE, sep=",") 
 
df$Site<-substr(df$Image_FileName_DNA, 14,14) 
df$Well<-substr(df$Image_FileName_DNA, 1,2) 
df$Wellsite<-paste(df$Well,df$Site,sep = "_") 
well<-levels(as.factor(df$Well)) 
 
image<-levels(as.factor(do$ImageNumber)) 
# add Well column to the table 
dn<-factor(do$ImageNumber,labels = df$Wellsite) 
do$Well<-substr(dn,1,regexpr("_",dn)-1) 
do$Wellsite<-dn 
do$row<-substr(dn,1,1) 
## 
do<-compute(do) 
 
## For this example, lets filter the data down to a few wells. 
measurements <- 
  do %>% 
  dplyr::filter(Well %in% well) 
 
# How many rows does this table have? 
measurements %>% 
  dplyr::tally() %>% 
  knitr::kable() 
 
# Next, do some setup stuff that we will need later 
qualities <- c("Cytoplasm_AreaShape_Area") 
groupings <- 
  c("ImageNumber", "ObjectNumber", "Cytoplasm_Number_Object_Number", 
"Cells_Number_Object_Number", "Nuclei_Number_Object_Number", 
"Well","Wellsite","row") 
 
dn<-colnames(measurements) 
b2<- which (dn %in% groupings) 
variables <- dn[-b2] 
 
measurements %<>% 
  dplyr::select(dplyr::one_of(c(qualities,groupings, variables))) 
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## Clean 
 
# Then, remove cells where all the measurements are NA's - this may happen 
# if the identified cell mask was too small to measure any of the features. 
 
debris_removed <- measurements %>% dplyr::filter(Cytoplasm_AreaShape_Area != 0) 
 
na_rows_removed <- 
  cytominer::drop_na_rows( 
    population = debris_removed, 
    variables = variables 
  ) %>% 
  dplyr::compute() 
 
##Split data set 1 and 2 before normalisation 
## Data set 1 includes images 1,2,3,7,8,9 
## Data set 2 includes images 4,5,6,10,11,12 
 
#Set up data set 1 object factors to include data from images (4,5,6,10,11,12) 
 
datset1 <- na_rows_removed 
datset1_list <- c (4,5,6,10,11,12) 
 
#Remove these data to get data set 1 
datset1 <- datset1[which(datset1$ImageNumber %in% datset1_list),] 
 
#Set up data set 2 object factors to inclulde data from ImageNumber (1,2,3,7,8,9) 
 
datset2 <- na_rows_removed 
datset2_list <- c (1,2,3,7,8,9) 
 
#Remove these data to get data set 2 
datset2 <- datset2[which(datset2$ImageNumber %in% datset2_list),] 
 
 
## Normalize the combined data so that features are on the same scale 
normalized <- 
  cytominer::normalize( 
    population = na_rows_removed, 
    variables = variables, 
    strata = "Well", 
    sample = na_rows_removed ) 
 
normalized %<>% dplyr::collect() 
 
##Normalise dataset 1 and 2 so that the data and features are on the same scale 
 
# For Dataset 1 
dat1_norm <- 
  cytominer::normalize( 
    population = datset1, 
    variables = variables, 
    strata = "Well", 
    sample = datset1 ) 
 
dat1_norm %<>% dplyr::collect() 
 
# For Dataset 2 
 
dat2_norm <- 
  cytominer::normalize( 
    population = datset2, 
    variables = variables, 
    strata = "Well", 
    sample = datset2 ) 
 
dat2_norm %<>% dplyr::collect() 
Appendix 2  Van T. T. Nguyen 
158 
 
 
#In some cases, we may have features that have no variance at all (e.g. Euler 
#number). If these features have not already been removed by this stage, the 
#standardization step will result in all values for that feature being NA ( 
#because s.d. = 0). Lets remove them: 
 
#First, count how many cells have NA values per feature: 
 
#In combined data 
na_frequency <- 
  cytominer::count_na_rows( 
    population = normalized, 
    variables = variables) 
 
na_frequency %>% 
  tidyr::gather(feature, na_count) %>% 
  knitr::kable() 
 
#In dataset 1 
 
dat1_na_frequency <- 
  cytominer::count_na_rows( 
    population = dat1_norm, 
    variables = variables) 
 
dat1_na_frequency %>% 
  tidyr::gather(feature, na_count) %>% 
  knitr::kable() 
 
#In dataset 2 
 
dat2_na_frequency <- 
  cytominer::count_na_rows( 
    population = dat2_norm, 
    variables = variables) 
 
dat2_na_frequency %>% 
  tidyr::gather(feature, na_count) %>% 
  knitr::kable() 
 
##Next, let's run this cleaning operation 
 
# For combined data 
cleaned <- 
  cytominer::variable_select( 
    population = normalized, 
    variables = variables, 
    operation = "drop_na_columns" 
  ) 
 
#For dataset 1 
 
dat1_cleaned <- 
  cytominer::variable_select( 
    population = dat1_norm, 
    variables = variables, 
    operation = "drop_na_columns" 
  ) 
# For dataset 2 
 
dat2_cleaned <- 
  cytominer::variable_select( 
    population = dat2_norm, 
    variables = variables, 
    operation = "drop_na_columns" 
  ) 
 
## Transform 
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#Tranform the data so that assumptions we may later make about the data 
#distribution are satisfied (e.g. Gaussianity). The default here is 
#`generalized_log`. 
 
#For combined data 
 
dn1<-colnames(cleaned) 
excluded<-setdiff(dn,dn1) 
ad<- which (variables %in% excluded) 
na_removed_variables<- variables[-ad] 
 
transformed <- 
  cytominer::transform( 
    population = cleaned, 
    variables =na_removed_variables 
  ) 
 
#For dataset 1 
 
dat1<-colnames(dat1_cleaned) 
excluded<-setdiff(dn,dat1) 
ad<- which (variables %in% excluded) 
dat1_removed_variables<- variables[-ad] 
 
dat1_transformed <- 
  cytominer::transform( 
    population = dat1_cleaned, 
    variables =dat1_removed_variables 
  ) 
 
#For dataset 2 
 
dat2<-colnames(dat2_cleaned) 
excluded<-setdiff(dn,dat2) 
ad<- which (variables %in% excluded) 
dat2_removed_variables<- variables[-ad] 
 
dat2_transformed <- 
  cytominer::transform( 
    population = dat2_cleaned, 
    variables =dat2_removed_variables 
  ) 
## Select features: 
# Finally, we typically perform feature selection on the data. Feature selection is  
#an expensive operation, so we usually want to train the feature selection model on  
#a sample of the dataset. Here, we choose to aggregate the data instead of sampling  
#it (i.e. collapse it to per-well aggregates) 
 
#For combined data 
 
aggregated <- 
  cytominer::aggregate( 
    population = transformed, 
    variables = na_removed_variables, 
    strata = "Wellsite" 
  ) %>% 
  dplyr::collect() 
 
#For dataset1 
 
dat1_aggregated <- 
  cytominer::aggregate( 
    population = dat1_transformed, 
    variables = dat1_removed_variables, 
    strata = "Wellsite" 
  ) %>% 
  dplyr::collect() 
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#For dataset2 
 
dat2_aggregated <- 
  cytominer::aggregate( 
    population = dat2_transformed, 
    variables = dat2_removed_variables, 
    strata = "Wellsite" 
  ) %>% 
  dplyr::collect() 
 
## write the aggreagated file to save a record 
write.csv(aggregated, "image_aggregated.csv", row.names = FALSE) 
write.csv(dat1_aggregated, "dat1_aggregated.csv", row.names = FALSE) 
write.csv(dat2_aggregated, "dat2_aggregated.csv", row.names = FALSE) 
 
# Then apply feature selection on the per-cell data. Here  
#`correlation_threshold` - a method that reduces the redundancy of features -  
#is used. 
 
#For the combined data 
selected <- 
  cytominer::variable_select( 
    population = transformed, 
    variables = na_removed_variables, 
    sample = aggregated, 
    operation = "correlation_threshold" 
  ) %>% 
  dplyr::collect() 
 
#For dataset1 
 
dat1_selected <- 
  cytominer::variable_select( 
    population = dat1_transformed, 
    variables = dat1_removed_variables, 
    sample = dat1_aggregated, 
    operation = "correlation_threshold" 
  ) %>% 
  dplyr::collect() 
 
#For dataset 2 
 
dat2_selected <- 
  cytominer::variable_select( 
    population = dat2_transformed, 
    variables = dat2_removed_variables, 
    sample = dat2_aggregated, 
    operation = "correlation_threshold" 
  ) %>% 
  dplyr::collect() 
 
#remove the variables of Eulernumber 
 
 
t<-colnames(selected) %>% stringr::str_subset("Euler") 
d2<- which (colnames(selected) %in% t) 
selected<-selected[,-d2] 
 
selected_variable<-names(selected)[-c(1:8)] 
aggregated<-aggregate( 
  population = selected, 
  variables = selected_variable, 
  strata = "Wellsite" 
) %>% 
  dplyr::collect() 
 
#for dataset 1 
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t1 <-colnames(dat1_selected) %>% stringr::str_subset("Euler") 
dt1<- which (colnames(dat1_selected) %in% t1) 
 
#there is no "Euler" feature in dataset 1 anymore, so no need to remove it. 
 
dat1_selected_variable<-names(dat1_selected)[-c(1:8)] 
dat1_aggregated <- aggregate( 
  population = dat1_selected, 
  variables = dat1_selected_variable, 
  strata = "Wellsite" 
) %>% 
  dplyr::collect() 
 
#for dataset 2 
t2 <-colnames(dat2_selected) %>% stringr::str_subset("Euler") 
dt2<- which (colnames(dat2_selected) %in% t2) 
 
#there is no "Euler" feature in dataset 2 anymore, so no need to remove it. 
 
dat2_selected_variable<-names(dat2_selected)[-c(1:8)] 
dat2_aggregated <- aggregate( 
  population = dat2_selected, 
  variables = dat2_selected_variable, 
  strata = "Wellsite" 
) %>% 
  dplyr::collect() 
 
## Perform PCA  
 
# for the combined data 
combined_pca <- prcomp(aggregated[,2:176], scale. = TRUE) 
 
# for dataset 1 
dat1_pca <- prcomp(dat1_aggregated[,2:9], scale. = TRUE) 
 
# for dataset 2 
dat2_pca <- prcomp(dat2_aggregated[,2:14], scale. = TRUE) 
 
#load packages for plotting 
library(ggbiplot) 
library(factoextra) 
 
 
#PCA plotting, separated by cell types 
#For combined data 
comb_samples <-aggregated$Wellsite 
comb_gplot <- ggbiplot(combined_pca, obs.scale = 1, var.scale = 1, groups = 
comb_samples, circle = TRUE) 
comb_gplot <- comb_gplot + scale_color_discrete(names('')) 
comb_gplot <- comb_gplot + theme(legend.direction = 'horizontal', legend.position = 
'top') 
print(comb_gplot) 
 
#For dataset 1 
dat1_samples <- dat1_aggregated$Wellsite 
dat1_gplot <- ggbiplot(dat1_pca, obs.scale = 1, var.scale = 1, groups = 
dat1_samples, circle = TRUE) 
dat1_gplot<- dat1_gplot + scale_color_discrete(names('')) 
dat1_gplot <- dat1_gplot + theme(legend.direction = 'horizontal', legend.position = 
'top') 
print(dat1_gplot) 
 
#For dataset 2 
dat2_samples <- dat2_aggregated$Wellsite 
dat2_gplot <- ggbiplot(dat2_pca, obs.scale = 1, var.scale = 1, groups = 
dat2_samples, circle = TRUE) 
dat2_gplot<- dat2_gplot + scale_color_discrete(names('')) 
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dat2_gplot <- dat2_gplot + theme(legend.direction = 'horizontal', legend.position = 
'top') 
print(dat2_gplot) 
 
#variance plotting/Scre Plot 
#For combined data 
fviz_eig(combined_pca) 
 
#For dataset1 
fviz_eig(dat1_pca) 
 
#For dataset2 
fviz_eig(dat2_pca) 
 
#eigenvalues 
#For combined data 
eig.val_comb <- get_eigenvalue(combined_pca) 
#for dataset1 
eig.val_dat1 <- get_eigenvalue(dat1_pca) 
#for dataset2 
eig.val_dat2 <- get_eigenvalue(dat2_pca) 
 
#results for variables: how much each variable (feature) contribute to each PC 
#For combined data 
comb_res.var <- get_pca_var(combined_pca) 
#for dataset1 
dat1_res.var <- get_pca_var(dat1_pca) 
#for dataset2 
dat2_res.var <- get_pca_var(dat2_pca) 
 
#how does each variable correlate to each PC in terms of: 
#For combined data 
comb_res.var$coord          # Coordination with each PC 
comb_res.var$contrib        # Contribution to each PC-which is used to determine 
important features 
comb_res.var$cos2           # Quality of representation in each PC 
 
#For dataset 1 
dat1_res.var$coord          # Coordination with each PC 
dat1_res.var$contrib        # Contribution to each PC-which is used to determine 
important features 
dat1_res.var$cos2           # Quality of representation in each PC 
 
#For dataset 2 
dat2_res.var$coord          # Coordination with each PC 
dat2_res.var$contrib        # Contribution to each PC-which is used to determine 
important features 
dat2_res.var$cos2           # Quality of representation in each PC 
 
#Export the aggregated data 
write.csv(aggregated,"combined_aggregated.csv", row.names = TRUE) 
write.csv(dat1_aggregated,"dat1_aggregated.csv", row.names = TRUE) 
write.csv(dat2_aggregated,"dat2_aggregated.csv", row.names = TRUE) 
 
#Export the contribution values of each feature to the PCs 
write.csv(comb_res.var$contrib,"combined_contrib.csv", row.names = TRUE) 
write.csv(dat1_res.var$contrib,"dat1_contrib.csv", row.names = TRUE) 
write.csv(dat2_res.var$contrib,"dat2_contrib.csv", row.names = TRUE) 
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